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Clostridium	  difficile	  is	  an	  anaerobic,	  gram-­‐positive	  bacterium,	  known	  to	  be	  the	  
foremost	  cause	  of	  in-­‐hospital	  infectious	  diarrhoea.	  Almost	  all	  cases	  follow	  the	  use	  
of	  antibiotics	  and	  infection	  leads	  to	  increased	  hospital	  stay	  and	  worse	  health	  
outcomes.	  The	  incidence	  of	  the	  infection	  has	  risen	  in	  the	  last	  decade	  and	  there	  is	  
an	  emerging	  evidence	  base	  about	  the	  epidemiology	  of	  the	  infection	  in	  Australia.	  
However,	  to	  date	  there	  are	  no	  published	  papers	  about	  the	  economics	  of	  the	  
infection,	  in	  particular	  the	  cost	  effectiveness	  of	  potential	  control	  programmes.	  
	  
Objectives	  
Healthcare	  decision-­‐makers	  are	  increasingly	  expected	  to	  balance	  an	  increasing	  
demand	  for	  health	  services	  with	  a	  finite	  budget.	  As	  such,	  the	  role	  of	  economic	  
evaluation	  in	  healthcare	  is	  increasing	  and	  this	  research	  provides	  decision-­‐makers	  
with	  new	  information	  about	  the	  management	  of	  Clostridium	  difficile	  infection,	  
from	  an	  economic	  perspective.	  
Specifically,	  the	  research	  questions	  that	  are	  addressed	  in	  this	  project	  are:	  
	  
1. What	  interventions	  are	  relevant	  to	  reduce	  Clostridium	  difficile	  infection	  




2. What	  is	  the	  most	  cost-­‐effective	  approach	  to	  managing	  Clostridium	  difficile	  
infection?	  
3. How	  does	  uncertainty	  in	  competing	  decisions	  impact	  on	  decision-­‐making?	  




A	  model-­‐based	  economic	  evaluation	  has	  been	  undertaken	  to	  identify	  the	  most	  
cost-­‐effective	  healthcare	  intervention	  relating	  to	  the	  reduction	  of	  Clostridium	  
difficile	  transmission.	  The	  evaluation	  included	  stand-­‐alone	  interventions,	  such	  as	  
antimicrobial	  stewardship	  (AMS),	  fecal	  microbiota	  transplantation	  (FMT)	  and	  
reducing	  patient	  length	  of	  stay	  (LOS).	  The	  following	  bundled	  interventions,	  where	  
practical	  combinations	  were	  coupled	  together,	  were	  also	  included:	  hygiene	  
improvement	  (hand	  hygiene	  and	  environmental	  cleaning),	  hygiene	  improvement	  
and	  AMS,	  hygiene	  improvement	  and	  FMT,	  reducing	  LOS	  and	  AMS,	  reducing	  LOS	  
and	  hygiene	  improvement.	  The	  economic	  model	  uses	  results	  from	  the	  most	  up-­‐to-­‐
date	  and	  realistic	  mathematical	  transmission	  model	  for	  Clostridium	  difficile	  to	  
estimate	  the	  efficacy	  of	  a	  number	  of	  healthcare	  interventions.	  A	  thorough	  costing	  
analysis	  has	  also	  been	  undertaken	  to	  inform	  the	  model’s	  cost-­‐related	  parameters	  






The	  results	  show	  that	  compared	  to	  standard	  care,	  seven	  of	  the	  ten	  infection	  
control	  interventions	  result	  in	  health	  gains	  and	  cost-­‐savings.	  A	  bundled	  approach	  
of	  improving	  hand	  hygiene	  and	  environmental	  cleaning	  together	  (‘HYG	  1’)	  
produces	  the	  best	  combination	  of	  increased	  health	  benefits	  and	  cost-­‐savings.	  This	  
intervention	  generates	  126.68	  QALYs	  and	  cost-­‐savings	  of	  approximately	  $2.2M.	  
After	  undertaking	  probabilistic	  analysis,	  HYG	  1	  remains	  the	  optimal	  choice	  of	  
intervention	  at	  a	  willingness-­‐to-­‐pay	  threshold	  of	  $42,000/QALY.	  It	  has	  the	  highest	  
mean	  net	  monetary	  benefit	  ($7,459,667)	  when	  compared	  to	  all	  other	  interventions.	  
The	  intervention	  with	  the	  lowest	  net	  monetary	  benefit	  is	  reducing	  antibiotic	  usage	  
within	  a	  hospital	  by	  10%	  (‘AMS	  1’),	  which	  has	  a	  mean	  NMB	  of	  $15,029.	  Multiple	  
clinically	  plausible	  scenarios	  were	  analysed,	  the	  results	  showing	  that	  HYG	  1	  
remains	  the	  optimal	  decision	  under	  different	  clinical	  circumstances.	  This	  includes	  
when	  the	  mortality	  rate	  was	  increased	  (127.9	  QALYs	  gained,	  $2.02M	  saved)	  and	  
when	  an	  infected	  patient’s	  length-­‐of-­‐stay	  increases	  (123.8	  QALYs	  gained,	  $2.1M	  
saved).	  Only	  when	  the	  underlying	  infection	  rate	  was	  doubled	  was	  another	  
intervention	  optimal,	  in	  this	  case,	  the	  AMS/HYG	  bundle	  (164.6	  QALYs	  gained,	  
$4.6M	  saved).	  
	  
The	  results	  also	  show	  that	  bundled	  interventions,	  as	  opposed	  to	  stand-­‐alone	  
interventions,	  offer	  the	  best	  opportunity	  for	  health	  improvements.	  The	  four	  
highest-­‐ranking	  interventions	  in	  terms	  of	  highest	  expected	  QALY	  gains	  were	  all	  




HYG/FMT	  1	  produced	  122.18	  QALYs	  and	  HYG/FMT	  2	  produced	  120.73	  QALYs.	  The	  
results	  demonstrate	  that	  there	  is	  an	  economic	  benefit	  to	  implementing	  infection	  
control	  interventions	  in	  bundles,	  with	  the	  four	  highest	  performing	  interventions	  
from	  a	  net	  monetary	  benefit	  perspective	  all	  being	  bundles.	  These	  findings	  
complement	  current	  wisdom	  within	  the	  infection	  control	  community	  where	  a	  
preference	  for	  bundled	  approaches	  to	  prevention,	  compared	  to	  stand-­‐alone	  
interventions,	  is	  shown.	  
	  
Conclusions	  
Until	  now,	  economic	  evidence	  relating	  to	  Clostridium	  difficile	  infection	  has	  not	  
been	  available	  for	  the	  Australian	  setting	  and	  the	  results	  of	  this	  project	  should	  be	  
used	  to	  inform	  improvements	  in	  the	  management	  of	  this	  problematic	  infection.	  
The	  findings	  from	  this	  project	  provide	  healthcare	  decision-­‐makers	  with	  novel	  
information	  about	  the	  allocation	  of	  scarce	  resources	  and	  are	  relevant	  to	  inform	  
change	  at	  a	  policy	  level,	  as	  well	  as	  ‘on	  the	  shop	  floor’,	  in	  hospitals.	  It	  is	  clear	  that	  if	  
decision-­‐makers	  do	  not	  adopt	  any	  of	  the	  proposed	  interventions,	  improvements	  in	  
health	  outcomes	  will	  be	  forgone.	  If	  investments	  are	  not	  made	  in	  interventions	  that	  
clearly	  yield	  gains	  in	  health	  outcomes	  compared	  to	  the	  status	  quo,	  the	  allocation	  
and	  use	  of	  scarce	  healthcare	  resources	  is	  inappropriate.	  This	  novel	  evidence	  is	  of	  
value	  to	  the	  infection	  control	  department	  within	  a	  hospital,	  who	  petition	  for	  
resources	  alongside	  other	  clinical	  departments.	  It	  should	  also	  serve	  to	  guide	  




resources	  from	  one	  intervention	  to	  another	  in	  search	  of	  more	  cost-­‐effective	  
outcomes.	  The	  findings	  of	  this	  project	  should	  be	  considered	  together	  with	  other	  
relevant	  information	  that	  is	  appropriate	  at	  a	  local	  level,	  such	  as	  clinical	  outcomes,	  
budget	  constraints	  and	  treatment	  priorities	  to	  ensure	  decision-­‐making	  is	  
comprehensive	  and	  well	  informed.	  If	  this	  occurs,	  the	  findings	  will	  be	  a	  beneficial	  
addition	  to	  support	  logical	  and	  thorough	  decision-­‐making	  about	  Clostridium	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Chapter	  1:	  Introduction	  
Chapter	  Overview	  
This	  chapter	  is	  an	  introduction	  to	  the	  research	  project	  and	  is	  divided	  into	  four	  
sections.	  Section	  1.1	  is	  a	  description	  of	  the	  context	  within	  which	  this	  research	  fits,	  
while	  section	  1.2	  describes	  the	  purpose	  of	  the	  research	  project.	  Section	  1.3	  is	  an	  
outline	  of	  the	  significance	  of	  the	  project	  and	  details	  the	  scope	  of	  the	  study.	  Section	  
1.4	  is	  a	  summary	  of	  the	  remainder	  of	  the	  thesis.	  
	  
Section	  1.1:	  Context	  
This	  research	  project	  is	  part	  of	  a	  wider	  programme	  of	  investigation	  under	  the	  
Centre	  of	  Research	  Excellence	  in	  Reducing	  Healthcare	  Associated	  Infections	  (CRE-­‐
RHAI).	  The	  CRE-­‐RHAI	  is	  a	  research	  collaboration	  focused	  on	  exploring	  a	  number	  
of	  factors	  relating	  to	  various	  Healthcare	  Associated	  Infections	  (HAIs).	  Research	  
areas	  include	  surveillance	  of	  HAIs,	  transmission	  dynamics	  of	  HAIs	  and	  assessment	  
of	  clinical	  effectiveness	  of	  intervention	  programmes.	  The	  National	  Health	  and	  
Medical	  Research	  Council	  (NHMRC)	  fund	  the	  CRE-­‐RHAI.	  This	  research	  project	  is	  
focused	  on	  Clostridium	  difficile	  infection	  and	  will	  analyse	  the	  cost-­‐effectiveness	  of	  a	  
number	  of	  interventions	  that	  are	  designed	  to	  reduce	  its	  transmission.	  
	  
Clostridium	  difficile	  is	  an	  anaerobic,	  gram-­‐positive	  bacterium,	  known	  to	  be	  the	  




transmitted	  via	  the	  faecal-­‐oral	  pathway	  when	  spores	  containing	  the	  bacterium	  are	  
ingested	  (5).	  Almost	  all	  cases	  of	  Clostridium	  difficile	  infection	  follow	  the	  use	  of	  
antibiotics	  (5)	  and	  infection	  leads	  to	  extra	  length	  of	  hospital	  stay,	  increased	  
morbidity	  and	  increased	  chance	  of	  mortality	  (6).	  Many	  papers	  report	  that	  
incidence,	  deaths	  and	  costs	  due	  to	  Clostridium	  difficile	  have	  been	  on	  an	  upward	  
trend	  in	  the	  past	  two	  decades	  (5-­‐9).	  However,	  there	  are	  no	  published	  papers	  from	  
Australia	  that	  estimate	  the	  cost	  of	  the	  infection	  using	  economic	  methods.	  	  
	  
Section	  1.2:	  Purpose	  
In	  the	  current	  healthcare	  climate,	  decision-­‐makers	  are	  expected	  to	  balance	  stable	  
supply	  with	  increased	  demand	  for	  services	  and	  are	  encouraged	  to	  do	  so	  not	  only	  
with	  patient	  safety,	  but	  also	  budgetary	  constraints	  in	  mind	  (10-­‐11).	  This	  research	  
project	  will	  provide	  decision-­‐makers	  with	  new	  information	  relating	  to	  Clostridium	  
difficile	  infection.	  It	  will	  provide	  an	  economic	  rationale	  for	  decision-­‐makers,	  who	  
may	  be	  hospital	  executives,	  clinicians	  or	  bureaucrats,	  regarding	  the	  cost-­‐
effectiveness	  of	  competing	  interventions	  that	  are	  designed	  to	  reduce	  Clostridium	  
difficile.	  Specifically,	  the	  research	  questions	  that	  this	  project	  will	  answer	  are:	  
	  
1. What	  interventions	  are	  relevant	  to	  reduce	  Clostridium	  difficile	  infection	  
and	  what	  do	  they	  cost?	  	  





3. How	  does	  uncertainty	  in	  competing	  decisions	  impact	  on	  decision-­‐making?	  
4. What	  is	  the	  expected	  value	  of	  perfect	  information	  relating	  to	  this	  decision	  
problem?	  
	  
To	  answer	  these	  research	  questions,	  an	  economic	  model	  that	  can	  simultaneously	  
handle	  information	  relating	  to	  costs	  and	  health	  effects	  of	  interventions	  has	  been	  
developed.	  The	  model	  will	  be	  populated	  with	  data	  that	  has	  been	  synthesised	  from	  
a	  variety	  of	  sources	  and	  includes	  explicit	  assumptions,	  in	  order	  to	  provide	  new	  
evidence	  for	  decision-­‐makers.	  This	  information	  will	  not	  only	  address	  an	  important	  
knowledge	  gap	  but	  will	  provide	  evidence	  for	  the	  uptake	  of	  one,	  or	  discontinuation	  
of	  another	  clinical	  intervention.	  	  
	  
Section	  1.3:	  Significance,	  scope	  and	  definitions	  
The	  purpose	  of	  economic	  evaluation	  in	  health	  is	  to	  find	  the	  best	  health	  gain	  per	  
dollar	  spent	  from	  an	  intervention	  or	  programme	  (10,12).	  It	  is	  the	  comparative	  
analysis	  of	  alternative	  courses	  of	  action	  and	  weighs	  up	  both	  costs	  and	  healthcare	  
consequences	  (13).	  
	  
The	  allocation	  of	  healthcare	  resources	  has	  long	  been	  a	  debated	  issue	  (14).	  
Resources	  spent	  on	  healthcare	  have	  an	  opportunity	  cost	  measured	  by	  less	  
education,	  infrastructure	  and	  defence,	  for	  example	  and	  vice-­‐versa.	  This	  being	  the	  




framework	  for	  such	  justification.	  Economic	  evaluation	  is	  widely	  accepted	  as	  a	  
valuable	  method	  for	  the	  appraisal	  of	  healthcare	  programmes	  and	  is	  an	  important	  
instrument	  for	  any	  decision-­‐maker’s	  toolkit	  (14).	  Thorough	  evaluations	  utilise	  
information	  from	  a	  variety	  of	  sources	  and	  should	  be	  transparent.	  Information	  
about	  which	  sources	  have	  and	  have	  not	  been	  included	  in	  an	  analysis	  is	  a	  sign	  of	  a	  
good	  evaluation	  (12).	  
	  
Decision	  models	  are	  not	  a	  replacement	  of	  randomised	  control	  trials;	  rather	  they	  
provide	  a	  structure	  within	  which	  evidence	  from	  a	  range	  of	  sources	  can	  be	  directed	  
at	  a	  specific	  decision	  problem	  (12).	  Model	  based	  evaluations	  are	  recognised	  as	  
valuable	  resources	  for	  healthcare	  decision-­‐makers	  (15).	  This	  research	  project	  will	  
utilise	  a	  decision	  analytic	  model	  in	  order	  to	  compare	  a	  number	  of	  competing	  
interventions.	  For	  a	  number	  of	  reasons,	  this	  type	  of	  analysis	  would	  not	  be	  possible	  
if	  only	  data	  from	  randomised	  controlled	  trials	  were	  relied	  upon.	  Clinical	  trials	  are	  
limited	  by	  the	  fact	  that	  they	  are	  only	  ever	  concerned	  with	  a	  strictly	  defined	  (albeit	  
carefully	  randomised)	  population,	  which	  is	  not	  always	  easily	  generalisable	  to	  the	  
mainstream	  population.	  Furthermore,	  due	  to	  restrictive	  time	  constraints,	  budgets	  
and	  participation	  issues,	  clinical	  trials	  are	  not	  as	  flexible	  or	  adaptable	  when	  
compared	  with	  modelling	  studies.	  As	  Sculpher	  argues,	  allowing	  a	  single	  trial	  to	  





Modelling	  studies	  are	  not	  without	  fault;	  the	  literature	  does	  sound	  warnings	  and	  
concerns	  that	  decision-­‐makers	  might	  heed.	  However,	  it	  has	  been	  consistently	  
argued	  that	  modelling	  studies	  are	  preferable	  when	  conducting	  economic	  
evaluations	  in	  healthcare	  because	  of	  their	  ability	  to	  forecast	  over	  long	  time	  
periods,	  their	  transparency	  relating	  to	  uncertainty	  within	  chosen	  parameters	  and	  
their	  low	  cost	  (16).	  Because	  of	  their	  design,	  randomised-­‐control	  trials	  cannot	  
handle	  all	  the	  comparisons	  that	  a	  model-­‐based	  study	  can	  handle.	  
	  
Section	  1.4:	  Thesis	  Outline	  
The	  remainder	  of	  the	  thesis	  will	  be	  presented	  in	  the	  following	  chapters;	  literature	  
review	  (Chapter	  2),	  cost-­‐effectiveness	  models	  (Chapter	  3),	  methods	  (Chapter	  4),	  
results	  (Chapter	  5)	  and	  discussion	  (Chapter	  6).	  
Chapter	  2	  is	  an	  examination	  of	  the	  published	  evidence	  relating	  to	  various	  sub-­‐
categories	  that	  are	  of	  importance	  to	  the	  overall	  aims	  of	  the	  research	  project.	  
Chapter	  3	  is	  an	  explanation	  of	  economic	  modelling	  and	  chapter	  4	  is	  an	  explanation	  
of	  the	  methods	  underpinning	  the	  research	  project.	  It	  includes	  a	  critique	  of	  the	  
pathway	  chosen	  for	  this	  particular	  study.	  	  
Chapter	  5	  is	  where	  the	  results	  of	  the	  research	  project	  are	  presented.	  The	  chapter	  
includes	  the	  comparison	  of	  all	  competing	  interventions	  under	  scrutiny	  and	  the	  
results	  of	  sensitivity	  analyses	  and	  parameter	  uncertainty.	  The	  outcome	  of	  scenario	  




Chapter	  6	  contains	  the	  discussion	  of	  the	  results.	  The	  implications	  of	  the	  results,	  
limitations	  of	  the	  study	  and	  recommendations	  as	  a	  result	  of	  the	  findings	  can	  be	  
found	  in	  this	  chapter.	  Opportunities	  for	  further	  research	  and	  action	  are	  also	  
presented	  in	  chapter	  6.	  




Chapter	  2:	  Literature	  Review	  	  
Chapter	  Overview	  
This	  chapter	  is	  a	  review	  of	  the	  literature	  and	  covers	  the	  following	  topics:	  
epidemiology	  (section	  2.1);	  at-­‐risk	  population	  (section	  2.2);	  clinical	  interventions	  
(section	  2.3);	  mathematical	  modelling	  (section	  2.4);	  economic	  burden	  of	  
Clostridium	  difficile	  (section	  2.5);	  and	  cost-­‐effectiveness	  studies	  for	  interventions	  to	  
reduce	  risk	  of	  infection	  (section	  2.6).	  Section	  2.7	  is	  the	  summary	  and	  a	  reflection	  of	  
the	  literature	  review.	  	  
	  
Section	  2.1:	  Epidemiology	  	  
Clostridium	  difficile	  is	  the	  most	  common	  cause	  of	  hospital-­‐acquired	  infectious	  
diarrhoea	  (2;	  17-­‐18).	  It	  is	  an	  anaerobic,	  spore	  forming	  bacterium	  that	  disrupts	  
colonic	  flora	  upon	  ingestion	  and	  is	  transmitted	  via	  the	  fecal-­‐oral	  route	  (19-­‐20).	  The	  
pathogen	  produces	  toxins	  upon	  colonisation	  of	  the	  gut	  and	  is	  capable	  of	  causing	  a	  
wide	  range	  of	  disease,	  from	  diarrhoea	  to	  pseudomembranous	  colitis,	  resulting	  in	  
adverse	  outcomes	  such	  as	  increased	  length	  of	  hospitalisation	  and	  death	  (20-­‐21).	  It	  
is	  recognised	  as	  being	  a	  problematic	  condition	  in	  the	  developed	  world,	  with	  
studies	  from	  the	  United	  Kingdom,	  Europe	  and	  North	  America	  reporting	  the	  
changing	  epidemiological	  landscape	  (4;	  22-­‐23).	  Although	  the	  disease	  has	  
traditionally	  been	  associated	  with	  healthcare	  facilities	  in	  the	  developed	  world,	  it	  is	  




developing	  countries	  (24).	  Studies	  in	  Argentina,	  Chile,	  India	  and	  Iran	  have	  shown	  a	  
consistently	  high	  prevalence	  of	  Clostridium	  difficile	  infection	  (6-­‐17%)	  among	  
hospital	  patients	  (25-­‐28).	  
	  
Clinical	  manifestations	  range	  from	  asymptomatic	  colonisation	  to	  severe	  diarrhoea,	  
pseudomembranous	  colitis,	  toxic	  megacolon	  and	  death	  (29).	  Kelly	  and	  Lamont	  
(30)	  suggest	  that	  there	  are	  consistent	  increases	  in	  the	  number	  of	  patients	  suffering	  
from	  ‘severe	  illness’	  and	  other	  studies	  suggest	  that	  the	  incidence	  of	  Clostridium	  
difficile	  has	  increased	  significantly	  in	  the	  last	  two	  decades	  (31-­‐32).	  In	  2008,	  the	  
European	  Centre	  for	  Disease	  Prevention	  and	  Control	  (ECDC)	  initiated	  a	  large,	  pan-­‐
European	  study	  of	  Clostridium	  difficile	  infection,	  in	  order	  to	  estimate	  baseline	  
incidence	  (33).	  The	  study	  included	  data	  from	  34	  countries	  and	  reported	  a	  mean	  
incidence	  rate	  of	  4.1	  per	  10,000	  patient	  days	  (34).	  Studies	  from	  Denmark,	  Germany,	  
Finland	  and	  Spain	  have	  all	  reported	  increases	  in	  infection	  incidence	  in	  the	  last	  
decade	  (35-­‐38).	  It	  has	  been	  reported	  that	  between	  1996	  and	  2005,	  incidence	  in	  the	  
USA	  almost	  trebled;	  increasing	  from	  31	  per	  100,000	  population	  to	  84	  per	  100,000	  
population	  (30).	  Rupnik	  et	  al	  (39)	  also	  found	  that	  in	  the	  USA	  the	  number	  of	  
discharged	  patients	  who	  had	  been	  diagnosed	  with	  Clostridium	  difficile	  infection	  
exceeded	  300,000	  per	  year	  in	  2006	  –	  an	  increase	  from	  <150,000	  in	  the	  year	  2000.	  	  
Not	  only	  has	  there	  been	  increased	  incidence	  of	  morbidity	  associated	  with	  
Clostridium	  difficile,	  there	  has	  been	  an	  increased	  reporting	  of	  mortality	  attributed	  




attributing	  cause	  of	  death	  to	  Clostridium	  difficile	  quadrupled	  in	  England	  and	  Wales	  
(40).	  It	  is	  clear	  that	  due	  to	  the	  infection,	  three	  negative	  outcomes	  have	  increased;	  
(1)	  more	  cases	  of	  infection	  are	  being	  identified,	  (2)	  infected	  patients	  are	  suffering	  
worse	  symptoms	  due	  to	  pathogen	  virulence	  and	  (3)	  there	  are	  more	  deaths	  
associated	  with	  the	  infection	  than	  in	  previous	  years.	  
	  
Arora	  et	  al	  (23)	  note	  that	  ribotype	  027,	  a	  well-­‐documented	  ‘hypervirulent’	  strain	  of	  
Clostridium	  difficile,	  has	  contributed	  to	  the	  overall	  increase	  in	  incidence,	  with	  the	  
United	  Kingdom	  and	  Canada	  being	  particularly	  affected	  by	  this	  strain.	  Two	  large	  
outbreaks	  of	  Clostridium	  difficile	  occurred	  in	  the	  United	  Kingdom	  in	  the	  mid-­‐
2000s,	  where	  over	  150	  new	  cases	  of	  infection	  and	  19	  deaths	  in	  each	  outbreak	  were	  
attributed	  to	  ribotype	  027	  	  (41).	  The	  discovery	  of	  this	  strain	  has	  also	  been	  made	  in	  
other	  countries	  outside	  Europe,	  such	  as	  Japan,	  where	  the	  first	  known	  case	  was	  
described	  in	  a	  paper	  in	  2014	  (42).	  Other	  strains	  that	  are	  associated	  with	  
hypervirulence	  and	  particularly	  damaging	  health	  outcomes	  include	  types	  001,	  053	  
and	  078.	  These	  strains	  are	  the	  focus	  of	  multiple	  studies,	  from	  different	  countries,	  
that	  attribute	  an	  increase	  in	  Clostridium	  difficile	  incidence	  to	  strain	  virulence	  (43-­‐
44).	  The	  global	  spread	  of	  epidemic-­‐related	  strains	  of	  the	  infection	  is	  a	  concern	  for	  
healthcare	  practitioners	  and	  infection	  control	  policy	  makers,	  who	  have	  sought	  to	  
reduce	  the	  impact	  of	  Clostridium	  difficile	  in	  the	  hospital	  environment	  by	  





A	  unique	  feature	  of	  Clostridium	  difficile’s	  epidemiology	  is	  the	  role	  of	  recurrent	  
infection.	  Recurrences	  occur	  when	  a	  patient	  is	  treated	  for	  their	  initial	  infection	  but	  
suffer	  either	  a	  relapse	  with	  the	  same	  strain,	  or	  reinfection	  with	  a	  different	  strain	  
within	  a	  specified	  time	  period,	  usually	  2	  months	  (45-­‐47).	  Recurrent	  infection	  
causes	  a	  number	  of	  management	  problems	  for	  the	  healthcare	  system	  as	  patient	  
length	  of	  stay	  and	  hospitalisation	  costs	  are	  increased	  when	  patients	  have	  multiple	  
hospital	  stays	  for	  their	  ongoing	  issue	  (48).	  It	  is	  common	  for	  patients	  to	  suffer	  
multiple	  recurrences,	  with	  the	  risk	  of	  subsequent	  recurrences	  increasing	  after	  each	  
episode	  of	  infection	  (49).	  It	  is	  estimated	  that	  at	  least	  25%	  of	  all	  first-­‐time	  infections	  
result	  in	  a	  recurrent	  episode	  and	  that	  2nd	  and	  3rd	  time	  recurrences	  occur	  in	  at	  least	  
40-­‐50%	  of	  cases	  (50-­‐52).	  
	  
It	  is	  a	  commonly	  held	  view	  that	  there	  are	  large	  differences	  in	  capacity	  to	  undertake	  
routine	  surveillance	  and	  report	  even	  the	  most	  basic	  epidemiological	  measures	  for	  
Clostridium	  difficile	  infection.	  Surveillance	  systems	  for	  Clostridium	  difficile	  have	  
generally	  come	  into	  hospitals	  after	  there	  has	  been	  an	  epidemic	  or	  as	  a	  response	  to	  
some	  other	  emergent	  situation.	  This	  usually	  means	  that	  there	  is	  a	  compromised	  
understanding	  of	  the	  epidemiological	  history	  of	  the	  disease	  (33).	  This	  lack	  of	  
consistency	  in	  surveillance	  practice	  makes	  it	  difficult	  to	  fully	  quantify	  the	  impact	  
of	  the	  infection	  and	  challenging	  to	  measure	  the	  success	  of	  interventions	  that	  are	  
designed	  to	  reduce	  it.	  Another	  obstacle	  to	  maintaining	  good	  quality	  Clostridium	  




used	  to	  identify	  cases.	  According	  to	  a	  systematic	  review	  of	  diagnosis	  techniques,	  
enzyme	  immunoassay	  (EIA),	  toxigenic	  culture	  (TC)	  and	  polymerase	  chain	  reaction	  
(PCR)	  are	  the	  three	  most	  common	  approaches	  that	  are	  used	  for	  diagnosing	  
Clostridium	  difficile	  (53).	  However,	  it	  has	  been	  reported	  that	  the	  sensitivity	  and	  
specificity	  of	  all	  of	  these	  tests	  is	  far	  from	  perfect,	  leaving	  infection	  diagnosis	  widely	  
variable	  both	  across	  and	  within	  jurisdictions,	  according	  to	  the	  microbiological	  
approach	  chosen	  by	  each	  individual	  hospital/laboratory	  (54).	  Eastwood	  et	  al	  
compared	  routine	  diagnostic	  tests	  and	  found	  that	  toxin	  detection	  assays	  were	  
more	  sensitive	  in	  comparison	  to	  cytotoxin	  assay	  (82.8%	  vs.	  75.0%)	  but	  were	  less	  
specific	  (95.4%	  vs.	  96.1%).	  PCR	  assay	  had	  the	  highest	  sensitivity	  (92.2%;	  88.5%)	  
and	  specificity	  in	  comparison	  to	  toxin	  detection	  assay	  and	  cytotoxin	  assay	  (94.0%;	  
95.5%)	  (54).	  
In	  Australia,	  Slimings	  et	  al	  (55)	  report	  that	  incidence	  rates	  of	  both	  Hospital-­‐
Associated	  and	  Community-­‐Associated	  Clostridium	  difficile	  infections	  have	  risen	  in	  
the	  past	  decade.	  A	  total	  of	  12,683	  cases	  of	  infection	  were	  identified	  in-­‐hospital	  
between	  January	  2011	  and	  December	  2012	  (55).	  Community-­‐Associated	  infections	  
have	  been	  reported	  to	  rise	  substantially	  in	  Australia	  since	  2011	  (55).	  To	  date,	  
Hospital-­‐Associated	  infection	  has	  been	  the	  focus	  of	  the	  majority	  of	  studies,	  leaving	  
the	  risk-­‐factors	  associated	  with	  Community-­‐Associated	  infection	  unclear	  and	  




The	  incidence	  of	  Hospital-­‐Associated	  infection	  across	  all	  Australian	  states	  rose	  
from	  3.2/10	  000	  bed	  days	  to	  4.1/10	  000	  bed	  days	  between	  2011	  and	  2012	  (55).	  There	  
was	  no	  significant	  difference	  in	  incidence	  rate	  between	  State/Territory	  
jurisdictions	  (55).	  Links	  between	  climate	  characteristics	  and	  infection	  have	  been	  
explored	  for	  some	  areas	  of	  Australia,	  with	  one	  paper	  in	  2014	  suggesting	  that	  
atmospheric	  conditions,	  such	  as	  increased	  rainfall,	  are	  associated	  with	  an	  
increased	  number	  of	  infections	  (57).	  
It	  has	  been	  noted	  that	  surveillance	  of	  the	  infection	  in	  Australia	  requires	  
amendment	  and	  improvement	  if	  it	  is	  to	  reach	  the	  same	  standard	  that	  is	  evident	  in	  
countries	  such	  as	  Canada,	  England	  and	  the	  United	  States	  (5).	  Specific	  
improvements	  that	  have	  been	  suggested	  and	  debated	  in	  Australia	  include;	  greater	  
uptake	  of	  strain	  typing,	  mandatory	  reporting	  of	  severe	  cases	  to	  a	  National	  
infectious	  diseases	  body	  and	  increasing	  capacity	  to	  link	  infective	  cases	  to	  specific	  
antibiotic	  use	  (58).	  
	  
Section	  2.2:	  At-­‐risk	  population	  
Overuse	  of,	  and	  frequent	  exposure	  to	  antibiotics	  is	  proposed	  to	  be	  the	  most	  
important	  risk	  factor	  for	  contracting	  Clostridium	  difficile	  (21).	  The	  resistance	  to	  
colonisation	  of	  the	  bowel	  is	  reduced	  when	  antibiotic	  use	  is	  increased;	  although	  it	  is	  
not	  yet	  clearly	  understood	  which	  specific	  antibiotic	  classes	  are	  the	  most	  




suggested	  that	  third-­‐generation	  cephalosporins	  –	  commonly	  known	  as	  ‘broad-­‐
spectrum’	  antibiotics	  -­‐	  are	  to	  blame	  for	  increased	  cases	  of	  infection	  due	  to	  their	  
lack	  of	  specificity	  (61).	  However	  it	  has	  also	  been	  reported	  that	  Clindamycin	  is	  likely	  
to	  be	  an	  inciting	  agent	  for	  infection	  (62).	  	  
There	  is	  consensus	  throughout	  the	  literature	  that	  factors	  such	  as	  extended	  hospital	  
stay,	  comorbidity,	  gastrointestinal	  surgery	  and	  low	  hygiene	  standard	  of	  caregivers	  
are	  also	  common	  risk	  factors	  for	  the	  population	  (6;	  32).	  There	  is	  evidence	  that	  
immunosuppressed	  patients	  (e.g.	  HIV	  positive	  patients	  or	  those	  who	  have	  had	  
chemotherapy)	  face	  higher	  risk	  of	  Clostridium	  difficile	  infection	  (63).	  The	  impact	  of	  
environmental	  cleanliness	  (as	  a	  risk	  factor)	  is	  less	  well	  understood	  (4)	  and	  papers	  
exploring	  obesity	  as	  a	  risk	  factor	  have	  been	  published	  but	  are	  considered	  marginal	  
when	  compared	  with	  the	  aforementioned	  factors	  (64).	  Interestingly,	  a	  study	  
conducted	  in	  Western	  Australia	  concluded	  that	  there	  was	  a	  significant	  difference	  
in	  overall	  infection	  rate	  between	  men	  and	  women,	  with	  incidence	  rate	  for	  women	  
being	  higher	  (2.14	  cases	  per	  1,000	  discharges)	  than	  for	  men	  (1.60	  cases	  per	  1,000	  
discharges)	  (60).	  	  
Advanced	  age	  is	  noted	  as	  a	  key	  risk	  factor	  for	  this	  disease	  (6;	  23;	  30).	  Al-­‐Eidan	  et	  al	  
(65)	  reported	  that	  patients	  with	  Clostridium	  difficile	  infection	  were	  significantly	  
older	  than	  non-­‐infected	  patients	  in	  the	  equivalent	  hospital	  population	  (71	  vs.	  49	  
years).	  Studies	  show	  that	  attributable	  mortality	  for	  those	  aged	  >65	  was	  up	  to	  3.5	  




severe	  illness	  (67).	  Findings	  from	  a	  Canadian	  study	  suggest	  that	  risk	  of	  mortality	  is	  
greater	  for	  elderly	  patients,	  even	  when	  comorbidity	  factors	  were	  controlled	  for	  
(68).	  This	  is	  likely	  due	  to	  the	  weakened	  innate	  immune	  response	  in	  the	  body	  that	  
occurs	  with	  advancing	  years	  (69).	  
The	  literature	  describing	  where	  patients	  suffer	  from	  Clostridium	  difficile	  infection	  
varies	  (70).	  It	  is	  generally	  accepted	  that	  the	  infection	  is	  the	  most	  common	  cause	  of	  
in-­‐hospital	  infectious	  diarrhoea,	  although	  there	  are	  an	  increasing	  number	  of	  
studies	  relating	  to	  the	  presence	  of	  the	  infection	  in	  the	  community	  setting	  -­‐	  more	  
specifically	  in	  nursing	  homes	  and	  residential	  care	  facilities	  (71-­‐73).	  The	  exact	  split	  
of	  infections	  between	  hospital	  and	  community	  facilities	  is	  debated.	  Khanna	  et	  al	  
conducted	  a	  population-­‐based	  study	  in	  the	  USA	  with	  the	  purpose	  of	  trying	  to	  
better	  understand	  the	  origin	  of	  infections.	  The	  results	  of	  this	  study	  showed	  that	  
Community-­‐Acquired	  infection	  accounted	  for	  40%	  of	  all	  confirmed	  cases	  (70),	  
which	  was	  the	  same	  as	  the	  results	  reported	  by	  Arora	  et	  al	  (23).	  However,	  studies	  
from	  Australia	  and	  the	  Netherlands	  suggest	  that	  the	  number	  of	  Community-­‐
Acquired	  infections	  is	  lower	  –	  only	  representing	  around	  25%	  of	  all	  infections	  (19;	  
55).	  
Understanding	  the	  location	  of	  infections	  is	  an	  important	  step	  toward	  developing	  a	  
more	  accurate	  review	  of	  the	  interventions	  designed	  to	  reduce	  transmission.	  
Knowing	  the	  proportion	  of	  patients	  who	  show	  symptoms	  in-­‐hospital	  but	  were	  




strategies	  should	  be	  made.	  If	  a	  considerable	  proportion	  of	  cases	  in-­‐hospital	  are	  due	  
to	  community-­‐based	  infections,	  the	  investment	  in	  hospital-­‐level	  interventions	  is	  
never	  going	  to	  be	  entirely	  effective.	  
	  
Section	  2.3:	  Clinical	  intervention	  studies	  
Studies	  of	  the	  clinical	  effectiveness	  of	  drug	  therapy,	  antimicrobial	  stewardship,	  
probiotic	  therapy	  (including	  fecal	  transplant),	  hand	  hygiene	  programmes	  and	  
environmental	  cleaning	  are	  available.	  These	  studies	  are	  mostly	  from	  Europe,	  North	  
America	  and	  Great	  Britain	  with	  much	  of	  the	  clinical	  evidence	  base	  coming	  from	  
the	  northern	  hemisphere.	  	  
Literature	  describing	  the	  most	  clinically	  effective	  drug	  therapies	  for	  treatment	  of	  
Clostridium	  difficile	  infection	  is	  abundant	  (74-­‐76).	  Wenisch	  et	  al	  (77)	  compared	  
common	  antimicrobials,	  including	  vancomycin,	  metronidazole	  and	  teicoplanin,	  
concluding	  that	  metronidazole	  should	  be	  the	  drug	  of	  choice	  for	  first	  line	  treatment	  
of	  infection.	  These	  findings	  are	  supported	  in	  Australia,	  with	  clinical	  guidelines	  
recommending	  metronidazole	  for	  the	  treatment	  of	  initial	  disease	  and	  for	  the	  first	  
recurrence	  (75).	  There	  is	  little	  doubt	  that	  metronidazole	  is	  effective	  for	  non-­‐severe	  
illness	  but	  its	  efficacy	  compared	  to	  other	  antimicrobials	  for	  treating	  severe	  illness	  
has	  been	  questioned.	  Zar	  et	  al	  (78)	  conducted	  a	  double-­‐blind,	  randomised	  
controlled	  trial	  comparing	  metronidazole	  and	  vancomycin	  for	  treatment	  of	  




that	  vancomycin	  is	  superior	  to	  metronidazole	  for	  the	  treatment	  of	  severe	  disease	  
and	  should	  be	  prescribed	  accordingly	  (78).	  This	  approach	  to	  treatment	  has	  been	  
confirmed	  in	  clinical	  guidelines	  from	  North	  America	  (74)	  and	  Australia	  in	  the	  last	  
decade	  (75).	  
Due	  to	  Clostridium	  difficile	  flourishing	  in	  the	  gut	  when	  that	  microbiome	  has	  been	  
degraded	  by	  antibiotic	  exposure,	  the	  influence	  of	  enhancing	  the	  gut	  microbiome	  
has	  been	  an	  area	  of	  interest	  for	  clinicians.	  The	  therapeutic	  impact	  that	  probiotic	  
supplementation	  has	  on	  the	  microbiome	  has	  been	  considered	  for	  two	  different	  
treatments;	  a	  probiotic	  drink	  and	  fecal	  transplant.	  Results	  of	  a	  recent	  systematic	  
review	  showed	  that	  there	  was	  no	  convincing	  evidence	  to	  suggest	  that	  probiotic	  
drinks	  improved	  the	  gut	  microbiota	  in	  healthy	  adults	  (79),	  however	  papers	  
suggesting	  an	  improvement	  in	  Clostridium	  difficile	  susceptible	  patients	  do	  exist	  
(80-­‐82).	  Hickson	  et	  al	  reported	  a	  statistically	  significant	  finding	  from	  a	  small	  
(n=135)	  double-­‐blind,	  placebo-­‐controlled	  study.	  Participants	  who	  routinely	  drank	  a	  
probiotic	  drink	  during	  and	  after	  a	  course	  of	  antibiotics	  were	  less	  likely	  to	  suffer	  
from	  Clostridium	  difficile	  infection	  than	  their	  counterparts	  receiving	  a	  placebo	  
(83).	  Fecal	  microbiota	  transplantation	  (FMT)	  has	  recently	  become	  a	  popular	  
clinical	  intervention	  for	  the	  management	  of	  Clostridium	  difficile	  infection	  (84).	  
Infusion	  of	  donated	  fecal	  material	  can	  occur	  either	  via	  a	  duodenal	  tube	  or	  via	  
colonoscopy,	  and	  in	  2014	  a	  small	  pilot	  study	  showed	  that	  there	  is	  no	  difference	  in	  
efficacy	  according	  to	  mode	  of	  delivery	  (85).	  A	  recent	  Australian	  study	  also	  showed	  




samples	  and	  stool	  samples	  that	  have	  been	  frozen	  for	  up	  to	  six	  months	  (86).	  
Multiple	  papers	  report	  that	  fecal	  transplant	  is	  efficacious,	  especially	  for	  patients	  
suffering	  from	  recurrent	  infection,	  some	  reporting	  >90%	  efficacy	  in	  resolving	  
recurrent	  infections	  (87-­‐88).	  Given	  such	  remarkable	  results,	  there	  is	  a	  substantial	  
desire	  to	  recommend	  FMT	  become	  first-­‐line	  treatment	  for	  severe	  and	  recurrent	  
cases	  (84;	  89).	  The	  recent	  spike	  in	  interest	  both	  clinically	  and	  with	  a	  wider,	  lay	  
audience,	  has	  ensured	  that	  it	  is	  the	  most	  topical	  clinical	  intervention	  relating	  to	  
Clostridium	  difficile	  in	  the	  last	  decade.	  
The	  limitation	  of	  certain	  antimicrobial	  agents	  as	  a	  clinical	  intervention	  for	  
reducing	  Clostridium	  difficile	  has	  also	  been	  described	  in	  a	  number	  of	  papers.	  
Thomas	  et	  al	  (60)	  suggest	  that	  broad-­‐spectrum	  antibiotics	  are	  responsible	  for	  
increased	  incidence	  of	  infection	  and	  that	  all	  hospitals	  should	  modify	  prescribing	  
behaviours	  in	  order	  to	  reduce	  infection	  rates.	  Jury	  et	  al	  (90)	  report	  that	  reducing	  
inappropriate	  prescriptions	  by	  implementing	  an	  antimicrobial	  stewardship	  
programme	  for	  the	  reduction	  of	  Clostridium	  difficile	  would	  improve	  timeliness	  of	  
treatment	  and	  capacity	  to	  adhere	  to	  clinical	  guidelines.	  Valiquette	  et	  al	  (91)	  
reported	  that	  antimicrobial	  stewardship	  resulted	  in	  a	  marked	  decrease	  in	  infection	  
incidence	  during	  an	  epidemic	  period	  relating	  to	  a	  hypervirulent	  strain	  (ribotype	  
027).	  Further	  studies	  from	  Sweden	  and	  the	  USA	  have	  reviewed	  the	  impact	  that	  
stringent	  prescription	  protocols	  have	  had	  on	  prescription	  practices	  and	  whether	  




placing	  restrictions	  on	  the	  kind	  of	  antimicrobials	  that	  could	  be	  prescribed	  had	  a	  
beneficial	  impact	  on	  infection	  outcomes.	  
Clostridium	  difficile	  spores	  can	  remain	  active	  for	  many	  months	  in	  the	  hospital	  
environment	  and	  as	  such	  represent	  a	  significant	  threat	  to	  preventing	  the	  spread	  of	  
infection	  (94-­‐95).	  The	  correct	  agent	  for	  use	  in	  routine	  environmental	  cleaning	  to	  
prevent	  the	  transmission	  of	  Clostridium	  difficile	  has	  been	  the	  subject	  of	  much	  
debate.	  In	  the	  USA,	  Mayfield	  et	  al	  (96)	  reported	  that	  a	  change	  in	  environmental	  
cleaning	  protocol,	  using	  hypochlorite	  instead	  of	  ammonium,	  resulted	  in	  a	  
reduction	  of	  Clostridium	  difficile	  cases	  from	  8.6	  per	  1,000	  patient	  days	  to	  3.3	  per	  
1,000	  patient	  days.	  These	  results	  are	  supported	  by	  a	  study	  in	  the	  UK,	  where	  Wilcox	  
et	  al	  (97)	  concluded	  that	  hypochlorite	  was	  more	  efficacious	  than	  neutral	  detergent	  
in	  reducing	  Clostridium	  difficile	  infection.	  The	  choice	  of	  cleaning	  agent	  can	  impact	  
the	  persistence	  of	  Clostridium	  difficile	  spores	  in	  the	  hospital	  environment	  (97).	  
Understanding	  the	  most	  efficacious	  approach	  to	  removing	  contamination	  is	  a	  
serious	  practical	  challenge	  concerning	  infection	  control	  practitioners	  in	  all	  
jurisdictions.	  
The	  benefits	  of	  a	  strict	  hand	  hygiene	  protocol	  on	  reducing	  healthcare	  associated	  
infections	  are	  well	  known	  (98-­‐100).	  A	  meta-­‐analysis	  of	  45	  studies	  relating	  to	  the	  
effectiveness	  of	  hand	  hygiene	  on	  reducing	  healthcare	  associated	  infections	  has	  
been	  published	  in	  order	  to	  try	  and	  identify	  the	  optimal	  structure	  of	  an	  intervention	  




patients	  and	  on	  the	  hands	  of	  healthcare	  providers	  (102-­‐103)	  and	  Clostridium	  
difficile	  presents	  a	  unique	  challenge	  given	  that	  alcohol-­‐based	  hand	  rub	  has	  been	  
shown	  to	  be	  ineffective	  at	  removing	  its	  spores	  (104).	  Performing	  hand	  hygiene	  with	  
soap	  and	  water	  has	  been	  shown	  to	  be	  the	  most	  efficacious	  for	  Clostridium	  difficile	  
(105)	  and	  as	  such,	  has	  been	  recommended	  as	  the	  appropriate	  infection	  prevention	  
measure	  in	  clinical	  guidelines	  from	  North	  America,	  the	  UK	  and	  Australia	  (74-­‐75).	  
Clearly,	  the	  literature	  relating	  to	  clinical	  interventions	  for	  the	  reduction	  of	  
Clostridium	  difficile	  are	  abundant.	  The	  impact	  that	  the	  infection	  has	  on	  the	  
hospital	  and	  healthcare	  system	  from	  a	  clinical	  perspective	  is	  well	  understood.	  
However,	  confusion	  remains	  about	  how	  clinical	  interventions	  that	  are	  designed	  to	  
reduce	  transmission	  impact	  the	  healthcare	  system	  in	  an	  economic	  sense.	  
	  
Section	  2.4:	  Mathematical	  modelling	  
Mathematical	  modelling	  is	  a	  powerful	  analytical	  tool	  and	  in	  the	  case	  of	  Clostridium	  
difficile	  is	  an	  important	  addition	  to	  the	  decision-­‐making	  framework.	  A	  
mathematical	  model	  has	  the	  capacity	  to	  accurately	  describe	  and	  predict	  the	  
transmission	  route	  of	  the	  infection,	  but	  it	  must	  be	  acknowledged	  that	  models	  are	  
not	  infallible	  (106).	  Despite	  their	  fallibility,	  a	  benefit	  of	  mathematical	  models	  is	  
that	  they	  are	  flexible	  and	  can	  easily	  be	  updated	  as	  new	  clinical	  information	  
becomes	  available	  (107).	  This	  is	  especially	  useful	  in	  healthcare,	  as	  up-­‐to-­‐date	  




modelling	  is	  also	  a	  useful	  tool	  for	  understanding	  transmission	  dynamics	  because	  it	  
has	  the	  capacity	  to	  characterise	  complex	  situations,	  incorporate	  time-­‐dependent	  
events	  and	  represent	  stochastic	  processes,	  which	  are	  random	  processes	  that	  evolve	  
over	  time	  (108).	  In	  infectious	  diseases,	  there	  are	  stochastic	  processes	  related	  to	  the	  
biological	  process	  of	  transmission	  and	  the	  dynamics	  of	  infection	  at	  a	  population	  
level,	  which	  can	  make	  the	  patterns	  of	  transmission	  complex	  and	  difficult	  to	  
understand	  (109).	  However,	  using	  models	  helps	  to	  break	  down	  complex	  issues	  into	  
smaller,	  more	  easily	  understood	  problems.	  The	  resulting	  output	  from	  a	  
mathematical	  model	  can	  provide	  useful	  information	  to	  help	  make	  predictions	  
about	  a	  disease	  and	  better	  inform	  decision-­‐making	  (106).	  	  
	  
There	  have	  been	  few	  mathematical	  models	  describing	  the	  transmission	  route	  of	  
Clostridium	  difficile	  and	  of	  those	  few;	  the	  majority	  have	  overlooked	  important	  
aspects	  of	  the	  pathogen	  (110).	  Lanzas	  et	  al	  (111)	  described	  Clostridium	  difficile	  using	  
mathematical	  modelling	  but	  did	  not	  include	  symptomatic	  disease	  in	  patients	  who	  
are	  not	  prescribed	  antibiotics.	  Starr	  et	  al	  (107)	  ignored	  a	  major	  potential	  source	  of	  
infection	  by	  excluding	  asymptomatic	  carriage	  in	  their	  model.	  As	  such,	  Yakob	  et	  al	  
(110)	  developed	  a	  model	  that	  is	  a	  more	  realistic	  representation	  of	  the	  transmission	  
pathways	  related	  to	  Clostridium	  difficile	  and	  have	  described	  the	  intricacies	  related	  
to	  Clostridium	  difficile’s	  distinctive	  susceptibility-­‐infection-­‐recovery	  OR	  reinfection	  
cycle.	  It	  is	  one	  of	  the	  few	  published	  models	  that	  includes	  asymptomatic	  carriers	  




development	  of	  Clostridium	  difficile	  infection	  in	  patients	  who	  have	  not	  previously	  
been	  exposed	  to	  antibiotics.	  These	  are	  novel	  inclusions	  and	  reflect	  recent	  
epidemiological	  evidence,	  which	  suggests	  that	  the	  at-­‐risk	  populations	  include	  
more	  than	  just	  patients	  with	  recent	  exposure	  to	  antimicrobials	  (112).	  Otete	  et	  al	  
(113)	  suggest	  in	  their	  systematic	  review	  that	  mathematical	  models	  are	  relevant	  and	  
useful	  in	  the	  approach	  to	  management	  of	  Clostridium	  difficile.	  However,	  they	  note	  
that	  there	  is	  a	  paucity	  of	  rigorous	  evidence	  relating	  to	  the	  specific	  transmission	  
dynamics	  of	  Clostridium	  difficile	  and	  suggest	  that	  further	  research	  in	  this	  area	  is	  
warranted	  (113).	  It	  is	  clear	  that	  mathematical	  models	  are	  powerful	  tools	  in	  the	  
approach	  to	  infectious	  diseases.	  They	  help	  inform	  decision-­‐makers	  of	  the	  most	  
appropriate	  infection	  control	  measure	  and	  can	  be	  used	  to	  identify	  the	  target	  
population,	  in	  order	  to	  help	  determine	  how	  to	  maximise	  the	  reduction	  of	  disease	  
transmission	  (114;	  115).	  
	  
Section	  2.5:	  Economic	  burden	  of	  Clostridium	  difficile	  
Dealing	  with	  cost-­‐calculations	  in	  economic	  evaluation	  appropriately	  is	  important	  
to	  ensure	  a	  robust	  analysis	  (116).	  Many	  authors	  have	  grappled	  with	  the	  concepts	  
relating	  to	  costing	  and	  many	  have	  noted	  issues	  relating	  to	  accuracy	  (117-­‐119).	  It	  is	  
clear	  from	  the	  literature	  that	  analysts	  should	  always	  undertake	  the	  most	  precise	  
costing	  method	  available	  to	  them,	  whilst	  bearing	  in	  mind	  that	  not	  all	  methods	  are	  




that	  certain	  methods	  result	  in	  greater	  precision,	  leading	  to	  a	  potentially	  more	  
robust	  evaluation.	  	  
	  
The	  methods	  used	  to	  calculate	  costs	  vary,	  and	  the	  literature	  is	  abundant	  with	  
discussion	  about	  the	  differing	  methods	  available	  to	  economic	  analysts.	  Specifically	  
with	  Clostridium	  difficile,	  there	  have	  been	  a	  number	  of	  studies	  that	  have	  reported	  
costs	  of	  the	  infection,	  but	  the	  majority	  of	  authors	  have	  noted	  that	  the	  costs	  
included	  in	  their	  research	  are	  highly	  likely	  to	  be	  underestimations	  (17;	  31;	  122).	  
These	  underestimations	  are	  usually	  due	  to	  issues	  with	  the	  methods	  chosen	  for	  
cost-­‐calculations	  and	  the	  inherent	  problems	  with	  costing	  in	  healthcare	  such	  as	  
data	  availability,	  reliability	  and	  the	  valuation	  process	  (120).	  
	  
There	  has	  been	  confusion	  when	  the	  terms	  ‘direct’	  and	  ‘indirect’	  have	  been	  used	  to	  
describe	  different	  types	  of	  costs	  in	  economic	  evaluations	  and	  many	  new	  economic	  
evaluations	  attempt	  to	  quantify	  ‘indirect	  costs’	  in	  some	  way	  or	  another	  (16;	  123).	  
The	  confusion	  stems	  from	  the	  way	  costs	  can	  be	  described	  according	  to	  the	  
framework	  within	  which	  one	  is	  working.	  ‘Indirect’	  costs	  in	  economics	  means	  
something	  different	  to	  ‘indirect’	  costs	  in	  accounting,	  and	  it	  is	  important	  to	  
differentiate	  between	  the	  two	  approaches	  when	  evaluating	  healthcare	  
interventions	  (16).	  There	  remains	  a	  lack	  of	  agreement	  between	  authors	  about	  
consistent	  terminology	  used	  to	  describe	  costs,	  with	  many	  authors	  suggesting	  that	  




are	  measured	  in	  a	  study	  (124).	  That	  is	  to	  say	  that	  the	  definition	  of	  costs	  in	  
economic	  evaluations	  produced	  for	  the	  hospital	  or	  health	  service	  will	  differ	  when	  
compared	  with	  evaluations	  that	  are	  prepared	  with	  a	  societal	  perspective,	  where	  
non-­‐hospital	  or	  healthcare	  system	  related	  costs	  are	  included	  (125).	  In	  this	  research	  
project,	  indirect	  costs	  will	  be	  defined	  as	  costs	  that	  are	  incurred	  due	  to	  productivity	  
losses	  that	  are	  a	  result	  of	  Clostridium	  difficile.	  Examples	  of	  indirect	  costs	  include;	  
• Valuing	  lost	  time	  from	  paid	  employment	  (for	  both	  the	  patient	  and	  for	  
informal	  carers)	  
• Valuing	  changes	  in	  leisure	  time	  (for	  both	  the	  patient	  and	  informal	  carers)	  
• Effect	  on	  the	  employer’s	  productivity	  
• Non-­‐hospital	  costs	  relating	  to	  treatment	  (e.g.)	  medications,	  travel	  to	  
outpatient	  clinics	  
Productivity	  costs	  are	  generally	  accepted	  as	  being	  important	  and	  there	  is	  support	  
in	  the	  literature	  for	  their	  inclusion	  in	  economic	  evaluations	  (16;	  126).	  However,	  
there	  is	  little	  agreement	  on	  the	  best	  method	  for	  including	  them	  in	  evaluations,	  
given	  that	  theory	  and	  practical	  application	  are	  quite	  different.	  Mattke	  et	  al	  (127)	  
undertook	  a	  systematic	  review	  of	  the	  different	  methods	  available	  for	  measuring	  the	  
cost	  of	  productivity	  loss	  due	  to	  illness,	  but	  found	  there	  are	  significant	  barriers	  to	  
accurately	  ‘monetizing’	  lost	  productivity	  (127).	  Sculpher	  presents	  three	  different	  
methods	  for	  valuing	  productivity	  costs;	  the	  human	  capital	  approach;	  the	  friction	  
cost	  approach	  and	  the	  US	  Panel’s	  approach	  (sometimes	  called	  the	  Washington	  




Opponents	  of	  the	  human	  capital	  approach	  suggest	  that	  it	  is	  not	  fit	  for	  use	  in	  cost-­‐
effectiveness	  analysis	  due	  to	  the	  risk	  of	  ‘double	  counting’,	  when	  productivity	  costs	  
are	  valued	  in	  monetary	  terms	  and	  quality	  of	  life	  adjustments	  are	  valued	  in	  a	  
generic	  measure	  of	  health	  (e.g.	  the	  quality	  –adjusted	  life	  year	  [‘QALY’])	  (128-­‐129).	  
The	  argument	  against	  this	  method	  suggests	  that	  double	  counting	  exists	  because	  
putting	  a	  monetary	  value	  on	  lost	  productivity	  due	  to	  mortality	  or	  morbidity	  (by	  
calculating	  productivity	  costs)	  and	  measuring	  QALYs	  ensures	  that	  the	  same	  effect	  
is	  valued	  twice	  (16).	  Critics	  of	  the	  friction	  cost	  approach	  also	  suggest	  it	  risks	  double	  
counting	  as	  well	  as	  suggesting	  that	  it	  ignores	  fundamental	  aspects	  of	  conventional	  
microeconomic	  theory	  as	  it	  rests	  on	  substantial	  assumptions	  about	  an	  individual’s	  
valuation	  of	  leisure	  and	  the	  labour	  market	  (130).	  The	  friction	  cost	  approach	  is	  not	  
regarded	  as	  being	  ideal	  for	  cost-­‐effectiveness	  analyses	  and	  was	  primarily	  developed	  
to	  support	  cost	  of	  illness	  studies	  (131).	  The	  US	  Panel’s	  approach	  was	  developed	  by	  a	  
multidisciplinary	  group,	  tasked	  with	  producing	  guidelines	  for	  the	  cost-­‐
effectiveness	  analysis	  of	  healthcare	  interventions	  (16).	  The	  Panel	  focused	  on	  5	  
possible	  ‘productivity	  effects’	  and	  developed	  guidelines	  for	  how	  to	  value	  each	  
productivity	  effect.	  For	  example,	  lost	  work	  time	  for	  an	  individual	  due	  to	  mortality	  
or	  morbidity	  is	  valued	  through	  the	  QALY.	  The	  effect	  this	  has	  on	  an	  employer	  is	  
valued	  by	  the	  Panel	  in	  monetary	  terms.	  The	  US	  Panel’s	  approach	  shows	  two	  
different	  methods	  to	  valuing	  productivity	  losses,	  within	  the	  same	  framework.	  
However,	  the	  methods	  that	  the	  Panel	  encouraged	  for	  valuation	  have	  been	  




productivity	  costs	  highlights	  the	  contention	  among	  analysts	  about	  the	  gold	  
standard	  approach	  to	  their	  inclusion	  and	  may	  be	  a	  reason	  why	  most	  studies	  
relating	  to	  Clostridium	  difficile	  have	  made	  no	  attempt	  to	  include	  these	  costs	  in	  
their	  analysis.	  	  
There	  is	  a	  paucity	  of	  published,	  peer-­‐reviewed	  articles	  assessing	  the	  economic	  
burden	  of	  Clostridium	  difficile	  infection,	  not	  only	  in	  Australia	  but	  throughout	  the	  
rest	  of	  the	  world	  (132).	  Ghantoji	  et	  al	  (22)	  undertook	  a	  systematic	  review	  of	  papers	  
relating	  to	  the	  economic	  burden	  of	  Clostridium	  difficile,	  where	  13	  papers	  were	  
included.	  None	  of	  the	  papers	  originated	  from	  Australia,	  with	  the	  majority	  (10/13)	  
coming	  from	  the	  United	  States;	  the	  remaining	  three	  were	  from	  the	  United	  
Kingdom,	  Canada	  and	  Ireland	  (132).	  Healthcare	  costs	  were	  estimated	  for	  primary	  
and	  recurrent	  infection	  and	  were	  grouped	  together	  in	  analysis	  according	  to	  
geographical	  location.	  The	  cost	  of	  a	  primary	  infection	  was	  found	  to	  be	  lower	  in	  the	  
USA-­‐based	  studies	  when	  compared	  with	  the	  non	  USA-­‐based	  studies.	  The	  cost	  of	  
an	  episode	  of	  Clostridium	  difficile	  in	  the	  USA	  ranged	  from	  $2,871	  -­‐	  $4,846	  per	  case	  
and	  the	  cost	  of	  an	  episode	  in	  the	  UK,	  Ireland	  or	  Canada	  ranged	  from	  $5,243	  -­‐	  
$8,570	  (22).	  However,	  the	  cost	  of	  a	  recurrent	  infection	  was	  estimated	  to	  be	  cheaper	  
in	  the	  non-­‐USA	  studies	  ($13,655	  per	  case)	  compared	  with	  the	  USA-­‐based	  studies	  
($18,067	  per	  case).	  Regrettably,	  an	  accurate	  estimate	  of	  indirect	  costs	  relating	  to	  
Clostridium	  difficile	  was	  not	  provided	  in	  any	  of	  the	  papers	  and	  most	  studies	  used	  
different	  methods	  for	  estimating	  costs,	  making	  generalisability	  and	  comparison	  




Frei	  &	  Lee	  note	  that	  there	  is	  need	  for	  comparative	  and	  cost-­‐effectiveness	  studies	  of	  
new	  therapies	  relating	  to	  Clostridium	  difficile	  prevention,	  given	  the	  dearth	  of	  
available	  information	  (31).	  The	  authors	  acknowledge	  that	  further	  study	  should	  
include	  accurate	  analysis	  of	  costs	  outside	  of	  the	  hospital.	  They	  suggest	  that	  at	  a	  
minimum,	  indirect	  costs,	  lost	  opportunity	  costs	  and	  costs	  associated	  with	  
recurrence	  of	  the	  infection	  should	  be	  included	  in	  any	  cost-­‐effectiveness	  analysis	  
relating	  to	  Clostridium	  difficile.	  
Bouza	  (17)	  argues	  that	  Clostridium	  difficile	  is	  a	  costly	  infection	  and	  worthy	  of	  
further	  research,	  but	  fails	  to	  provide	  any	  useful	  economic	  analysis.	  Vonberg	  et	  al	  
conducted	  a	  matched	  case-­‐control	  study	  on	  patients	  in	  Germany	  and	  found	  that	  
Clostridium	  difficile	  infected	  patients	  were	  more	  costly	  than	  non-­‐infected	  patients,	  
however	  they	  only	  manage	  to	  estimate	  the	  in-­‐hospital	  costs	  and	  do	  not	  accurately	  
estimate	  any	  indirect	  costs	  (122).	  This	  method,	  and	  subsequent	  underestimation	  of	  
the	  true	  costs	  of	  Clostridium	  difficile,	  is	  repeated	  in	  numerous	  other	  studies	  –	  for	  
example,	  by	  Pakyz	  et	  al	  in	  a	  multi-­‐centre	  trial	  in	  the	  United	  States,	  and	  by	  Kyne	  et	  
al	  who	  do	  not	  include	  doctors’	  costs	  or	  the	  costs	  of	  posthospital	  care	  of	  Clostridium	  
difficile	  associated	  diarrhoea	  (2;	  133).	  The	  conservative	  estimation	  of	  costs	  relating	  
to	  Clostridium	  difficile	  infection	  is	  a	  common	  theme	  throughout	  the	  literature.	  
Dubberke	  et	  al	  provide	  the	  study	  that	  most	  thoroughly	  estimates	  the	  cost	  of	  
Clostridium	  difficile.	  The	  authors	  note	  that	  most	  literature	  available	  does	  not	  




studies	  are	  limited	  by	  small	  sample	  sizes	  and	  lack	  clear	  methods	  (32).	  In	  order	  to	  
more	  accurately	  measure	  total	  costs	  compared	  with	  past	  papers,	  the	  authors	  
include	  estimates	  for	  in-­‐hospital	  costs	  as	  well	  as	  indirect	  costs	  up	  to	  180	  days	  from	  
hospital	  discharge	  (32).	  However,	  the	  study	  does	  not	  include	  cost	  estimations	  for	  
outpatient	  costs	  (e.g.	  outpatient	  clinic	  visits,	  outpatient	  medication	  costs	  and	  
other	  rehabilitation),	  nor	  does	  it	  factor	  in	  costs	  related	  to	  lost	  productivity	  (e.g.	  
non-­‐attendance	  at	  work).	  The	  results	  of	  this	  study	  estimated	  that	  the	  mean	  cost	  of	  
a	  single	  Clostridium	  difficile	  infection	  is	  $6,176.	  This	  result	  was	  similar	  to	  the	  results	  
produced	  by	  Kyne	  et	  al	  (2),	  who	  estimated	  the	  cost	  of	  a	  first-­‐time	  infection	  to	  be	  
$7,000.	  
Wiegand	  et	  al	  (132)	  conducted	  a	  systematic	  review	  on	  Clostridium	  difficile	  infection	  
and	  included	  aspects	  of	  the	  infection	  other	  than	  costs,	  such	  as	  length	  of	  stay,	  
mortality	  and	  recurrence	  of	  infection.	  The	  authors	  reviewed	  69	  articles	  and	  
abstracts	  from	  hospitals	  in	  Europe	  and	  noted	  that	  only	  3	  studies	  in	  their	  review	  
included	  costing	  data.	  This	  led	  to	  the	  conclusion	  that	  despite	  a	  commonly	  held	  
assumption	  that	  Clostridium	  difficile	  infection	  is	  costly,	  a	  rigorous	  economic	  
evaluation	  is	  yet	  to	  be	  undertaken.	  In	  comparison,	  from	  their	  review	  of	  69	  articles,	  
the	  authors	  note	  that	  other	  aspects	  of	  the	  infection,	  such	  as	  mortality,	  is	  the	  major	  
focus	  of	  at	  least	  31	  articles	  (132).	  
Opportunities	  to	  build	  on	  the	  knowledge	  base	  in	  relation	  to	  the	  estimation	  and	  




specifically	  targeted	  the	  economic	  costs	  of	  Clostridium	  difficile	  infection.	  Studies	  
mentioning	  the	  economic	  effect	  of	  the	  infection	  are	  more	  prevalent	  in	  North	  
America,	  Europe	  and	  the	  UK	  when	  compared	  with	  Australia,	  however	  there	  is	  
sufficient	  opportunity	  to	  contribute	  to	  the	  literature	  worldwide.	  Apart	  from	  Riley	  
et	  al	  rough	  estimate	  of	  the	  economic	  impact	  of	  Clostridium	  difficile	  infection,	  there	  
is	  no	  published	  evidence	  or	  recommendations	  available	  to	  clinicians,	  healthcare	  
decision-­‐makers	  or	  other	  interested	  stakeholders	  focusing	  on	  the	  Australian	  
healthcare	  setting	  (241).	  Given	  that	  this	  is	  the	  case,	  there	  is	  an	  opportunity	  for	  this	  
research	  project	  to	  fill	  the	  knowledge	  gap	  and	  contribute	  in	  a	  meaningful	  way	  to	  
our	  understanding	  of	  Clostridium	  difficile.	  	  
	  
Section	  2.6:	  Cost-­‐effectiveness	  studies	  for	  interventions	  to	  reduce	  
risk	  of	  Clostridium	  difficile	  
There	  are	  few	  cost-­‐effectiveness	  studies	  evaluating	  interventions	  that	  are	  designed	  
to	  reduce	  risk	  in	  the	  academic	  literature.	  Only	  recently	  have	  studies	  assessing	  the	  
cost-­‐effectiveness	  of	  hand	  hygiene	  and	  environmental	  cleaning	  become	  available.	  
Economic	  evaluation	  of	  fecal	  transplant	  has	  only	  recently	  become	  available,	  also.	  
There	  are	  no	  cost-­‐effectiveness	  studies	  relating	  to	  antimicrobial	  stewardship	  and	  
the	  reduction	  of	  Clostridium	  difficile	  infection	  specifically.	  
In	  2012,	  Bartsch	  et	  al	  published	  a	  study	  measuring	  the	  cost-­‐effectiveness	  of	  




States	  (134).	  The	  results	  showed	  that	  this	  intervention	  was	  cost-­‐effective	  when	  
modelled	  colonisation	  rates	  and	  infection	  probabilities	  were	  under	  specific	  
thresholds.	  The	  results	  suggested	  that	  screening	  patients	  was	  a	  cost-­‐effective	  
approach	  compared	  to	  the	  status	  quo	  (not	  screening	  patients),	  but	  the	  study	  did	  
not	  compare	  this	  intervention	  with	  other,	  common	  infection	  control	  practices,	  
such	  as	  hand	  hygiene	  or	  environmental	  cleaning.	  Furthermore,	  the	  authors	  noted	  
limitations	  to	  their	  study,	  such	  as	  the	  non-­‐inclusion	  of	  intervention	  
implementation	  costs,	  not	  including	  all	  treatment	  regimens	  and	  excluding	  
complicated	  scenarios	  (e.g.	  immunosuppressed	  or	  irritable	  bowel	  syndrome	  
patients)	  (134).	  The	  non-­‐inclusion	  of	  intervention-­‐related	  costs	  is	  a	  serious	  
oversight	  and	  may	  be	  an	  important	  reason	  that	  pleasing	  economic	  outcomes	  were	  
achieved.	  However,	  such	  limitations	  could	  be	  addressed	  in	  further	  research	  with	  
improved	  or	  varied	  methods.	  In	  order	  to	  make	  the	  results	  informative	  in	  the	  
Australian	  setting,	  the	  appropriation	  of	  the	  intervention	  would	  need	  to	  take	  place	  
relating	  to	  isolation	  using	  single-­‐patient	  rooms.	  Although	  isolating	  all	  infected	  
patients	  is	  seen	  as	  a	  gold	  standard	  approach	  to	  reducing	  transmission,	  it	  is	  not	  
always	  practical	  due	  to	  hospital	  infrastructure/layout	  (135-­‐136).	  
Lee	  et	  al	  conducted	  an	  economic	  evaluation	  of	  vaccination	  for	  Clostridium	  difficile	  
infection	  in	  the	  USA	  (137).	  They	  found	  that	  a	  vaccine	  might	  be	  cost-­‐effective	  after	  
initial	  treatment	  has	  failed,	  as	  it	  might	  be	  cheaper	  than	  recurrent	  infection.	  
However,	  a	  vaccine	  does	  not	  currently	  exist	  on	  the	  market	  and	  the	  price	  of	  the	  




as	  a	  guide.	  This	  represents	  a	  significant	  potential	  to	  skew	  the	  results	  of	  their	  
analysis	  although	  a	  range	  of	  costs	  was	  explored	  in	  sensitivity	  analysis	  (137).	  The	  
vaccine	  was	  found	  to	  be	  cost-­‐effective	  in	  all	  scenarios	  when	  the	  risk	  of	  infection	  
was	  greater	  than	  15%.	  It	  was	  not	  cost-­‐effective	  for	  every	  single	  scenario	  under	  this	  
level	  of	  infection	  and	  varied	  in	  cost-­‐effectiveness	  status	  according	  to	  differing	  
values	  for	  price	  (range	  $25-­‐$100)	  and	  efficacy	  (range	  25%-­‐100%).	  Unsurprisingly,	  
when	  vaccine	  efficacy	  was	  at	  its	  highest	  (100%),	  the	  intervention	  was	  found	  to	  be	  
the	  cost-­‐effective	  more	  often	  than	  at	  any	  other	  efficacy	  level	  (137).	  Given	  that	  a	  
vaccine	  does	  not	  yet	  exist	  on	  the	  market	  and	  does	  not	  appear	  high	  on	  
manufacturer’s	  priority	  lists,	  the	  exploration	  of	  a	  vaccine	  as	  a	  realistic	  intervention	  
appears	  to	  be	  less	  worthwhile	  compared	  with	  other	  interventions	  that	  either	  
currently	  exist	  in	  infection	  control	  practice	  or	  are	  likely	  to	  be	  able	  to	  be	  
implemented	  into	  a	  hospital.	  
There	  is	  a	  lack	  of	  research	  that	  evaluates	  the	  clinical	  and	  economic	  impact	  of	  
antimicrobial	  stewardship	  as	  an	  intervention	  designed	  to	  reduce	  Clostridium	  
difficile	  infection.	  The	  shortage	  of	  literature	  in	  Australia,	  Europe,	  North	  America	  
and	  Great	  Britain	  is	  obvious.	  Nowak	  et	  al	  undertook	  a	  study	  on	  the	  clinical	  and	  
economic	  impact	  of	  an	  antimicrobial	  stewardship	  programme,	  which	  aimed	  at	  
reducing	  hospital-­‐acquired	  infections	  (138).	  Its	  focus	  was	  not	  solely	  on	  Clostridium	  
difficile	  infection	  and	  included	  other	  common	  HAIs	  –	  vancomycin-­‐resistant	  
enterococci	  (VRE)	  and	  Methicillin-­‐resistant	  Staphylococcus	  aureus	  (MRSA)	  in	  the	  




Clostridium	  difficile,	  and	  subsequently	  is	  not	  optimal	  for	  decision-­‐making	  
purposes.	  The	  results	  of	  the	  study	  should	  be	  viewed	  with	  caution,	  given	  that	  they	  
are	  difficult	  to	  generalise	  or	  apply	  to	  the	  setting	  of	  the	  work	  being	  conducted	  in	  
this	  project.	  Climo	  et	  al	  (139)	  have	  also	  undertaken	  economic	  evaluation	  of	  
antimicrobial	  stewardship	  and	  its	  impact	  on	  Clostridium	  difficile	  infection.	  The	  
study	  notes	  a	  statistically	  significant	  relationship	  between	  reduced	  use	  of	  a	  specific	  
drug	  (Clindamycin)	  and	  falling	  rates	  of	  Clostridium	  difficile	  infection,	  however	  the	  
review	  of	  costs	  and	  savings	  is	  rudimentary	  because	  the	  analysis	  only	  cites	  savings	  
from	  reduction	  in	  drug	  use	  and	  projected	  reductions	  in	  overall	  infection	  numbers.	  
The	  study	  does	  not	  look	  at	  the	  reduction	  or	  restriction	  of	  other	  commonly	  used	  
antimicrobials	  and	  does	  not	  compare	  antimicrobial	  stewardship	  to	  other	  
interventions	  that	  are	  relevant	  for	  the	  reduction	  of	  infection.	  Smith	  and	  Coast	  
(140)	  argue	  that	  issues	  relating	  to	  antimicrobial	  use/misuse	  are	  misunderstood,	  
underestimated	  and	  of	  grave	  concern	  for	  modern	  infection	  control	  practitioners.	  
They	  suggest	  that	  if	  the	  issue	  of	  antimicrobial	  resistance	  is	  not	  afforded	  more	  
research	  space	  and	  attention,	  there	  may	  be	  an	  ‘apocalyptic’	  outcome	  on	  the	  
management	  of	  hospital	  acquired	  infections.	  Antimicrobial	  stewardship	  
programmes	  are	  designed	  to	  reduce	  antimicrobial	  resistance	  and	  foster	  a	  more	  
thorough	  approach	  to	  dealing	  with	  hospital	  infections.	  The	  issues	  of	  antimicrobial	  
resistance	  and	  stewardship	  are	  vitally	  important	  and	  researchers	  encourage	  the	  
further	  exploration	  from	  an	  economic	  perspective,	  so	  that	  accurate	  forecasts	  into	  




Since	  2014,	  there	  have	  been	  three	  economic	  evaluations	  published	  that	  focus	  on	  
the	  cost-­‐effectiveness	  of	  fecal	  microbiota	  transplant	  (FMT)	  in	  different	  settings	  
(141-­‐143).	  All	  of	  these	  evaluations	  focussed	  on	  FMT	  as	  a	  treatment	  for	  recurrent	  
infections	  and	  compared	  the	  treatment	  with	  existing	  drug	  regimens.	  Merlo	  et	  al	  
(141)	  conducted	  their	  evaluation	  in	  the	  Australian	  healthcare	  setting	  and	  found	  
that	  FMT	  was	  optimal	  compared	  to	  treatment	  with	  vancomycin,	  as	  FMT	  improved	  
quality	  of	  life	  and	  reduced	  costs	  (141).	  These	  findings	  were	  valid	  regardless	  of	  the	  
method	  of	  transplantation	  (duodenal	  or	  colonoscopy)	  and	  the	  authors	  reported	  
that	  if	  FMT	  became	  standard	  clinical	  practice	  in	  Australia,	  the	  cost	  of	  treating	  
recurrent	  cases	  would	  be	  reduced	  by	  $4,000	  per	  patient.	  Konijeti	  et	  al	  (142)	  also	  
compared	  the	  cost-­‐effectiveness	  of	  FMT	  compared	  to	  drug	  treatments.	  They	  
included	  metronidazole,	  vancomycin	  and	  fidaxomicin	  in	  their	  USA-­‐based	  
evaluation.	  Fecal	  transplant	  was	  found	  to	  be	  the	  optimal	  strategy	  for	  treatment	  of	  
recurrent	  infections	  in	  all	  scenarios	  (varied	  infection	  and	  cure	  rates)	  when	  
compared	  with	  metronidazole	  and	  fidaxomicin	  and	  in	  most	  cases	  compared	  with	  
vancomycin	  (142).	  LaPointe-­‐Shaw	  et	  al	  conducted	  a	  cost-­‐effectiveness	  analysis	  of	  
FMT	  vs.	  drug	  therapy	  in	  the	  Canadian	  healthcare	  setting	  and	  found	  that	  FMT	  via	  
colonoscopy	  was	  the	  optimal	  strategy	  in	  the	  majority	  of	  scenarios	  tested	  (143).	  The	  
recent	  interest	  in	  FMT	  as	  a	  treatment	  strategy	  is	  evident	  in	  the	  number	  of	  
economic	  evaluations	  that	  have	  become	  available	  in	  the	  last	  three	  years.	  	  All	  three	  




conventional	  treatment	  approach	  for	  recurrent	  infection,	  despite	  the	  studies	  being	  
based	  in	  different	  healthcare	  settings.	  
There	  are	  a	  number	  of	  studies	  evaluating	  the	  efficacy	  of	  environmental	  cleaning	  in	  
relation	  to	  the	  reduction	  of	  hospital-­‐acquired	  infections.	  However,	  these	  papers	  do	  
not	  include	  economic	  analysis,	  with	  the	  authors	  preferring	  to	  focus	  on	  the	  
effectiveness	  of	  preventing	  infection	  with	  different	  types	  of	  cleaning	  techniques	  or	  
chemical	  solutions	  (144-­‐146).	  Nelson	  et	  al	  (147)	  conducted	  an	  economic	  evaluation	  
of	  six	  different	  interventions	  in	  the	  USA-­‐setting.	  Included	  in	  the	  evaluation	  were	  
hand	  hygiene,	  contact	  precautions	  (glove	  and	  gown),	  environmental	  cleaning,	  
aggressive	  Clostridium	  difficile	  testing	  and	  isolation	  of	  symptomatic	  patients	  (147).	  
The	  main	  aim	  of	  the	  evaluation	  was	  to	  compare	  the	  cost-­‐effectiveness	  of	  individual	  
interventions	  with	  ‘bundled’	  approaches,	  where	  all	  strategies	  were	  considered	  as	  a	  
group.	  The	  results	  of	  the	  study	  show	  that	  at	  a	  willingness-­‐to-­‐pay	  threshold	  of	  
$100,000/QALY,	  bundled	  interventions	  are	  more	  cost-­‐effective	  than	  individual	  
interventions	  (147).	  Willingness-­‐to-­‐pay	  is	  the	  amount	  of	  money	  that	  decision-­‐
makers	  are	  prepared	  to	  spend	  to	  gain	  health	  benefits,	  which	  are	  usually	  presented	  
as	  QALYs.	  
There	  is	  scope	  for	  further	  economic	  analyses	  of	  interventions	  that	  are	  relevant	  to	  
infection	  control	  practice	  in	  the	  Australian	  healthcare	  system.	  Apart	  from	  Merlo	  et	  




to	  quantify	  the	  most	  cost-­‐effective	  approach	  to	  intervening	  in	  the	  transmission	  of	  
Clostridium	  difficile	  infection.	  
	  
Section	  2.7:	  Summary	  and	  implications	  
There	  is	  little	  knowledge	  in	  Australia	  or	  indeed	  the	  rest	  of	  the	  world,	  about	  the	  
true	  cost	  of	  Clostridium	  difficile	  infection,	  from	  a	  healthcare	  perspective.	  A	  
recurrent	  theme	  in	  the	  literature	  is	  that	  the	  infection	  is	  costly,	  but	  there	  is	  no	  
agreement	  on	  how	  costly	  from	  an	  economic	  perspective,	  due	  to	  the	  lack	  of	  robust	  
research	  in	  this	  area.	  In	  addition,	  there	  is	  little	  understanding	  about	  the	  economic	  
cost	  of	  common	  healthcare	  interventions	  that	  are	  designed	  and	  implemented	  in	  
order	  to	  reduce	  the	  incidence	  or	  transmission	  of	  Clostridium	  difficile	  infection.	  
This	  lack	  of	  understanding	  has	  an	  impact	  not	  only	  at	  ward	  level,	  where	  precious	  
resources	  may	  be	  being	  wasted	  on	  ineffective	  interventions,	  but	  it	  also	  has	  an	  
impact	  on	  the	  wider	  healthcare	  setting,	  where	  an	  improved	  understanding	  of	  these	  
interventions	  can	  lead	  to	  a	  better	  investment	  in	  disease	  management	  and	  
healthcare	  priority	  setting.	  Given	  that	  there	  is	  yet	  to	  be	  any	  cost-­‐effectiveness	  
studies	  completed	  in	  Australia	  regarding	  Clostridium	  difficile,	  there	  is	  no	  
understanding	  of	  how	  the	  adoption	  of	  certain	  interventions	  changes	  total	  costs	  
and	  improves	  health	  outcomes.	  
This	  literature	  review	  has	  shown	  that	  there	  is	  scope	  for	  rigorous	  and	  




By	  modelling	  the	  effects	  of	  a	  number	  of	  different	  healthcare	  interventions	  and	  
comparing	  clinical	  and	  economic	  improvements,	  this	  research	  project	  will	  help	  to	  
improve	  understanding	  about	  the	  most	  cost-­‐effective	  approach	  to	  reducing	  




Chapter	  3:	  Cost-­‐effectiveness	  Models	  
Chapter	  Overview	  
This	  chapter	  is	  a	  description	  of	  cost-­‐effectiveness	  modelling	  and	  is	  divided	  in	  seven	  
sections.	  Section	  3.1	  is	  an	  overview	  of	  economic	  evaluation	  and	  its	  role	  in	  
healthcare.	  Section	  3.2	  is	  an	  explanation	  of	  what	  economic	  models	  are	  and	  how	  
they	  can	  be	  used	  to	  inform	  decision-­‐making.	  Sections	  3.3	  and	  3.4	  are	  descriptions	  
of	  the	  core	  aspects	  of	  economic	  evaluation.	  The	  pros	  and	  cons	  of	  different	  types	  of	  
economic	  model	  are	  weighed	  up	  in	  section	  3.5.	  Section	  3.6	  is	  a	  review	  of	  how	  
uncertainty	  should	  be	  handled	  in	  economic	  evaluations	  and	  section	  3.7	  is	  a	  
summary	  of	  the	  chapter.	  
	  
3.1	  Overview	  of	  economic	  evaluation	  	  
Resources	  for	  funding	  healthcare	  services	  are	  limited	  and	  as	  a	  result,	  healthcare	  
decision-­‐makers	  are	  becoming	  more	  interested	  in	  information	  that	  helps	  to	  answer	  
resource	  allocation	  problems.	  In	  recent	  years,	  economic	  evaluation	  has	  become	  
popular	  in	  many	  countries,	  because	  of	  its	  capacity	  to	  provide	  evidence	  that	  helps	  
inform	  comparative	  decisions,	  particularly	  about	  value	  for	  money.	  Decisions	  about	  
resource	  allocation	  happen	  regularly	  in	  healthcare	  and	  because	  public	  funding	  for	  
services	  will	  never	  meet	  demand,	  decision-­‐makers	  need	  to	  run	  efficient	  and	  lean	  
health	  programmes	  without	  overlooking	  clinical	  effectiveness.	  Economic	  




their	  service	  uses	  their	  scarce	  resources.	  It	  provides	  decision-­‐makers	  with	  evidence	  
to	  make	  good	  decisions	  when	  choosing	  between	  multiple	  approaches	  for	  service	  
delivery	  and	  it	  can	  form	  strong	  evidence	  for	  service	  providers	  who	  want	  to	  
demonstrate	  the	  benefit	  of	  their	  programme.	  Due	  to	  a	  lack	  of	  research	  in	  this	  area,	  
healthcare	  decision-­‐makers	  have	  not	  been	  able	  to	  include	  an	  economic	  perspective	  
into	  their	  decision-­‐making	  framework	  when	  deciding	  which	  interventions	  are	  
optimal	  for	  reducing	  Clostridium	  difficile	  transmission.	  	  
Different	  types	  of	  economic	  evaluation	  are	  available	  and	  they	  can	  be	  undertaken	  
prospectively	  or	  retrospectively	  (148).	  The	  most	  common	  type	  of	  evaluation	  is	  cost-­‐
effectiveness	  analysis	  although	  occasionally	  cost-­‐benefit	  analyses	  are	  undertaken.	  
The	  two	  approaches	  differ	  in	  how	  they	  handle	  and	  report	  health	  outcomes,	  given	  
that	  they	  both	  report	  costs	  in	  dollars.	  A	  cost-­‐benefit	  analysis	  requires	  health	  
outcomes	  to	  be	  valued	  in	  monetary	  terms,	  whereas	  cost-­‐effectiveness	  analysis	  
represents	  health	  outcomes	  in	  a	  natural	  unit	  such	  as	  life	  years	  saved	  or	  QALYs	  
gained.	  Their	  appropriateness	  is	  dependent	  on	  the	  decision	  problem	  that	  is	  being	  
answered	  (105).	  In	  Australia	  it	  is	  common	  for	  decision-­‐makers	  to	  be	  interested	  in	  
health	  outcomes	  that	  are	  measured	  in	  QALYs	  gained,	  making	  a	  cost-­‐effectiveness	  
analysis	  more	  appropriate	  than	  a	  cost-­‐benefit	  analysis	  for	  this	  study	  (149).	  
	  
3.2	  Decision	  models	  	  
Given	  the	  increased	  acceptance	  of	  economic	  evaluation	  in	  the	  healthcare	  decision-­‐




Decision	  analytic	  modelling	  is	  an	  explicit	  quantitative	  approach	  to	  decision-­‐
making	  under	  uncertainty	  (16).	  The	  results	  of	  decision	  analytic	  models	  provide	  
healthcare	  decision-­‐makers	  with	  a	  guide	  to	  health	  resource	  allocation	  by	  
considering	  both	  costs	  and	  patient	  outcomes.	  Decision	  models	  are	  of	  value	  because	  
they	  should	  encourage	  decision-­‐makers	  to	  be	  explicit;	  they	  can	  combine	  evidence	  
from	  multiple	  sources	  and	  should	  be	  based	  on	  the	  best	  available	  evidence.	  Unlike	  
randomised	  controlled	  trials	  (RCTs),	  they	  enable	  extrapolation	  beyond	  observed	  
data	  and	  can	  compare	  multiple	  healthcare	  interventions	  at	  once,	  with	  uncertainty,	  
which	  is	  a	  significant	  advantage	  for	  decision-­‐makers	  who	  seek	  to	  make	  decisions	  
about	  differing	  approaches.	  The	  process	  used	  to	  develop,	  populate	  and	  analyse	  the	  
results	  of	  the	  model	  should	  always	  be	  transparent,	  reproducible	  and	  adhere	  to	  
good	  practice	  guidelines	  (16).	  The	  approach	  taken	  to	  developing	  the	  model	  used	  in	  
this	  project	  is	  described	  in	  detail	  in	  section	  4.3	  of	  the	  Methods	  chapter.	  
	  
3.3	  Essential	  aspects	  of	  economic	  evaluation	  	  
Perspective	  
The	  perspective	  of	  an	  economic	  evaluation	  should	  be	  determined	  before	  data	  
collection	  takes	  place,	  because	  it	  has	  an	  impact	  on	  which	  data	  are	  collected	  and	  
how	  it	  is	  collected	  (150).	  Commonly,	  studies	  can	  be	  from	  an	  institutional	  
perspective	  (single-­‐hospital	  perspective),	  a	  healthcare	  payer’s	  perspective	  (private	  
insurers	  perspective),	  a	  healthcare	  system	  perspective	  (system-­‐wide	  perspective),	  




consequences	  of	  an	  intervention	  are	  appraised	  varies	  according	  to	  the	  perspective	  
of	  the	  evaluation.	  For	  example,	  a	  societal	  perspective	  attempts	  to	  estimate	  the	  
broader	  costs	  to	  society	  –	  productivity	  losses	  that	  are	  a	  result	  of	  poor	  health	  –	  such	  
as	  family	  costs	  and	  costs	  to	  other	  sectors	  outside	  of	  health,	  such	  as	  the	  welfare	  
system	  (151).	  Approaching	  an	  evaluation	  from	  the	  healthcare	  system	  perspective,	  
direct	  medical	  costs	  and	  other	  costs	  incurred	  by	  the	  system	  to	  treat	  people	  with	  ill-­‐
health	  are	  the	  priority.	  There	  is	  no	  ‘correct’	  perspective	  to	  take	  for	  an	  evaluation	  
and	  it	  is	  noted	  that	  there	  is	  a	  lack	  of	  standardised	  definitions,	  leaving	  evaluations	  
open	  to	  some	  crossover	  or	  mixing	  of	  approach.	  However,	  by	  acknowledging	  the	  
perspective	  applied	  to	  an	  evaluation	  and	  the	  impact	  that	  this	  approach	  may	  have	  
on	  final	  results,	  the	  study	  preserves	  its	  transparency.	  This	  study	  aims	  to	  update	  
public	  health	  policy	  and	  to	  provide	  new	  evidence	  to	  inform	  infection	  control	  and	  
prevention	  practice,	  so	  a	  healthcare	  system	  or	  societal	  perspective	  for	  the	  
evaluation	  is	  most	  appropriate.	  	  
Target	  population	  and	  subgroups	  
Because	  cost-­‐effectiveness	  outcomes	  can	  be	  varied	  according	  to	  population-­‐
specific	  characteristics	  like	  age,	  gender	  and	  health	  status,	  it	  is	  vital	  to	  define	  the	  
target	  population	  of	  the	  study.	  The	  literature	  from	  which	  effectiveness	  estimates	  
are	  taken	  from	  to	  inform	  an	  evaluation	  is	  the	  recommended	  place	  to	  start	  for	  
baseline	  population	  characteristics.	  It	  has	  been	  widely	  reported	  that	  subgroup	  
analysis	  is	  often	  poorly	  conducted	  and	  reported	  (152-­‐153),	  however	  it	  is	  this	  analysis	  




detailed	  information.	  For	  example,	  comparison	  of	  cost-­‐effectiveness	  between	  
specific	  age	  groups	  or	  between	  patients	  with	  or	  without	  a	  chronic	  disease	  can	  
provide	  pragmatic	  information	  for	  decision-­‐makers,	  where	  there	  are	  practical	  
implications	  of	  a	  decision	  (151).	  
Setting	  &	  location	  
Economic	  evaluations	  should	  address	  questions	  that	  are	  pertinent	  to	  the	  location	  
and	  health	  system	  in	  which	  the	  decision	  about	  resource	  allocation	  is	  taking	  place	  
(151).	  Without	  a	  clear	  set	  of	  questions	  to	  be	  answered,	  the	  purpose	  and	  output	  of	  
any	  decision	  model	  is	  imprecise.	  Information	  relating	  to	  the	  geographical	  location	  
(i.e.	  country,	  group	  of	  countries)	  and	  the	  setting	  of	  the	  healthcare	  system	  (i.e.	  
hospital-­‐based,	  community-­‐care	  or	  primary	  care)	  where	  an	  evaluation	  has	  taken	  
place	  is	  vital.	  A	  detailed	  description	  of	  the	  location	  and	  setting	  of	  the	  evaluation	  
makes	  it	  more	  obvious	  for	  readers	  outside	  of	  that	  specific	  setting	  to	  determine	  if	  
the	  results	  are	  generalisable	  to	  their	  locale.	  Understanding	  the	  relevance	  of	  results	  
in	  one	  setting	  and	  their	  transferability	  to	  another	  has	  implications	  for	  a	  decision-­‐
maker	  who	  wishes	  to	  make	  use	  of	  an	  evaluation	  that	  has	  been	  conducted	  on	  a	  
clinical	  problem	  of	  interest,	  but	  in	  a	  different	  setting	  to	  their	  own	  (16).	  An	  
objective	  of	  this	  study	  is	  to	  provide	  Australian	  decision-­‐makers	  with	  evidence	  that	  
has	  been	  derived	  from	  the	  Australian	  setting.	  The	  data	  used	  to	  inform	  the	  results	  
comes	  from	  the	  same	  jurisdictions	  that	  will	  benefit	  from	  the	  new	  evidence,	  
removing	  any	  need	  to	  extrapolate	  or	  generalise	  findings	  from	  research	  conducted	  




Identify	  and	  synthesise	  the	  evidence	  
Decision	  models	  utilise	  numerous	  types	  of	  evidence,	  from	  multiple	  sources	  that	  
vary	  in	  quality.	  Identification	  of	  the	  evidence	  that	  will	  be	  included	  in	  any	  model	  
requires	  careful	  planning	  and	  thorough	  follow	  up.	  There	  are	  well-­‐documented	  
methods	  for	  the	  identification	  of	  data	  sources	  and	  there	  are	  agreed	  methods	  for	  
assessing	  the	  quality	  of	  evidence	  that	  has	  been	  collected	  (16).	  Hierarchies	  of	  data	  
sources	  vary	  according	  to	  the	  information	  required	  –	  whether	  it	  be	  clinical	  data,	  
resource	  use,	  health	  utilities	  or	  cost	  information	  (154).	  It	  is	  not	  uncommon	  for	  
single	  model	  parameters	  to	  be	  informed	  by	  multiple	  sources	  of	  evidence	  and	  
model	  inputs	  should	  be	  based	  on	  systematic	  searches	  when	  using	  current	  
literature	  to	  furnish	  the	  model.	  Given	  that	  each	  model	  parameter	  is	  likely	  to	  have	  
slightly	  different	  requirements,	  it	  is	  common	  for	  a	  decision	  model	  to	  be	  informed	  
by	  different	  evidence	  sources,	  which	  represent	  different	  strata	  on	  a	  hierarchical	  
scale.	  For	  example,	  data	  relating	  to	  cost	  and	  resource	  use	  might	  be	  best	  sourced	  
from	  an	  expert	  at	  the	  local	  level	  as	  it	  may	  be	  more	  accurate	  or	  applicable	  to	  the	  
setting	  of	  the	  evaluation	  than	  using	  data	  from	  a	  clinical	  trial	  in	  another	  
jurisdiction.	  To	  estimate	  health-­‐state	  transition	  probabilities	  it	  is	  likely	  to	  be	  
preferential	  to	  use	  appropriate	  clinical	  data	  from	  the	  setting	  of	  interest	  if	  it	  is	  
available,	  than	  relying	  on	  a	  summary	  of	  evidence	  from	  a	  systematic	  review.	  It	  is	  
paramount	  that	  the	  evidence	  that	  is	  included	  in	  a	  decision	  model	  is	  of	  the	  best	  
standard	  available	  and	  in	  order	  to	  maintain	  objectivity	  the	  evidence	  that	  is	  






Economic	  evaluations	  in	  healthcare	  should	  serve	  to	  inform	  decision-­‐making	  by	  
providing	  pragmatic	  and	  novel	  information.	  A	  significant	  advantage	  that	  a	  model-­‐
based	  economic	  evaluation	  has	  over	  a	  trial-­‐based	  evaluation	  is	  that	  it	  can	  
simultaneously	  compare	  a	  number	  of	  different	  healthcare	  interventions,	  as	  if	  they	  
are	  in	  direct	  competition	  with	  one	  another.	  Economic	  models	  also	  have	  the	  
capacity	  to	  be	  changed	  and	  added	  to,	  over	  time,	  if	  new	  interventions	  that	  are	  
worthy	  of	  review	  come	  into	  practice.	  A	  description	  of	  the	  comparators	  that	  are	  
included	  in	  an	  economic	  evaluation	  makes	  it	  clear	  to	  readers	  exactly	  what	  has	  
been	  included	  and	  what	  has	  not	  been	  included	  for	  comparison.	  If	  certain	  
comparators	  were	  excluded	  from	  the	  evaluation,	  a	  list	  of	  reasons	  explaining	  why	  
this	  was	  the	  case	  gives	  decision-­‐makers	  a	  clear	  context	  for	  how	  the	  assessment	  
took	  place	  and	  how	  this	  might	  impact	  their	  judgments.	  
Health	  outcomes	  
The	  choice	  of	  health	  outcome	  that	  is	  used	  in	  an	  evaluation	  is	  dependent	  upon	  the	  
type	  of	  evaluation	  that	  is	  being	  undertaken.	  When	  undertaking	  a	  cost-­‐benefit	  
analysis,	  health	  outcomes	  are	  required	  to	  be	  expressed	  in	  monetary	  terms	  (151)	  but	  
this	  approach	  has	  been	  criticised	  as	  being	  inappropriate	  and	  outdated	  (156).	  The	  
theory	  underpinning	  cost-­‐benefit	  analysis	  (welfarist	  economics)	  was	  developed	  
more	  than	  a	  century	  ago	  and	  assumes	  that	  individual	  responses	  to	  stated	  




This	  view	  has	  been	  vigorously	  challenged	  in	  recent	  decades,	  with	  economists,	  
healthcare	  payers	  and	  healthcare	  decision-­‐makers	  all	  showing	  a	  preference	  for	  
cost-­‐effectiveness	  analyses	  (157).	  This	  approach	  to	  analysis	  requires	  health	  
outcomes	  to	  be	  measured	  and	  expressed	  in	  natural	  units	  by	  using	  quality-­‐adjusted	  
life	  years	  (QALYs).	  
Costs	  	  
The	  source	  of	  information	  relating	  to	  resources	  used	  and	  costs	  incurred	  for	  
inclusion	  in	  the	  economic	  evaluation	  need	  to	  be	  clearly	  stated	  and	  are	  usually	  
derived	  from	  a	  number	  of	  different	  sources.	  A	  description	  of	  these	  sources	  
provides	  transparency	  to	  the	  evaluation	  and	  allows	  the	  method	  of	  data	  collection	  
to	  be	  verified,	  critiqued	  and	  repeated.	  The	  level	  of	  detail	  in	  the	  collection	  of	  costs	  
is	  important	  to	  note	  –	  for	  example,	  if	  tax	  is	  included	  in	  the	  final	  price	  or	  whether	  a	  
bulk	  purchase	  discount	  has	  been	  applied.	  Equally,	  any	  costs	  that	  have	  been	  
excluded,	  as	  well	  as	  the	  reasons	  for	  their	  exclusion,	  should	  be	  clearly	  stated.	  As	  
previously	  mentioned,	  the	  perspective	  of	  the	  economic	  evaluation	  dictates	  the	  
approach	  to	  estimating	  resources	  used	  and	  costs	  incurred.	  Availability	  of	  cost	  
information	  is	  also	  a	  known	  obstacle	  that	  may	  need	  to	  be	  reported	  as	  a	  limitation	  
in	  an	  evaluation.	  It	  is	  not	  uncommon	  for	  private	  companies	  to	  be	  unwilling	  to	  
share	  ‘confidential’	  cost	  information	  with	  anyone	  outside	  of	  their	  own	  enterprise.	  	  
Economic	  costs	  reflect	  opportunity	  costs	  of	  resources	  used,	  and	  whilst	  more	  
difficult	  to	  obtain	  are	  more	  appropriate	  for	  decision-­‐making	  and	  resource	  




interventions	  and	  will	  differentiate	  this	  research	  from	  other	  attempts	  to	  address	  
the	  cost	  of	  Clostridium	  difficile	  infection.	  
Measurement	  of	  intervention	  effectiveness	  
The	  measurement	  of	  the	  clinical	  efficacy	  of	  healthcare	  interventions	  is	  a	  
cornerstone	  of	  economic	  evaluations.	  The	  approach	  to	  measurement	  and	  
incorporation	  in	  an	  evaluation	  can	  differ	  if	  the	  study	  is	  based	  on	  a	  single	  study	  or	  
on	  multiple	  studies.	  If	  a	  single	  study	  has	  been	  used	  to	  inform	  all	  effectiveness	  
parameters,	  sufficient	  justification	  should	  be	  presented	  to	  the	  reader.	  In	  order	  to	  
maintain	  a	  transparent	  and	  sound	  approach	  to	  the	  evaluation,	  details	  regarding	  
the	  strategy	  to	  search	  and	  select	  evidence,	  methods	  for	  dealing	  with	  bias	  and	  
generalisability	  must	  be	  included	  so	  that	  comment	  and	  critique	  can	  be	  applied	  by	  
those	  who	  are	  interested	  in	  doing	  so	  (151).	  
Assumptions	  
A	  clear	  description	  of	  the	  assumptions	  that	  underpin	  the	  decision	  model	  is	  vital	  to	  
ensure	  good	  practice	  is	  maintained.	  Assumptions	  can	  come	  in	  many	  forms	  and	  
impact	  a	  number	  of	  different	  parameters	  in	  various	  ways.	  Information	  about	  the	  
assumptions	  relating	  to	  characteristics	  of	  the	  modelled	  population,	  structure	  of	  the	  
model	  and	  the	  choice	  of	  comparators	  for	  analysis	  should	  be	  listed	  in	  detail	  to	  







3.4	  Other	  considerations	  for	  an	  evaluation	  
Time	  horizon	  
Time	  horizon	  refers	  to	  the	  length	  of	  time	  that	  costs	  and	  health	  outcomes	  are	  being	  
estimated	  (151).	  The	  appropriate	  timeframe	  for	  an	  evaluation	  should	  be	  long	  
enough	  to	  capture	  in	  full	  the	  differences	  in	  resource	  use,	  costs	  and	  benefits	  of	  the	  
interventions	  that	  are	  being	  appraised	  (155).	  The	  economic	  time	  horizon	  does	  not	  
always	  match	  up	  with	  the	  clinical	  time	  horizon,	  which	  by	  definition	  is	  the	  period	  
of	  time	  between	  when	  a	  patient	  presents	  with	  the	  diagnosis	  of	  a	  clinical	  condition	  
and	  concludes	  when	  such	  a	  condition	  has	  been	  resolved	  (158).	  The	  economic	  time	  
horizon	  refers	  to	  the	  period	  of	  time	  that	  costs	  return	  to	  the	  level	  that	  previously	  
existed,	  when	  the	  clinical	  condition	  was	  not	  present	  (159).	  
Discounting	  
There	  is	  consensus	  among	  economists	  that	  costs	  and	  benefits	  that	  occur	  at	  
different	  times	  should	  not	  be	  treated	  equally	  and	  that	  they	  should	  be	  weighted	  
according	  to	  some	  measure	  (160).	  Resources	  that	  are	  not	  spent	  today	  can	  be	  
invested	  at	  a	  real	  rate	  of	  return,	  so	  there	  is	  an	  opportunity	  cost	  of	  incurring	  them	  
now.	  There	  is	  also	  a	  preference	  for	  incurring	  costs	  in	  the	  future,	  rather	  than	  
straight	  away,	  so	  to	  account	  for	  time	  preference	  and	  opportunity	  cost,	  a	  discount	  
rate	  is	  applied	  (155).	  According	  to	  the	  Pharmaceutical	  Benefits	  Advisory	  
Committee	  (PBAC)	  guidelines	  for	  economic	  evaluations	  in	  Australia,	  future	  costs	  




common	  practice	  for	  evaluations	  that	  have	  a	  time	  horizon	  of	  less	  than	  1	  year	  to	  not	  
apply	  any	  discounting	  to	  costs	  or	  benefits	  (151).	  	  
Currency,	  price	  date	  and	  conversion	  
During	  the	  course	  of	  collecting	  data	  for	  economic	  evaluations,	  not	  all	  costs	  are	  
collected	  in	  the	  same	  year	  or	  some	  costs	  that	  have	  been	  used	  for	  certain	  
parameters	  have	  been	  collected	  from	  a	  different	  time	  to	  others.	  As	  such,	  it	  is	  
important	  that	  some	  form	  of	  adjustment	  is	  made	  to	  the	  price	  that	  is	  used	  in	  the	  
evaluation	  to	  ensure	  that	  the	  costs	  are	  calculated	  from	  the	  same	  year	  (151).	  Further,	  
some	  evaluations	  rely	  on	  cost	  information	  that	  is	  from	  outside	  the	  jurisdiction	  that	  
is	  under	  review	  and	  as	  such,	  should	  be	  converted	  to	  the	  appropriate	  currency.	  
When	  currency	  conversion	  takes	  place,	  the	  method	  for	  conversion	  should	  be	  
clearly	  stated	  and	  justified.	  
3.5	  Choice	  of	  model	  type	  
A	  number	  of	  different	  types	  of	  decision	  models	  are	  available	  for	  use	  in	  economic	  
evaluations,	  including	  Markov	  models,	  decision	  trees	  and	  discrete	  event	  
simulation.	  The	  most	  appropriate	  choice	  of	  model	  is	  based	  on	  a	  variety	  of	  factors,	  
including	  the	  decision	  problem	  that	  is	  being	  addressed,	  natural	  history	  of	  the	  
disease	  under	  review	  and	  the	  type	  of	  evidence	  available	  to	  be	  included	  (162).	  
Markov	  models	  are	  particularly	  suitable	  for	  evaluations	  of	  chronic	  or	  recurrent	  
conditions	  as	  they	  are	  able	  to	  simultaneously	  handle	  information	  about	  both	  costs	  
and	  health	  outcomes	  that	  may	  occur	  over	  a	  long	  period	  of	  time	  (91;	  155).	  This	  is	  




for	  patients	  to	  suffer	  recurrences	  of	  infection.	  A	  Markov	  model	  requires	  the	  disease	  
under	  review	  to	  be	  broken	  down	  into	  a	  number	  of	  mutually	  exclusive	  ‘states’,	  
which	  represent	  the	  health	  states	  of	  the	  simulated	  cohort	  according	  to	  their	  
disease	  progression.	  Patients	  are	  in	  finite	  health	  states	  for	  a	  specified	  period	  of	  
time	  (‘cycle(s)’)	  and	  are	  ‘cycled’	  through	  the	  model	  according	  to	  defined	  transition	  
probabilities.	  A	  further	  feature	  of	  Markov	  models	  is	  that	  no	  patient	  leaves	  the	  
model	  and	  all	  patients	  eventually	  end	  up	  in	  one	  of	  the	  ‘absorbing	  states’,	  generally	  
death.	  Costs	  and	  health	  utilities	  are	  attached	  to	  each	  health	  state	  and	  are	  used	  to	  
determine	  cost-­‐effectiveness	  during	  analysis.	  A	  basic	  example	  of	  a	  Markov	  model	  
can	  be	  seen	  in	  Figure	  2.	  









In	  this	  example,	  a	  cohort	  of	  people	  starts	  in	  the	  ‘asymptomatic	  disease’	  state	  and	  
has	  three	  options	  for	  movement	  around	  the	  model	  –	  remain	  in	  the	  ‘asymptomatic’	  
state,	  move	  into	  the	  second	  state,	  ‘progressive	  disease’,	  or	  to	  the	  third	  state,	  ‘dead’.	  
The	  rate	  of	  movement	  from	  state	  to	  state	  within	  the	  model	  is	  known	  as	  a	  transition	  
probability.	  Transition	  probabilities	  govern	  how	  the	  simulated	  cohort	  of	  patients	  
moves	  through	  the	  model’s	  health	  states	  and	  take	  place	  with	  every	  cycle	  of	  the	  
model.	  Cycle	  length	  is	  determined	  by	  how	  often	  events	  that	  incur	  costs	  or	  alter	  
health	  outcomes	  occur,	  and	  can	  range	  from	  days	  to	  a	  patient’s	  lifetime.	  The	  
probability	  of	  leaving	  or	  remaining	  in	  a	  state	  must	  always	  sum	  to	  one	  in	  each	  cycle	  
and	  transition	  probabilities	  can	  be	  seen	  in	  the	  example	  matrix	  below.	  
	  
Table	  1:	  Transition	  matrix	  showing	  the	  probability	  of	  moving	  through	  health	  states	  
Health	  State	   Asymptomatic	   Progressive	   Dead	   Total	  
Asymptomatic	   0.85	   0.05	   0.1	   1	  
Progressive	   0	   0.6	   0.4	   1	  
Dead	   0	   0	   1	   1	  
	  
The	  table	  shows	  the	  probability	  of	  moving	  from	  state	  to	  state	  in	  the	  model.	  It	  can	  
be	  seen	  that	  the	  probability	  of	  moving	  from	  the	  asymptomatic	  state	  to	  the	  
progressive	  disease	  state	  is	  5%	  (0.05)	  and	  that	  there	  is	  an	  85%	  probability	  of	  
remaining	  in	  the	  asymptomatic	  state	  (0.85).	  As	  indicated,	  moving	  from	  the	  dead	  




state.	  The	  cohort	  of	  patients	  will	  usually	  be	  cycled	  through	  the	  model	  until	  all	  of	  
them	  are	  in	  the	  absorbing	  state	  of	  death.	  Some	  models	  have	  multiple	  absorbing	  
states	  and	  the	  rule	  for	  stopping	  the	  model	  cycles	  remains	  in	  the	  hands	  of	  the	  
analyst.	  
3.6	  Handling	  uncertainty	  
Uncertainty	  in	  economic	  evaluation	  is	  inescapable	  and	  takes	  a	  variety	  of	  different	  
forms	  -­‐	  these	  include	  uncertainty	  relating	  to	  methodology,	  parameters,	  modelling	  
and	  with	  the	  generalisability	  or	  transferability	  of	  results	  (16).	  Utilising	  an	  agreed	  
method	  of	  conducting	  an	  evaluation	  can	  reduce	  methodological	  uncertainty.	  This	  
gives	  structure	  and	  repeatability	  to	  the	  evaluation	  and	  encourages	  transparency,	  
which	  are	  equally	  important	  components	  of	  a	  good	  evaluation.	  In	  this	  research,	  a	  
structured	  approach	  to	  building	  and	  operating	  the	  economic	  model	  has	  been	  
followed,	  and	  has	  been	  explained	  in	  detail	  in	  section	  4.3	  of	  the	  methods	  chapter.	  
The	  structured	  approach	  has	  been	  validated	  through	  publication	  and	  thus,	  has	  
been	  accepted	  as	  an	  example	  of	  good	  practice.	  
	  
Uncertainty	  relating	  to	  the	  generalisability	  and	  transferability	  of	  results	  relates	  to	  
the	  ease	  and	  accuracy	  with	  which	  results	  can	  be	  transferred	  to	  another	  setting.	  The	  
model	  used	  in	  this	  project	  has	  used	  Australian	  data	  and	  is	  most	  relevant	  to	  the	  
Australian	  healthcare	  setting.	  However,	  despite	  this,	  the	  results	  of	  the	  project	  can	  
be	  generalised,	  with	  some	  degree	  of	  caution,	  to	  other	  countries	  that	  share	  




healthcare’	  approach	  to	  funding	  and	  that	  have	  similar	  demographic	  profiles	  to	  
Australia	  would	  be	  the	  most	  appropriate	  to	  attempt	  to	  generalise	  and	  transfer	  
results	  to.	  In	  addition,	  countries	  with	  similar	  rates	  of	  Clostridium	  difficile	  incidence	  
and	  a	  similar	  approach	  to	  preventing	  the	  infection	  as	  Australia	  would	  be	  more	  
amenable	  to	  generalisation	  than	  those	  that	  differ	  substantially.	  	  
	  
All	  models	  require	  the	  synthesis	  of	  data	  from	  numerous	  sources	  in	  order	  to	  be	  
structured	  and	  fit	  for	  analysis	  (164).	  Seeking	  advice	  from	  a	  wide	  range	  of	  experts	  
ensures	  that	  the	  parameters	  included	  in	  a	  model	  have	  been	  subject	  to	  much	  
scrutiny	  prior	  to	  analysis	  and	  an	  appraisal	  of	  modelling	  uncertainty	  has	  been	  
performed.	  
	  
Parameter	  uncertainty	  is	  addressed	  by	  applying	  probabilistic	  sensitivity	  analysis	  
(PSA),	  as	  is	  recommended	  in	  the	  literature	  (16;	  165).	  Statistical	  distributions	  are	  
applied	  to	  each	  parameter	  in	  the	  model	  to	  reflect	  the	  uncertainty	  in	  the	  data	  used	  
to	  inform	  that	  parameter.	  Monte	  Carlo	  simulation	  methods,	  where	  a	  random	  draw	  
from	  anywhere	  in	  each	  parameter’s	  distribution	  will	  be	  used	  to	  represent	  the	  
parameter	  uncertainty	  and	  provide	  a	  range	  of	  estimated	  results	  for	  use	  in	  the	  final	  
analysis.	  Many	  draws,	  or	  ‘simulations’	  of	  the	  model	  are	  required	  to	  provide	  a	  range	  





Although	  decisions	  should	  be	  based	  on	  current	  and	  up-­‐to-­‐date	  information,	  there	  
will	  always	  be	  an	  element	  of	  uncertainty	  in	  any	  healthcare	  decision.	  Analysing	  the	  
expected	  value	  of	  perfect	  information	  (EVPI)	  relating	  to	  the	  decision	  problem	  can	  
indicate	  whether	  further	  research	  is	  potentially	  worthwhile	  (166).	  Perfect	  
information,	  if	  it	  were	  available,	  would	  eliminate	  the	  possibility	  of	  making	  the	  
wrong	  decision	  and	  places	  an	  upper	  bound	  on	  the	  expected	  returns	  to	  further	  
research	  (166).	  The	  value	  of	  extra	  information	  differs	  according	  to	  the	  
circumstances	  that	  relate	  to	  the	  decision	  problem	  –	  the	  healthcare	  system,	  patient	  
case-­‐mix	  and	  different	  decision-­‐making	  thresholds	  ($/QALY),	  all	  have	  an	  impact.	  
Estimating	  the	  value	  of	  further	  research	  is	  valuable	  for	  decision-­‐makers	  as	  it	  is	  
calculated	  with	  specific	  patient	  populations	  in	  mind.	  The	  EVPI	  should	  be	  
presented	  not	  only	  at	  an	  individual	  level	  (e.g.)	  per	  infection,	  but	  also	  according	  to	  
the	  size	  of	  the	  potential	  patient	  population	  that	  could	  benefit	  from	  additional	  
research.	  
	  
Expected	  value	  of	  perfect	  information	  can	  also	  be	  estimated	  for	  parameters	  and	  is	  
known	  as	  EVPPI	  (167).	  Expected	  value	  of	  perfect	  parameter	  information	  combines	  
the	  ‘importance’	  of	  a	  parameter	  and	  the	  uncertainty	  that	  relates	  to	  it,	  in	  the	  
decision	  model	  (168).	  Reducing	  uncertainty	  related	  to	  specific	  parameters	  should	  
be	  pursued	  in	  order	  to	  narrow	  the	  research	  focus	  and	  direct	  future	  research	  
studies,	  focusing	  on	  collecting	  evidence	  that	  would	  be	  of	  greatest	  value	  (169).	  From	  




similarity,	  e.g.)	  all	  cost	  parameters	  grouped	  together,	  or	  can	  be	  analysed	  on	  their	  
own,	  e.g.)	  diagnosis	  costs,	  treatment	  costs	  and	  bed-­‐day	  costs	  analysed	  by	  
themselves.	  The	  results	  of	  the	  value	  of	  perfect	  information	  analysis	  are	  shown	  in	  
the	  results	  chapter	  (section	  5.1.5).	  	  
3.7	  Summary	  of	  the	  chapter	  
This	  chapter	  has	  given	  an	  overview	  of	  the	  methods	  used	  to	  conduct	  an	  economic	  
evaluation	  and	  has	  discussed	  why	  such	  evaluation	  is	  a	  vital	  tool	  for	  decision-­‐
makers	  who	  are	  in	  charge	  of	  allocating	  scarce	  healthcare	  resources.	  An	  explanation	  
of	  how	  decision	  models	  can	  be	  used	  to	  contribute	  to	  the	  body	  of	  evidence	  that	  
decision-­‐makers	  need	  to	  make	  explicit	  choices	  has	  been	  provided.	  A	  detailed	  
overview	  of	  good	  modelling	  practice	  and	  the	  essential	  components	  of	  a	  modelling	  
study	  have	  been	  explained	  in	  detail.	  The	  role	  of	  uncertainty	  in	  decision-­‐making	  
and	  how	  best	  to	  deal	  with	  it	  from	  a	  theoretical	  viewpoint	  has	  also	  been	  discussed	  
in	  detail.	  Economic	  evidence	  is	  required	  for	  infection	  control	  decision-­‐makers	  to	  
ensure	  that	  they	  can	  appropriately	  assess	  their	  approach	  to	  the	  management	  of	  
Clostridium	  difficile	  infection.	  Without	  it	  there	  is	  little	  evidence	  to	  support	  the	  




Chapter	  4:	  Methods	  
Chapter	  Overview	  
This	  chapter	  is	  a	  description	  of	  the	  methods	  that	  underpin	  this	  research	  project.	  
The	  chapter	  is	  divided	  into	  five	  sections.	  Section	  4.1	  is	  an	  overview	  of	  the	  objectives	  
of	  the	  research	  project.	  Section	  4.2	  is	  a	  detailed	  review	  of	  the	  methods	  used	  to	  
select	  the	  interventions	  for	  inclusion	  in	  the	  evaluation.	  It	  also	  includes	  a	  
description	  of	  the	  interventions	  that	  are	  included.	  The	  methods	  used	  to	  develop	  
the	  economic	  model	  are	  described	  in	  detail	  in	  section	  4.3	  of	  the	  chapter.	  The	  
methods	  used	  to	  ascertain	  intervention	  related	  costs	  are	  described	  in	  section	  4.4.1	  
and	  the	  methods	  used	  to	  ascertain	  infection	  related	  costs	  are	  described	  in	  section	  
4.4.2.	  Section	  4.5	  is	  a	  summary	  of	  the	  chapter.	  
	  
4.1	  Objectives	  	  
The	  aim	  of	  this	  research	  is	  to	  inform	  infection	  control	  policy	  in	  hospitals,	  relating	  
to	  the	  management	  of	  Clostridium	  difficile.	  This	  research	  project	  focuses	  on	  
evaluating	  the	  cost	  effectiveness	  of	  a	  number	  of	  healthcare	  interventions	  that	  are	  
designed	  to	  reduce	  the	  rate	  of	  Clostridium	  difficile	  infection	  in	  hospitals.	  The	  
design	  of	  the	  project	  is	  such	  that	  the	  following	  research	  questions	  can	  be	  
addressed:	  
1. What	  interventions	  are	  relevant	  to	  reduce	  Clostridium	  difficile	  infection	  and	  




2. What	  is	  the	  most	  cost-­‐effective	  approach	  to	  managing	  Clostridium	  difficile	  
infection?	  
3. How	  does	  uncertainty	  in	  competing	  decisions	  impact	  on	  decision-­‐making?	  
4. What	  is	  the	  expected	  value	  of	  perfect	  information	  relating	  to	  this	  decision	  
problem?	  
	  
The	  methods	  employed	  in	  this	  project	  will	  ensure	  that	  each	  research	  question	  can	  
be	  answered,	  providing	  new	  information	  about	  an	  important	  emerging	  infection	  
that	  is	  under-­‐researched	  in	  Australia.	  Specifically,	  question	  one	  will	  be	  answered	  
by	  evaluating	  the	  results	  of	  the	  cost-­‐effectiveness	  analyses.	  Answering	  question	  
two	  has	  required	  collaboration	  with	  Dr	  Laith	  Yakob	  of	  the	  London	  School	  of	  
Hygiene	  and	  Tropical	  Medicine.	  Results	  from	  the	  most	  up	  to	  date	  transmission	  
model	  are	  utilised	  to	  estimate	  intervention	  effectiveness	  and	  cost	  data	  that	  has	  
been	  obtained	  through	  the	  life	  of	  the	  project	  about	  intervention	  implementation.	  
The	  cost-­‐effectiveness	  model	  developed	  for	  this	  project	  is	  explained	  in	  detail	  in	  
section	  4.3	  of	  this	  chapter.	  The	  model	  enables	  the	  healthcare	  interventions	  to	  be	  
compared	  side-­‐by-­‐side	  and	  provides	  decision-­‐makers	  with	  a	  guide	  to	  resource	  
allocation	  by	  considering	  both	  costs	  and	  health	  outcomes.	  Question	  three	  is	  
addressed	  by	  analysing	  how	  uncertainty	  is	  handled	  throughout	  the	  economic	  
modelling	  process.	  The	  methods	  chosen	  to	  handle	  uncertainty	  are	  described	  




value	  of	  perfect	  information	  for	  the	  whole	  model,	  as	  well	  as	  the	  expected	  value	  of	  
perfect	  parameter	  information.	  
	  
4.2	  Selection	  of	  interventions	  for	  evaluation	  
There	  are	  a	  number	  of	  health	  services	  strategies	  mentioned	  in	  the	  literature	  that	  
are	  designed	  to	  reduce	  the	  transmission	  and	  incidence	  of	  Clostridium	  difficile.	  The	  
focus	  of	  this	  research	  project	  will	  be	  on	  the	  strategies	  that	  are	  deemed	  most	  
relevant	  to	  the	  Australian	  setting.	  It	  is	  important	  to	  note	  that	  given	  that	  economic	  
modelling	  studies	  are	  tremendously	  adaptable,	  strategies	  that	  have	  not	  been	  
included	  in	  this	  research	  project	  could	  be	  included	  at	  another	  date,	  if	  their	  
inclusion	  was	  deemed	  to	  be	  beneficial.	  	  
	  
In	  the	  first	  instance,	  all	  strategies	  will	  be	  compared	  with	  ‘standard	  care’,	  which	  is	  
the	  baseline	  definition	  of	  the	  comparator.	  For	  the	  purpose	  of	  this	  evaluation,	  it	  has	  
been	  assumed	  that	  all	  hospitals	  have	  a	  current	  infection	  prevention	  and	  control	  
strategy	  for	  the	  management	  of	  hospital-­‐acquired	  infections.	  This	  would	  include	  a	  
current	  antimicrobial	  stewardship	  programme	  or	  antimicrobial	  restriction	  policy,	  a	  
hand	  hygiene	  and	  environmental	  cleaning	  programme	  for	  the	  whole	  hospital	  and	  
the	  capacity	  to	  undertake	  fecal	  microbiota	  transplant.	  The	  baseline	  level	  of	  
antimicrobial	  exposure	  in	  a	  hospital	  at	  any	  given	  time	  is	  assumed	  to	  be	  50%	  of	  
inpatients,	  the	  average	  time	  for	  gut	  flora	  to	  be	  properly	  restored	  is	  90	  days	  post-­‐




to	  be	  5.8	  days	  (110).	  The	  implementation	  of	  successful	  interventions	  has	  been	  
modelled	  in	  the	  cost-­‐effectiveness	  analyses	  and	  the	  range	  of	  modelled	  values,	  
which	  show	  different	  capacity	  for	  intervention	  effectiveness,	  is	  explained	  in	  detail	  
in	  subsequent	  sections	  of	  this	  document.	  
	  
Secondly,	  the	  included	  interventions	  will	  be	  compared	  with	  one	  another	  in	  order	  
to	  ascertain	  which	  option,	  or	  bundle	  of	  options,	  delivers	  the	  most	  cost-­‐effective	  
outcome.	  A	  rationale	  for	  the	  inclusion	  and	  brief	  description	  of	  each	  intervention	  is	  
below.	  	  
	  
1. Hygiene	  improvement	  (hand	  hygiene	  and	  environmental	  cleaning)	  
Hand	  hygiene	  has	  long	  been	  considered	  a	  foundation	  of	  the	  prevention	  of	  
healthcare	  associated	  infection	  transmission.	  Several	  published	  papers	  report	  a	  
reduction	  of	  HAI	  rates	  and	  attribute	  the	  improvement	  to	  greater	  hand	  hygiene	  
compliance	  amongst	  healthcare	  workers	  (170).	  In	  Australia,	  hand	  hygiene	  
programmes	  are	  part	  of	  routine	  hospital	  infection	  control	  practice	  and	  in	  many	  
hospitals	  a	  standard	  hand	  hygiene	  programme	  is	  in	  place	  (171).	  According	  to	  
clinical	  guidelines	  for	  managing	  Clostridium	  difficile	  in	  adults,	  it	  is	  imperative	  to	  
emphasise	  compliance	  with	  the	  practice	  of	  hand	  hygiene	  for	  healthcare	  workers,	  
patients	  and	  visitors.	  A	  large	  majority	  of	  Australian	  hospitals	  have	  implemented	  
the	  WHO’s	  ‘5	  moments	  for	  hand	  hygiene’	  programme	  and	  take	  part	  in	  




Visitors	  of	  those	  patients	  who	  are	  confirmed	  to	  have	  Clostridium	  difficile	  should	  
always	  be	  instructed	  to	  wash	  their	  hands	  with	  antimicrobial	  soap	  and	  water	  (172).	  
There	  is	  also	  significant	  evidence	  that	  suggests	  healthcare	  workers	  should	  
routinely	  use	  protective	  gowns	  and	  gloves	  whenever	  entering	  the	  room	  of	  a	  patient	  
who	  has	  been	  confirmed	  as	  positive	  for	  Clostridium	  difficile	  (74).	  
	  
Clostridium	  difficile	  spores	  are	  capable	  of	  surviving	  in	  the	  hospital	  environment	  for	  
years	  and	  can	  be	  found	  in	  many	  clinical	  spaces	  (173).	  Clinical	  guidelines	  suggest	  
that	  an	  effective	  disinfection	  regimen	  is	  vital	  to	  good	  practice,	  making	  it	  a	  worthy	  
intervention	  for	  further	  investigation	  (74).	  
	  
Contamination	  of	  toilets,	  oral	  and	  rectal	  thermometers	  as	  well	  as	  blood	  pressure	  
cuffs	  are	  known	  to	  be	  common	  vehicles	  for	  transmission	  (174-­‐176).	  The	  
identification	  and	  subsequent	  removal	  of	  possible	  environmental	  sources	  of	  
transmission,	  by	  using	  disposable	  products,	  can	  reduce	  the	  incidence	  of	  
Clostridium	  difficile	  transmission.	  Furthermore,	  it	  is	  recommended	  that	  chlorine	  
based	  or	  sporicidal	  agents	  for	  cleaning	  the	  patient	  environment	  are	  used	  as	  these	  
agents	  have	  been	  deemed	  the	  most	  effective	  for	  removing	  Clostridium	  difficile	  
spores.	  The	  use	  of	  new	  technology	  for	  environmental	  cleaning	  has	  become	  a	  ‘hot	  
topic’	  for	  discussion	  in	  recent	  years,	  with	  specific	  focus	  being	  on	  cleaning	  robots	  
and	  the	  use	  of	  hydrogen	  peroxide	  or	  ultraviolet	  light	  systems	  for	  whole-­‐room	  




practical	  issues	  with	  this	  technology	  remain	  unsolved	  given	  the	  need	  to	  vacate	  
and/or	  seal	  off	  rooms	  for	  the	  duration	  of	  the	  clean	  (177).	  As	  a	  result,	  the	  cost	  of	  
including	  new	  technology	  for	  environmental	  cleaning	  will	  not	  be	  considered	  in	  
this	  project	  and	  a	  more	  ‘traditional’	  approach	  to	  cleaning	  has	  been	  included	  for	  
evaluation.	  This	  reflects	  current	  practice	  in	  Australian	  hospitals.	  
	  
2. Antimicrobial	  stewardship	  
The	  major	  risk	  factor	  for	  Clostridium	  difficile	  infection	  is	  exposure	  to	  antibiotics	  
(21).	  Increased	  use	  and	  increased	  lifetime	  exposure	  to	  antibiotics	  has	  been	  
associated	  with	  increased	  risk	  of	  infection	  due	  to	  the	  disruption	  that	  antibiotics	  
cause	  to	  the	  natural	  gut	  flora	  (178).	  In	  the	  case	  of	  Clostridium	  difficile,	  it	  is	  
somewhat	  of	  a	  double-­‐edged	  sword,	  where	  antibiotics	  are	  used	  to	  treat	  infection,	  
but	  exposure	  to	  antibiotics	  promotes	  recurrence	  and	  places	  patients	  in	  a	  
vulnerable	  state.	  Antimicrobial	  stewardship	  programmes	  are	  designed	  to	  
encourage	  more	  careful	  and	  controlled	  prescribing	  practices	  to	  improve	  patient	  
outcomes	  and	  limit	  antibiotic	  associated	  disease	  and	  resistance	  (138-­‐139).	  
Implementing	  an	  antimicrobial	  stewardship	  programme	  is	  a	  common	  approach	  to	  
managing	  healthcare	  associated	  infections	  in	  Australia	  and	  there	  is	  data	  available	  
from	  sites	  that	  have	  implemented	  a	  change	  in	  management	  strategy.	  Despite	  
antimicrobial	  stewardship	  being	  a	  common	  intervention,	  there	  is	  scope	  for	  
economic	  evaluation	  as	  this	  work	  is	  yet	  to	  be	  completed	  in	  Australia	  in	  relation	  to	  





3. Fecal	  microbiota	  transplantation	  (FMT)	  
As	  numbers	  of	  Clostridium	  difficile	  infections	  steadily	  rise,	  the	  search	  for	  novel	  
treatments	  of	  the	  disease	  also	  increase.	  Fecal	  transplant,	  where	  a	  stool	  sample	  from	  
a	  non-­‐infected	  donor	  is	  transplanted	  into	  the	  infected	  patient	  in	  an	  attempt	  to	  
rejuvenate	  their	  gut	  microbiota,	  is	  a	  recent	  addition	  to	  therapeutic	  options	  
available	  in	  some	  jurisdictions	  (179).	  The	  novel	  approach	  to	  treatment	  has	  been	  
viewed	  with	  caution	  in	  Australia,	  but	  uptake	  is	  beginning	  to	  increase	  and	  is	  
available	  in	  specialist	  clinics	  across	  the	  country.	  Recent	  publications	  have	  shown	  
that	  the	  procedure	  has	  impressive	  results,	  especially	  for	  sufferers	  of	  recurrent	  
infection	  or	  for	  treatment	  of	  varied	  strains	  (80;	  89).	  Its	  inclusion	  ensures	  that	  the	  
evaluation	  presents	  a	  range	  of	  intervention	  options,	  both	  traditional	  and	  
contemporary.	  
	  
4. Reduction	  in	  length	  of	  stay	  
An	  important	  risk	  factor	  for	  infection	  is	  length	  of	  hospital	  stay.	  The	  risk	  of	  
infection	  increases	  at	  a	  steady	  rate	  during	  hospitalisation,	  with	  risk	  increasing	  
cumulatively,	  for	  each	  day	  spent	  hospitalised	  (74;	  180).	  It	  is	  logical	  that	  the	  longer	  
a	  patient	  stays	  in	  hospital,	  the	  greater	  chance	  they	  are	  of	  succumbing	  to	  infection	  
(181).	  The	  reduction	  of	  patient’s	  length	  of	  stay,	  by	  effective	  bed	  management	  
among	  the	  admitted	  population	  is	  expected	  to	  have	  a	  positive	  impact	  on	  




of	  stay	  in	  the	  project	  is	  an	  acknowledgment	  of	  the	  motivation	  that	  hospital	  
managers	  and	  clinicians	  have	  to	  reduce	  inpatient	  duration,	  as	  they	  work	  within	  a	  
system	  that	  seeks	  to	  reward	  efficiency.	  	  
5. Developing	  infection	  prevention	  bundles	  for	  the	  model	  
In	  reality,	  infection	  prevention	  measures	  are	  rarely	  undertaken	  as	  stand	  alone	  
interventions	  and	  approaches	  that	  utilise	  infection	  control	  ‘bundles’	  are	  
increasingly	  popular.	  Bundled	  strategies	  were	  conceptualised	  using	  a	  logical	  
approach	  that	  combined	  single	  interventions.	  Each	  possible	  combination	  of	  single	  
interventions	  was	  then	  critiqued	  for	  clinical	  plausibility	  and	  those	  that	  were	  
deemed	  to	  be	  either	  clinically	  impractical	  or	  implausible	  were	  excluded.	  To	  assist	  
in	  the	  decision-­‐making	  process	  about	  exclusion,	  clinical	  advice	  was	  sought	  to	  
ensure	  the	  evaluation	  only	  includes	  interventions	  that	  make	  clinical	  sense	  and	  
meet	  organisational	  reality	  in	  the	  Australian	  healthcare	  setting.	  Of	  the	  10	  possible	  
combinations	  of	  strategies,	  two	  were	  excluded	  due	  to	  being	  either	  unrealistic	  
combination	  of	  a	  treatment	  and	  preventative	  intervention	  (AMS	  &	  FMT)	  or	  
because	  of	  clinical	  impracticality.	  This	  was	  the	  case	  for	  Reduce	  LOS	  &	  FMT	  
because	  it	  is	  a	  clinically	  impractical	  and	  illogical	  combination.	  Fecal	  transplant	  is	  a	  
surgical,	  treatment-­‐based	  intervention	  which	  would	  likely	  result	  in	  an	  increased	  
hospital	  stay	  –	  counteracting	  any	  intervention	  designed	  to	  reduce	  a	  patient’s	  LOS.	  











There	  is	  scope	  for	  further	  healthcare	  interventions	  to	  be	  added	  to	  the	  model	  in	  the	  
future	  if	  data	  relating	  to	  efficacy	  and	  costs	  becomes	  available.	  Some	  interventions	  
that	  may	  be	  valuable	  to	  analyse	  should	  they	  become	  routine	  practice	  in	  Australia	  
include;	  the	  isolation	  of	  known	  infected	  patients,	  screening	  of	  all	  admitted	  patients	  
for	  Clostridium	  difficile	  colonisation	  and	  the	  vaccination	  of	  at-­‐risk	  patients.	  The	  
reason	  for	  omission	  from	  this	  study	  is	  due	  to	  a	  lack	  of	  robust	  efficacy	  data	  relating	  
to	  these	  interventions.	  
	  
4.3	  Model	  development	  
The	  development	  of	  a	  decision	  analytic	  model	  to	  evaluate	  interventions	  relating	  to	  
Clostridium	  difficile	  followed	  the	  well-­‐defined	  methods	  laid	  out	  by	  Gray	  et	  al	  (155).	  	  
	  
Choice	  of	  model	  
Given	  the	  chronic	  and	  somewhat	  repetitive	  nature	  of	  the	  disease,	  the	  model	  
needed	  to	  be	  state-­‐based	  and	  able	  to	  handle	  recursive	  events.	  A	  feature	  of	  
Clostridium	  difficile	  infection	  is	  a	  high	  rate	  of	  recurrent	  illness,	  so	  a	  Markov	  model	  
was	  favoured	  over	  a	  decision-­‐tree.	  Models	  are	  governed	  by	  the	  natural	  history	  of	  
the	  disease	  of	  interest	  and	  require	  significant	  expert	  input	  throughout	  the	  iterative	  
design	  process.	  Numerous	  experts	  –	  including	  infection	  control	  nurses,	  infectious	  
disease	  physicians,	  health	  economists,	  statisticians	  and	  health	  services	  researchers	  
examined	  the	  model	  during	  the	  various	  design	  stages,	  to	  ensure	  that	  it	  resembles	  a	  




determining	  the	  final	  structure	  and	  the	  model	  configuration	  was	  changed	  a	  
number	  of	  times	  throughout	  the	  project	  before	  a	  final	  structure	  was	  agreed	  upon.	  
The	  diagrams	  in	  Appendix	  B	  show	  how	  the	  model	  changed	  over	  time	  until	  the	  
final	  structure	  was	  agreed	  upon.	  	  
	  
Health	  states	  that	  do	  not	  represent	  a	  large	  change	  in	  health	  outcome	  or	  economic	  
costs	  have	  been	  deliberately	  omitted	  to	  ensure	  model	  parsimony.	  For	  example,	  
instead	  of	  including	  patients	  who	  have	  asymptomatic	  infection,	  only	  patients	  who	  
have	  symptomatic	  infection	  are	  included	  in	  the	  model.	  This	  is	  because	  patients	  
who	  are	  asymptomatic,	  whilst	  capable	  of	  contributing	  to	  the	  transmission	  of	  
infection,	  do	  not	  themselves	  accrue	  costs	  or	  experience	  a	  reduction	  in	  health	  
outcomes.	  
	  
Figure	  3	  is	  a	  pictorial	  representation	  of	  the	  Markov	  model	  that	  was	  used	  in	  the	  
analysis	  of	  Clostridium	  difficile	  infection.	  
The	  model	  that	  was	  constructed	  for	  this	  evaluation	  includes	  two	  absorbing	  states	  –	  
‘death’	  and	  ‘censored’.	  Patients	  who	  cannot	  be	  accounted	  for	  elsewhere	  in	  the	  
model	  due	  to	  their	  hospital	  stay	  continuing	  after	  the	  data	  collection	  cut-­‐off	  date	  
are	  categorised	  as	  being	  ‘censored’.	  Patients	  are	  able	  to	  remain	  in	  the	  same	  state	  
that	  they	  were	  in	  during	  the	  previous	  cycle	  and	  are	  represented	  by	  a	  circular	  arrow	  
in	  the	  diagram.	  The	  model	  is	  designed	  to	  replicate	  the	  natural	  history	  of	  the	  




represented	  wherever	  feasible.	  It	  depicts	  the	  movement	  of	  patients	  through	  a	  
number	  of	  health	  states,	  where	  patients	  begin	  by	  being	  categorised	  by	  the	  severity	  
of	  their	  disease.	  All	  patients	  who	  survive	  one	  infection	  are	  classified	  as	  being	  
‘discharged	  vulnerable’.	  Patients	  can	  then	  suffer	  recurrence	  of	  infection	  or	  remain	  
in	  a	  vulnerable	  state.	  It	  is	  also	  possible	  to	  enter	  and	  remain	  in	  a	  state	  of	  healthy	  
survival.	  Death	  can	  occur	  from	  all	  states,	  except	  ‘censored’	  and	  is	  not	  shown	  in	  
Figure	  3	  as	  a	  health	  state	  of	  its	  own.	  
	  
All	  patients	  begin	  in	  the	  health	  state	  ‘at-­‐risk’	  and	  represent	  patients	  that	  are	  newly	  
admitted	  into	  hospital.	  Patients	  can	  either	  remain	  in	  this	  state	  or	  are	  transitioned	  
into	  one	  of	  three	  possible	  health	  states:	  ‘severe	  infection’,	  ‘non-­‐severe	  infection’	  or	  
‘discharged	  healthy’.	  These	  states	  represent	  clinically	  important	  categories	  and	  
have	  been	  determined	  by	  clinical	  guidelines	  (139-­‐140).	  Patients	  from	  each	  severity	  
category	  either	  enter	  the	  state	  ‘discharged	  vulnerable	  1’	  or	  ‘death’.	  All	  patients	  who	  
have	  suffered	  Clostridium	  difficile	  infection	  are	  classified	  as	  ‘vulnerable’	  due	  to	  the	  
damage	  done	  to	  the	  gut’s	  microbiota	  and	  due	  to	  their	  exposure	  to	  antibiotics	  used	  
for	  treatment.	  Due	  to	  a	  lack	  of	  data	  precision,	  an	  assumption	  is	  made	  that	  patients	  
cannot	  transition	  between	  the	  infected	  health	  states.	  In	  reality,	  it	  is	  a	  clinically	  
plausible	  outcome	  that	  a	  patient	  could	  begin	  with	  ‘non-­‐severe’	  infection	  and	  then	  
move	  to	  ‘severe’	  infection	  in	  the	  ensuing	  days,	  but	  this	  reality	  is	  not	  represented	  in	  
the	  model.	  If	  better	  information	  about	  date	  of	  diagnosis	  was	  recorded,	  this	  




Patients	  in	  the	  state	  ‘discharged	  vulnerable	  1’	  can	  remain	  in	  this	  state	  or	  
alternatively	  can	  experience	  a	  recurrence	  of	  infection,	  known	  in	  the	  model	  as	  
‘recurrent	  infection’.	  They	  can	  enter	  either	  absorbing	  state	  from	  ‘discharged	  
vulnerable	  1’	  due	  to	  death	  or	  being	  ‘censored’	  where	  the	  time	  frame	  for	  data	  
collection	  has	  been	  surpassed.	  Recurrent	  infection	  is	  reported	  to	  occur	  in	  up	  to	  
25%	  of	  cases	  (182-­‐184)	  and	  the	  term	  ‘recurrent’	  incorporates	  both	  reinfections	  
(which	  may	  be	  a	  different	  strain	  of	  the	  pathogen)	  and	  relapse	  with	  the	  same	  strain	  
(84).	  Patients	  with	  a	  recurrent	  infection	  typically	  suffer	  worse	  health	  outcomes	  and	  
consequently	  incur	  greater	  health	  decrement	  and	  accrue	  higher	  costs	  than	  patients	  
who	  are	  only	  infected	  once	  (185).	  Due	  to	  a	  lack	  of	  detail	  in	  available	  data,	  recurrent	  
patients	  are	  not	  categorised	  according	  to	  the	  severity	  of	  their	  disease.	  There	  is	  no	  
record	  keeping	  of	  the	  severity	  of	  recurrent	  infections,	  making	  it	  impossible	  to	  
accurately	  separate	  diseased	  patients	  into	  clinically	  relevant	  categories.	  However,	  
the	  dataset	  used	  for	  estimating	  transitions	  between	  health	  states	  is	  detailed	  
enough	  for	  an	  accurate	  understanding	  of	  overall	  recurrence	  rates.	  As	  previously	  
occurs,	  patients	  are	  transitioned	  from	  their	  infective	  category,	  ‘recurrent	  infection’,	  
to	  a	  vulnerable	  state	  -­‐	  ‘discharged	  vulnerable	  2’	  or	  one	  of	  the	  absorbing	  states	  –	  
‘censored’	  or	  ‘death’.	  Patients	  who	  have	  had	  a	  recurrent	  infection	  are	  significantly	  
more	  likely	  to	  suffer	  further	  recurrences,	  with	  studies	  showing	  that	  in	  45%	  of	  
cases,	  patients	  who	  have	  suffered	  one	  recurrence	  are	  likely	  to	  have	  at	  least	  one	  
other	  (186).	  Patients	  who	  are	  ‘discharged	  vulnerable	  2’	  but	  who	  avoid	  recurrent	  




Figure	  3:	  Pictorial	  representation	  of	  economic	  model	  used	  in	  evaluation	  
	  
	  
Building	  the	  model	  
The	  model	  was	  built	  using	  Microsoft	  excel	  (2014,	  version	  14.4.6).	  Microsoft	  excel	  is	  
one	  of	  two	  software	  packages	  preferred	  by	  the	  United	  Kingdom’s	  governing	  body	  




is	  useful	  because	  it	  is	  widely	  available,	  allowing	  review	  and	  evaluation	  to	  occur	  
more	  easily	  than	  using	  specialist	  software.	  For	  this	  reason,	  the	  end	  product	  is	  also	  
more	  transparent	  than	  if	  the	  model	  was	  built	  using	  specialist	  software	  where	  fewer	  
expert	  users	  exist.	  
	  
Identify	  starting	  probabilities	  	  
It	  is	  fundamental	  to	  define	  where	  the	  simulated	  cohort	  starts	  in	  the	  model	  and	  
what	  the	  starting	  probabilities	  are.	  It	  is	  possible	  for	  the	  cohort	  to	  be	  spread	  across	  
health	  states	  prior	  to	  the	  model	  commencing	  –	  when	  this	  is	  the	  case,	  the	  
probabilities	  of	  starting	  in	  each	  health	  state	  are	  informed	  by	  the	  literature	  or	  
another	  data	  source.	  In	  this	  research	  project,	  patients	  who	  have	  been	  admitted	  to	  
hospital	  and	  are	  deemed	  ‘at	  risk’	  of	  acquiring	  Clostridium	  difficile	  infection	  as	  a	  
result	  of	  their	  admission	  are	  of	  interest.	  As	  such,	  in	  this	  project’s	  model,	  the	  whole	  
cohort	  start	  in	  the	  health	  state	  ‘at	  risk’.	  This	  is	  the	  same	  as	  saying	  that	  the	  starting	  
probability	  is	  equal	  to	  1.	  The	  model	  depicts	  860,000	  people	  going	  through	  the	  
model.	  This	  number	  was	  chosen	  as	  it	  replicates	  the	  total	  number	  of	  patients	  that	  
were	  accounted	  for	  in	  the	  raw	  dataset	  from	  Western	  Australia,	  which	  captured	  a	  
year’s	  worth	  of	  hospital	  admissions	  (188).	  It	  is	  also	  the	  same	  as	  the	  number	  of	  
patients	  used	  to	  estimate	  transition	  probabilities	  for	  each	  transition	  in	  the	  model.	  
	  




Table	  2	  is	  a	  transition	  matrix	  containing	  values	  that	  show	  the	  probability	  of	  
moving	  from	  one	  state	  to	  another,	  in	  the	  model.	  For	  example,	  those	  in	  the	  ‘non-­‐
severe’	  state	  can	  remain	  in	  that	  state	  with	  probability	  0.752,	  move	  to	  ‘DV1’	  with	  
probability	  of	  0.247	  or	  die	  with	  probability	  0.0001.	  
Table	  2:	  Transition	  Matrix	  
	   At	  
Risk	  
NonSevere	   Severe	   DisHlthy	   DV1	   RecInf	   DV2	   Censored	   Dead	  
At	  Risk	   0.273	   0.0001	   4.6E-­‐06	   0.725	   0	   0	   0	   0	   0.001	  
NonSevere	   0	   0.752	   0	   0	   0.247	   0	   0	   0	   0.0001	  
Severe	   0	   0	   0.75	   0	   0.249	   0	   0	   0	   0.0001	  
DisHlthy	   0	   0	   0	   0.999	   0	   0	   0	   0	   0.0001	  
DV1	   0	   0	   0	   0	   0.829	   0.110	   0	   0.012	   0.047	  
RecInf	   0	   0	   0	   0	   0	   0.671	   0.268	   0	   0.059	  
DV2	   0	   0	   0	   0	   0	   0.126	   0.846	   0.021	   0.005	  
Censored	   0	   0	   0	   0	   0	   0	   0	   1	   0	  
Dead	   0	   0	   0	   0	   0	   0	   0	   0	   1	  
	  
Transition	  probabilities	  were	  estimated	  using	  a	  large	  dataset	  from	  Western	  
Australia	  (n=866,125),	  which	  contained	  clinical	  information	  for	  all	  patient	  
admissions	  over	  12	  months.	  A	  wide	  range	  of	  clinical	  information	  was	  captured	  in	  
this	  dataset,	  including	  admission	  dates,	  time	  spent	  in	  ICU	  and	  clinical	  coding	  for	  
each	  patient	  describing	  the	  medical	  reason(s)	  for	  admission.	  Mortality	  information	  
was	  also	  provided.	  Patients	  with	  an	  ICD-­‐10	  code	  for	  Clostridium	  difficile	  infection	  
(AO4.7)	  were	  extracted	  and	  examined	  in	  further	  detail.	  
There	  were	  844	  Clostridium	  difficile	  infections	  identified	  when	  non-­‐severe	  (749)	  
and	  severe	  (95)	  cases	  were	  combined.	  Those	  patients	  who	  suffered	  an	  infection	  but	  




illness	  and	  were	  used	  to	  inform	  the	  probability	  of	  moving	  from	  the	  ‘at	  risk’	  health	  
state	  to	  the	  ‘non-­‐severe’	  health	  state.	  Patients	  with	  an	  infection	  and	  a	  concurrent	  
stay	  in	  ICU	  were	  considered	  to	  be	  suffering	  from	  ‘severe’	  illness	  and	  were	  used	  to	  
inform	  the	  probability	  of	  moving	  from	  the	  ‘at	  risk’	  health	  state	  to	  the	  ‘severe’	  
health	  state.	  
	  
Given	  that	  there	  were	  866,125	  admissions	  in	  the	  dataset,	  the	  probability	  of	  getting	  
an	  infection	  is	  0.001065.	  The	  majority	  of	  patients	  (791,901)	  who	  began	  in	  the	  ‘at	  
risk’	  health	  state	  were	  ‘discharged	  healthy’.	  The	  majority	  of	  patients	  who	  had	  
suffered	  a	  Clostridium	  difficile	  infection	  returned	  for	  another	  hospital	  admission	  
(718	  of	  844)	  before	  the	  censoring	  date	  of	  30/6/2012.	  Those	  patients	  who	  suffered	  a	  
recurrent	  infection	  (the	  definition	  of	  which	  has	  been	  explained	  previously)	  were	  
tracked	  according	  to	  a	  non-­‐identifiable	  code	  and	  used	  to	  inform	  the	  probability	  of	  
recurrent	  infection.	  In	  many	  cases,	  the	  return	  visit	  to	  hospital	  was	  associated	  with	  
another	  Clostridium	  difficile	  infection	  (405	  of	  718).	  Patients	  whose	  cause	  of	  death	  
included	  the	  ICD-­‐10	  code	  for	  Clostridium	  difficile	  infection	  were	  used	  to	  inform	  the	  
probability	  of	  dying	  from	  any	  of	  the	  infected	  health	  states.	  There	  was	  no	  clear	  
difference	  in	  the	  risk	  of	  death	  between	  the	  ‘non-­‐severe’	  and	  ‘severe’	  health	  states.	  
Twenty-­‐eight	  percent	  of	  patients	  who	  suffered	  a	  ‘non-­‐severe’	  infection	  died	  (211	  of	  
749),	  while	  29.5%	  of	  patients	  who	  suffered	  a	  ‘severe’	  infection	  died	  (28	  of	  95).	  
However,	  given	  that	  there	  were	  only	  95	  ‘severe’	  infections	  in	  the	  total	  sample,	  




from	  the	  ‘discharged	  healthy’	  state	  was	  derived	  from	  Australian	  life	  tables,	  
published	  by	  the	  Australian	  Institute	  of	  Health	  and	  Welfare	  (AIHW)	  (189).	  	  
	  
Decide	  on	  cycle	  length	  
Two	  different	  cycle	  lengths	  were	  chosen	  so	  that	  they	  represent	  as	  accurately	  as	  
possible	  what	  happens	  in	  the	  real	  world	  and	  reflect	  the	  underlying	  natural	  history	  
of	  the	  disease.	  As	  most	  infections	  occurred	  in	  the	  first	  few	  weeks,	  daily	  cycles	  were	  
fitted	  for	  the	  first	  28	  days.	  Following	  the	  daily	  cycles,	  monthly	  cycles	  were	  fitted	  
and	  this	  accounted	  for	  the	  decreasing	  occurrence	  of	  infections	  following	  the	  first	  
few	  weeks.	  Given	  that	  the	  cycle	  length	  was	  not	  homogenous	  for	  the	  entire	  model,	  
the	  corresponding	  input	  parameters	  relating	  to	  transition	  probability,	  cost	  and	  
health	  outcome	  were	  adjusted	  accordingly.	  This	  approach	  and	  requirement	  for	  
adjustment	  is	  not	  uncommon	  in	  economic	  evaluations	  and	  examples	  of	  non	  
homogenous	  cycle	  length	  can	  be	  found	  in	  the	  literature	  (190-­‐191).	  
	  
Set	  the	  stopping	  rule	  
Decision	  models	  can	  be	  run	  for	  an	  extended	  period	  of	  time	  –	  i.e.	  for	  the	  estimated	  
remaining	  life	  expectancy	  of	  the	  study	  population.	  A	  decision	  about	  the	  time	  frame	  
that	  a	  model	  should	  run	  has	  to	  be	  made,	  as	  it	  must	  have	  a	  defined	  endpoint.	  In	  this	  
project,	  the	  model	  runs	  until	  nearly	  all	  of	  the	  entire	  simulated	  population	  ends	  up	  





Determine	  costs	  and	  outcomes	  
Each	  health	  state	  has	  been	  assigned	  a	  value	  that	  reflects	  the	  cost	  of	  being	  in	  that	  
state	  during	  a	  cycle.	  Health	  utility	  weights	  are	  attached	  to	  each	  health	  state	  and	  
vary	  according	  to	  the	  severity	  of	  the	  infection	  –	  logically,	  there	  is	  a	  larger	  
decrement	  in	  health	  utility	  for	  those	  from	  the	  cohort	  in	  the	  ‘severe’	  health	  state	  
when	  compared	  to	  those	  in	  the	  ‘at-­‐risk’	  state.	  A	  full	  explanation	  of	  how	  costs	  were	  
determined	  for	  each	  health	  state	  can	  be	  seen	  in	  section	  4.4	  of	  this	  chapter.	  A	  
thorough	  description	  of	  how	  health	  utility	  weights	  were	  measured	  and	  valued	  can	  
be	  seen	  under	  the	  sub-­‐heading	  value	  health	  states	  in	  this	  section	  of	  the	  chapter.	  	  
	  
Populate	  the	  model	  
The	  evidence	  that	  has	  been	  identified	  and	  synthesised	  is	  used	  to	  populate	  the	  
model’s	  parameters.	  The	  quality	  of	  the	  evidence	  used	  in	  the	  decision	  model	  has	  
been	  assessed	  according	  to	  the	  hierarchy	  of	  data	  sources	  published	  by	  Cooper	  et	  al	  
(192).	  Each	  model	  parameter	  was	  fitted	  with	  a	  distribution	  using	  a	  variety	  of	  
statistical	  methods	  and	  the	  choice	  of	  distribution	  that	  is	  fitted	  reflects	  the	  nature	  
of	  the	  data	  that	  is	  included	  in	  that	  parameter	  (155).	  A	  beta	  distribution	  is	  a	  
continuous	  probability	  distribution	  defined	  on	  the	  interval	  (0,1)	  and	  was	  used	  for	  
all	  baseline	  transition	  probabilities.	  Treatment	  effects	  for	  each	  intervention	  were	  
incorporated	  using	  relative	  risks.	  Ideally,	  if	  the	  right	  cost	  data	  are	  available,	  the	  
gamma	  distribution	  is	  ideal	  to	  reflect	  the	  uncertainty	  in	  costs.	  However,	  in	  this	  




use	  the	  uniform	  distribution.	  A	  uniform	  distribution	  was	  used	  to	  reflect	  the	  
uncertainty	  relating	  to	  the	  health	  utilities	  in	  the	  model.	  The	  parameters	  included	  
in	  the	  model	  are	  explored	  in	  detail	  below.	  Table	  3	  shows	  the	  distributions	  that	  
have	  been	  applied	  to	  each	  parameter.	  It	  also	  shows	  the	  source	  of	  the	  evidence	  and	  
the	  hierarchy	  of	  evidence,	  according	  to	  the	  scale	  published	  by	  Cooper	  et	  al	  (see	  
Appendix	  A).	  	  
	  
Table	  3:	  Parameters	  included	  in	  the	  economic	  model	  
Variable	   Base	  Case	   Range	   Distribution	   Ref	   Evidence	  level	  
Utility	  
Parameters	  
	   	   	   	   	  
uAtRisk	   0.92	   0.84-­‐0.96	   Uniform	   142	   E-­‐2	  
uNonSev	   0.82	   0.72-­‐0.93	   Uniform	   142	   E-­‐2	  
uSev	   0.71	   0.50-­‐0.72	   Uniform	   142	   E-­‐2	  
uDV1	   0.85	   0.75-­‐0.90	   Uniform	   193	   E-­‐6	  
uRecInf	   0.61	   0.50-­‐0.72	   Uniform	   193	   E-­‐6	  
uDV2	   0.80	   0.70-­‐0.85	   Uniform	   193	   E-­‐6	  
uDisHlthy	   0.88	   0.84-­‐0.92	   Uniform	   194	   E-­‐2	  
Cost	  Parameters	   (Daily)	   	   	   	   	  
cNonSev_diagnosis	   $58.48	   $52.63-­‐$64.33	   Uniform	   195	   D-­‐2	  
cSev_diagnosis	   $29.24	   $26.32-­‐$32.16	   Uniform	   195	   D-­‐2	  
cRecInf_diagnosis	   $16.08	   $14.48-­‐$17.69	   Uniform	   195	   D-­‐2	  
cNonSev_hosp	   $800	   $720-­‐$880	   Uniform	   196	   D-­‐2	  
cSev_hosp	   $3000	   $2700-­‐$3300	   Uniform	   196	   D-­‐2	  
cRecInf_hosp	   $1900	   $1710-­‐$2090	   Uniform	   196	   D-­‐2	  
cNonSev_treatment	   $3.71	   $3.34-­‐$4.08	   Uniform	   197	   D-­‐2	  
cSev_treatment	   $47.43	   $42.69-­‐$52.17	   Uniform	   197	   D-­‐2	  




Transition	  Probs	   	   (alpha;	  beta)	   	   	   	  
TpRemAR	   0.273	   (236461;	  629636)	   Beta	   188	   B-­‐2	  
TpAR_NonSev	   0.0001	   (93;	  866004)	   Beta	   188	  	   B-­‐2	  
TpAR_Severe	   4.61E-­‐06	   (4;	  866093)	   Beta	   188	   B-­‐2	  
TpAR_DisHlthy	   0.725	   (628408;	  237689)	   Beta	   188	   B-­‐2	  
TpAR_Dead	   0.001	   (1131;	  864966)	   Beta	   189	   B-­‐2	  
TpRemNonSev	   0.752	   (70;	  23)	   Beta	   188	   B-­‐2	  
TpNonSev_Dead	   0.000	   (0.1;	  93.1)	   Beta	   188	   B-­‐2	  
TpNonSev_DV1	   0.247	   (23;	  70)	   Beta	   188	   B-­‐2	  
TpRemSev	   0.75	   (3;	  1)	   Beta	   188	   B-­‐2	  
TpSev_Dead	   0.000	   (0.1;	  4.1)	   Beta	   188	   B-­‐2	  
TpSev_DV1	   0.25	   (1;	  3)	   Beta	   188	   B-­‐2	  
TpRemDV1	   0.829	   (85;	  632)	   Beta	   188	   B-­‐2	  
TpDV1_Censored	   0.012	   (1.3;	  715.7)	   Beta	   188	   B-­‐2	  
TpDV1_RecInf	   0.110	   (11.3;	  705.7)	   Beta	   188	   B-­‐2	  
TpDV1_Dead	   0.047	   (4.9;	  712.1)	   Beta	   188	   B-­‐2	  
TpRemDV2	   0.846	   (22.9;	  166.1)	   Beta	   188	   B-­‐2	  
TpDV2_Censored	   0.021	   (0.6;	  188.4)	   Beta	   188	   B-­‐2	  
TpDV2_RecInf	   0.126	   (3.4;	  185.6)	   Beta	   188	   B-­‐2	  
TpDV2_Dead	   0.005	   (0.1;	  188.9)	   Beta	   188	   B-­‐2	  
TpRemRecInf	   0.671	   (19.3;	  181.7)	   Beta	   188	   B-­‐2	  
TpRecInf_Dead	   0.059	   (1.71;	  199)	   Beta	   188	   B-­‐2	  
TpRecInf_DV2	   0.268	   (7.7;	  193.3)	   Beta	   188	   B-­‐2	  
TpRemDisHlthy	   0.999	   (847653;	  88)	   Beta	   188	   B-­‐2	  
TpDisHlthy_Dead	   0.0001	   (9.4;	  623113)	   Beta	   188	   B-­‐2	  
	  
Value	  health	  states	  
Preference-­‐based	  utility	  measures	  for	  patients	  with	  Clostridium	  difficile	  infection	  
are	  not	  as	  well	  defined	  as	  for	  other	  diseases	  (198).	  It	  was	  possible,	  however,	  to	  
estimate	  some	  health	  utility	  weights	  based	  on	  previously	  published	  studies.	  Utility	  




preference-­‐based	  valuation	  of	  the	  health	  state	  relevant	  to	  the	  patient’s	  Clostridium	  
difficile	  infection	  status.	  
	  
Economic	  evaluations	  relating	  to	  Clostridium	  difficile	  infection	  were	  searched	  in	  
order	  to	  gather	  any	  information	  that	  could	  inform	  estimates	  for	  this	  research	  
project.	  Three	  economic	  evaluations	  that	  were	  similar	  to	  this	  evaluation	  were	  
found	  to	  be	  fit	  for	  further	  critique.	  The	  structure	  of	  each	  published	  model	  was	  
reviewed	  in	  order	  to	  find	  the	  one	  that	  was	  most	  comparable	  to	  this	  research.	  Of	  
those	  evaluations,	  the	  recently	  published	  findings	  by	  Konijeti	  et	  al	  (142)	  provided	  
the	  best	  fit	  for	  transfer	  into	  this	  project.	  The	  structure	  of	  their	  model	  shared	  a	  
number	  of	  features	  with	  the	  model	  used	  in	  this	  project,	  with	  half	  of	  the	  health	  
states	  from	  the	  Konijeti	  model	  being	  equivalent.	  
	  	  
Face-­‐to-­‐face	  interviews	  with	  a	  prominent	  Australian	  clinical	  microbiologist	  were	  
conducted	  in	  order	  to	  estimate	  utility	  weights	  for	  those	  health	  states	  that	  could	  
not	  be	  informed	  from	  the	  literature	  (193).	  This	  was	  necessary	  given	  that	  the	  model	  
for	  this	  evaluation	  contains	  health	  states	  that	  have	  not	  been	  included	  in	  previously	  
published	  findings	  and	  because	  the	  time	  and	  cost	  required	  to	  gather	  first-­‐hand	  
valuations	  from	  a	  cohort	  of	  Australian	  patients	  was	  not	  realistic.	  
	  
Initial	  discussion	  focused	  on	  ensuring	  that	  the	  natural	  history	  of	  the	  infection	  and	  




discussion,	  value	  ranges	  were	  proposed	  and	  validated	  by	  the	  clinical	  expert.	  In	  
order	  to	  adequately	  handle	  uncertainty	  relating	  to	  these	  estimates,	  a	  distribution	  
was	  applied	  to	  each	  health	  state	  and	  is	  listed	  in	  Table	  4.	  
	  
Table	  4	  shows	  the	  health	  utility	  weights	  that	  are	  used	  in	  the	  economic	  model	  and	  
includes	  details	  about	  the	  base	  case	  and	  range	  of	  values	  associated	  with	  each	  
health	  state.	  The	  source	  of	  information	  is	  also	  provided	  in	  the	  table.	  
 
Table	  4:	  Health	  utility	  weights	  for	  each	  health	  state	  in	  the	  economic	  model	  
Health	  Utilities	   Base	  Case	   Range	   Distribution	   Reference	  
At	  Risk	   0.92	   0.84-­‐0.96	   Uniform	   142	  
Discharged	  Healthy	   0.88	   0.84-­‐0.92	   Uniform	   142	  
Non	  Severe	   0.82	   0.72-­‐0.93	   Uniform	   142	  
Severe	   0.71	   0.50-­‐0.72	   Uniform	   142	  
DV	  1	   0.85	   0.75-­‐0.90	   Uniform	   193	  
Recurrent	  Infection	   0.61	   0.50-­‐0.72	   Uniform	   193	  
DV	  2	   0.80	   0.70-­‐0.85	   Uniform	   193	  
Dead	   0.00	   -­‐	   -­‐	   -­‐	  
	  
Published	  estimates	  to	  inform	  the	  base	  case,	  ‘At	  Risk’	  health	  state,	  are	  available	  for	  
healthy	  adults	  older	  than	  65	  years,	  which	  is	  the	  assumed	  age	  of	  the	  modelled	  
cohort.	  The	  utility	  weight	  for	  this	  state	  reflects	  the	  fact	  that	  people	  in	  this	  category	  
are	  not	  infected	  with	  Clostridium	  difficile.	  
The	  utility	  weights	  for	  the	  infectious	  health	  states	  differ	  according	  to	  severity	  and	  




such,	  the	  state	  ‘severe’	  has	  a	  health	  decrement	  that	  is	  greater	  than	  the	  health	  state	  
‘non-­‐severe’.	  The	  range	  of	  utility	  weights	  for	  the	  ‘severe’	  health	  state	  is	  more	  
weighted	  towards	  the	  minimum	  score,	  when	  compared	  to	  the	  ‘non-­‐severe’	  health	  
state.	  Published	  estimates	  have	  been	  used	  for	  these	  two	  health	  states.	  The	  third	  
infectious	  health	  state	  –	  ‘recurrent	  infection’,	  has	  a	  lower	  base	  value	  than	  the	  
‘severe’	  and	  ‘non-­‐severe’	  states.	  It	  has	  a	  range	  of	  values	  that	  is	  the	  same	  as	  those	  in	  
the	  ‘severe’	  state.	  This	  ensures	  a	  realistic	  representation	  of	  quality	  of	  life	  given	  that	  
recurrent	  infection	  is	  widely	  considered	  to	  be	  less	  desirable	  than	  a	  one-­‐off	  
infection.	  This	  does	  not	  mean	  that	  all	  recurrent	  infections	  are	  clinically	  classified	  
as	  ‘severe’	  but	  it	  does	  account	  for	  the	  decrement	  in	  quality	  of	  life	  of	  having	  
recurrent	  episodes	  of	  Clostridium	  difficile.	  In	  the	  absence	  of	  published	  evidence,	  
estimates	  for	  this	  health	  state	  have	  been	  informed	  by	  expert	  clinical	  opinion.	  The	  
utility	  weights	  applied	  to	  the	  health	  states	  where	  patients	  are	  discharged	  having	  
had	  an	  episode	  of	  infection	  are	  lower	  than	  those	  applied	  to	  the	  ‘At	  Risk’	  and	  
‘Discharged	  Healthy’	  states.	  This	  reflects	  the	  reality	  that	  patients	  who	  have	  
previously	  been	  infected	  remain	  vulnerable	  to	  recurrence	  for	  anywhere	  between	  4-­‐
8	  weeks.	  Those	  patients	  in	  the	  ‘DV	  1’	  state	  have	  a	  higher	  health	  utility	  when	  
compared	  with	  those	  in	  the	  ‘DV	  2’	  state,	  to	  account	  for	  the	  fact	  that	  the	  patients	  in	  
‘DV	  2’	  have	  had	  at	  least	  1	  recurrent	  infection.	  Estimates	  for	  these	  health	  states	  have	  






Measurement	  of	  intervention	  effectiveness	  
The	  identification	  and	  synthesis	  of	  clinical	  effectiveness	  outcomes	  for	  each	  
intervention	  has	  been	  undertaken	  by	  Yakob	  et	  al	  (110)	  and	  the	  results	  of	  which	  
have	  been	  shared	  for	  use	  in	  this	  project	  as	  part	  of	  a	  formal	  collaboration.	  The	  
mathematical	  model	  in	  this	  project	  is	  stochastic,	  meaning	  that	  its	  progression	  is	  at	  
least	  partially	  random.	  Compared	  to	  deterministic	  models,	  stochastic	  models	  are	  
more	  realistic	  and	  useful	  when	  including	  small	  numbers,	  such	  as	  is	  the	  case	  with	  
modelling	  infection	  dynamics	  of	  diseases	  with	  relatively	  low	  incidence	  in	  small	  
populations.	  The	  model	  is	  being	  used	  to	  evaluate	  the	  impact	  of	  each	  of	  the	  
healthcare	  interventions	  on	  the	  sensitivity	  of	  two	  outputs:	  (1)	  the	  ratio	  of	  
colonisation	  in	  discharged	  versus	  admitted	  patients;	  and	  (2)	  incidence	  of	  
symptomatic	  Clostridium	  difficile	  infection.	  	  
	  
Figure	  4	  shows	  the	  compartmental	  model	  in	  full	  and	  illustrates	  the	  possible	  
epidemiological	  transitions.	  Individuals	  in	  the	  model	  are	  either	  ‘U’nexposed,	  
‘E’xposed,	  ‘C’olonised	  or	  ‘D’iseased	  and	  are	  increasingly	  ‘vul’nerable	  when	  they	  









Figure	  4:	  Transmission	  model	  showing	  all	  health	  states	  and	  allowed	  transitions	  
	  
From	  Yakob	  et	  al	  (110)	  
	  
The	  systematic	  analysis	  of	  the	  clinical	  literature	  for	  the	  level	  of	  health	  gains	  that	  
can	  be	  expected	  from	  the	  numerous	  available	  control	  methods	  has	  enabled	  the	  
first	  dynamic	  economics	  and	  transmission	  model	  to	  be	  realised.	  It	  is	  this	  dynamic	  
model	  that	  is	  used	  to	  evaluate	  the	  most	  cost-­‐effective	  intervention	  strategy	  for	  
reducing	  Clostridium	  difficile.	  The	  search	  strategy	  used	  to	  identify	  relevant	  studies	  















The	  synthesis	  of	  the	  efficacy	  information	  for	  each	  intervention	  was	  integrated	  into	  
a	  stochastic	  transmission	  model	  and	  simulations	  of	  the	  model	  were	  run	  to	  explore	  
the	  impact	  that	  each	  intervention	  had	  on	  Clostridium	  difficile	  incidence	  rate.	  The	  
effect	  of	  individual	  interventions	  as	  well	  as	  the	  effect	  of	  combined	  (‘bundled’)	  
interventions	  was	  modelled,	  with	  the	  output	  used	  to	  inform	  the	  dynamic	  
economic	  model.	  The	  detailed	  output	  of	  Yakob’s	  transmission	  model	  that	  was	  used	  




interventions	  as	  ‘bundles’	  is	  a	  reality	  of	  practice,	  given	  that	  infection	  control	  
initiatives	  are	  rarely	  undertaken	  in	  isolation.	  The	  inclusion	  of	  bundles	  in	  this	  
project	  provides	  an	  extra	  element	  of	  realism	  to	  the	  results	  and	  is	  novel	  work	  in	  the	  
economic	  evaluation	  of	  interventions	  relating	  to	  Clostridium	  difficile	  infection.	  
	  
Hygiene	  improvement	  was	  found	  to	  have	  a	  large	  effect	  in	  decreasing	  disease	  
incidence	  on	  its	  own	  (3.2	  per	  1000	  bed	  days	  to	  1.1	  per	  1000	  bed	  days),	  but	  when	  
coupled	  with	  another	  intervention,	  such	  as	  antimicrobial	  stewardship,	  little	  
additional	  benefit	  was	  gained	  (2.7	  per	  1000	  bed	  days	  to	  2.3	  per	  1000	  bed	  days).	  
Antimicrobial	  stewardship	  had	  meagre	  benefits	  in	  terms	  of	  reducing	  the	  incidence	  
of	  Clostridium	  difficile	  on	  its	  own	  (2.8	  per	  1000	  bed	  days	  to	  2.3	  per	  1000	  bed	  days)	  
but	  in	  combination	  with	  reducing	  length	  of	  stay,	  a	  large	  reduction	  was	  observed	  
(2.8	  per	  1000	  bed	  days	  to	  1.3	  per	  1000	  bed	  days).	  Fecal	  transplant	  was	  found	  to	  be	  
an	  ineffective	  control	  tool	  on	  its	  own	  (2.5	  per	  1000	  bed	  days	  to	  2.4	  per	  1000	  bed	  
days)	  and	  in	  combination	  with	  other	  transmission	  reduction	  strategies,	  such	  as	  
hygiene	  improvement,	  there	  did	  not	  appear	  to	  be	  any	  collective	  effect	  (2.5	  per	  1000	  
bed	  days	  to	  2.8	  per	  1000	  bed	  days).	  Reducing	  length	  of	  stay	  was	  deemed	  to	  be	  an	  
effective	  intervention	  by	  itself	  (2.5	  per	  1000	  bed	  days	  reduced	  to	  1.3	  per	  1000	  bed	  
days)	  and	  when	  in	  combination	  with	  hygiene	  improvement	  there	  was	  a	  significant	  






The	  modelled	  range	  of	  effectiveness	  for	  each	  intervention	  is	  shown	  in	  the	  
following	  graphs,	  where	  the	  range	  of	  impact	  that	  the	  intervention	  has	  on	  the	  CDI	  
incidence	  rate	  can	  be	  seen.	  Figure	  6	  shows	  the	  small	  decrease	  in	  CDI	  incidence	  
rate	  between	  the	  highest	  and	  lowest	  efficacy	  values	  for	  an	  AMS	  programme.	  The	  
range	  of	  modelled	  values	  is	  between	  50%	  (upper)	  and	  0%	  (lower)	  of	  simulated	  
patients	  receiving	  antimicrobials.	  
	  
Figure	  6:	  Impact	  of	  AMS	  programme	  on	  CDI	  incidence	  rate	  
	  
	  
Figure	  7	  shows	  the	  negligible	  decrease	  in	  CDI	  incidence	  rate	  between	  the	  highest	  
and	  lowest	  efficacy	  values	  for	  a	  fecal	  transplant.	  The	  range	  of	  modelled	  values	  is	  
between	  90	  days	  (upper)	  and	  10	  days	  (lower)	  for	  the	  simulated	  cohort	  of	  patient’s	  
gut	  flora	  to	  recover	  as	  a	  result	  of	  the	  transplant.	  Ninety	  days	  until	  full	  gut	  recovery	  
is	  the	  average	  time	  reported	  in	  the	  literature	  for	  self-­‐resolution	  (200)	  and	  10	  days	  





Figure	  7:	  Impact	  of	  fecal	  transplant	  on	  CDI	  incidence	  rate	  
	  
	  
Figure	  8	  shows	  the	  sizeable	  decrease	  in	  CDI	  incidence	  rate	  between	  the	  highest	  
and	  lowest	  efficacy	  values	  for	  a	  hygiene	  improvement	  intervention.	  The	  range	  of	  
modelled	  values	  is	  between	  one	  (upper),	  representing	  no	  intervention	  and	  zero	  
(lower),	  representing	  complete	  control	  of	  within-­‐hospital	  transmission.	  Note	  that	  
even	  with	  complete	  inhibition	  of	  hospital	  transmission	  of	  the	  pathogen,	  
Clostridium	  difficile	  incidence	  cannot	  be	  driven	  below	  1	  per	  1000	  bed	  days;	  these	  





Figure	  8:	  Impact	  of	  hygiene	  improvement	  programme	  on	  CDI	  incidence	  rate	  
	  
	  
Figure	  9	  shows	  the	  substantial	  decrease	  in	  CDI	  incidence	  rate	  between	  the	  highest	  
and	  lowest	  efficacy	  values	  for	  reducing	  LOS.	  The	  range	  of	  modelled	  values	  for	  
length	  of	  stay	  is	  between	  5.9	  days	  (upper)	  and	  2.9	  days	  (lower)	  for	  the	  simulated	  
cohort.	  	  






Given	  that	  the	  effectiveness	  of	  each	  intervention	  has	  been	  modelled	  for	  a	  range	  of	  
values,	  the	  analysis	  of	  a	  range	  of	  different	  scenarios	  for	  the	  economic	  evaluation	  is	  
possible.	  For	  example,	  the	  comparison	  between	  reducing	  antimicrobial	  use	  from	  
50%	  of	  patients	  to	  40%	  of	  patients	  can	  now	  be	  modelled	  using	  the	  dynamic	  
economic	  model.	  This	  is	  explored	  in	  further	  detail	  in	  the	  results	  and	  analysis	  
section	  of	  this	  document	  and	  is	  a	  novel	  aspect	  of	  this	  collaborative	  project.	  
	  
Analysis	  of	  economic	  results	  
Cost-­‐effectiveness	  analysis	  is	  a	  comparative	  analysis,	  measuring	  changes	  to	  total	  
costs	  and	  health	  outcomes,	  after	  the	  introduction	  of	  a	  new	  intervention	  or	  
technology.	  New	  interventions	  are	  usually	  only	  adopted	  if	  they	  offer	  some	  benefit	  
over	  treatment	  options	  that	  are	  currently	  provided.	  Changes	  to	  cost	  and	  health	  
outcome	  are	  generally	  measured	  by	  the	  incremental	  cost-­‐effectiveness	  ratio	  
(ICER),	  which	  is	  the	  amount	  that	  a	  decision-­‐maker	  would	  need	  to	  spend	  in	  order	  
to	  gain	  an	  improvement	  in	  health	  outcome.	  The	  formula	  used	  to	  calculate	  ICERs	  is	  
expressed	  as	  follows	  (163):	  
	  
	   ICER	  =	   C1	  –	  C2	  =	  Change	  in	  Costs	  
E1	  –	  E2	  	  	  	  	  Change	  in	  Effects	  
	  
Where	  C1	  represents	  the	  total	  cost	  of	  intervention	  1	  and	  C2	  represents	  the	  total	  
cost	  of	  intervention	  2,	  E1	  represents	  the	  total	  health	  outcomes	  of	  intervention	  1	  and	  




effectiveness	  ratios	  are	  usually	  used	  to	  compare	  single	  interventions	  to	  a	  
comparator.	  However,	  there	  are	  issues	  with	  using	  ICERs	  for	  decision-­‐making	  given	  
the	  awkward	  statistical	  properties	  of	  ratio	  information.	  	  
	  
The	  net	  monetary	  benefit	  framework	  is	  more	  appropriate	  for	  decision-­‐making	  
purposes,	  as	  it	  offers	  simpler	  comparison	  of	  multiple	  interventions	  and	  the	  
capacity	  to	  consider	  various	  thresholds	  for	  willingness	  to	  pay	  for	  health	  benefits.	  
Results	  are	  converted	  from	  the	  ICER	  to	  a	  net	  monetary	  benefit	  value,	  through	  the	  
linear	  rearrangement	  of	  the	  ICER	  equation,	  as	  follows	  (203):	  
	  
NMB	  =	  (WTP	  threshold	  *	  Change	  in	  Effects)	  –	  Change	  in	  Costs	  
	  
The	  interpretation	  about	  cost-­‐effectiveness	  becomes	  particularly	  simple	  using	  the	  
net	  monetary	  benefit	  framework;	  a	  positive	  NMB	  indicates	  that	  a	  strategy	  is	  cost-­‐
effective	  and	  a	  negative	  NMB	  indicates	  that	  a	  strategy	  is	  not	  cost-­‐effective.	  The	  
value	  of	  the	  willingness	  to	  pay	  threshold	  can	  be	  altered	  according	  to	  local	  
conditions,	  lending	  flexibility	  and	  pragmatism	  to	  the	  results.	  	  
	  
As	  such,	  for	  the	  results	  of	  the	  analysis	  to	  be	  used	  by	  decision-­‐makers,	  they	  need	  to	  
have	  a	  clear	  grasp	  of	  what	  their	  willingness	  to	  pay	  for	  additional	  QALYs	  is.	  This	  is	  
to	  understand	  and	  rationalise	  what	  their	  threshold	  for	  cost-­‐effectiveness	  is,	  




the	  willingness	  to	  pay	  threshold,	  decision-­‐makers	  should	  look	  to	  adopt	  
interventions	  that	  fall	  under	  this	  figure.	  There	  is	  robust	  debate	  around	  the	  world	  
about	  what	  amount	  the	  willingness	  to	  pay	  threshold	  should	  be,	  with	  the	  
suggestion	  that	  different	  thresholds	  are	  appropriate	  (204).	  The	  reality	  is	  that	  the	  
threshold	  itself	  is	  vulnerable	  to	  change	  according	  to	  the	  local	  decision-­‐making	  
context	  and	  is	  likely	  to	  differ	  across	  jurisdictions.	  For	  this	  study,	  a	  willingness	  to	  
pay	  threshold	  of	  $42,000/QALY	  has	  been	  used	  as	  the	  decision-­‐maker’s	  threshold.	  
This	  figure	  is	  less	  than	  published	  figures	  for	  some	  cost-­‐effectiveness	  studies	  in	  
Australia,	  where	  $64,000/QALY	  is	  used,	  but	  is	  in	  line	  with	  PBAC	  funding	  patterns,	  
which	  show	  a	  higher	  likelihood	  of	  funding	  interventions	  that	  fall	  beneath	  a	  
$42,000/QALY	  threshold	  (205).	  	  
	  
4.4	  Costing	  methods	  
Economic	  costs	  reflect	  opportunity	  costs	  of	  resources	  used	  and	  are	  more	  
appropriate	  for	  decision-­‐making	  and	  resource	  allocation	  (10).	  This	  approach	  is	  
useful	  for	  estimating	  the	  cost-­‐effectiveness	  of	  interventions	  and	  will	  differentiate	  
this	  research	  from	  other	  attempts	  to	  address	  the	  cost	  of	  Clostridium	  difficile	  
infection.	  
	  
Page	  et	  al	  note	  that	  when	  quantifying	  costs	  for	  infection	  control	  interventions,	  
there	  are	  three	  significant	  processes	  that	  need	  to	  take	  place	  to	  ensure	  a	  robust	  




be	  identified,	  measured	  and	  valued	  (120).	  The	  purpose	  of	  this	  method	  is	  to	  capture	  
all	  resource	  changes	  that	  occur	  if	  a	  health	  intervention	  is	  implemented	  and	  to	  
record	  the	  expenditure	  required	  to	  produce	  a	  health	  effect.	  
	  
Identifying	  resources:	  	  
The	  medical	  and	  non-­‐medical	  resources	  directly	  used	  for	  each	  intervention	  were	  
identified	  and	  are	  explained	  in	  further	  detail	  in	  the	  next	  section	  of	  this	  chapter	  
(4.4.1).	  Differentiating	  between	  medical	  resources	  and	  non-­‐medical	  resources	  was	  
undertaken	  by	  developing	  checklists	  and	  inventories	  of	  what	  is	  required	  for	  each	  
intervention	  to	  run	  in	  a	  real-­‐world	  hospital.	  The	  checklists	  can	  be	  viewed	  in	  the	  
next	  section	  of	  this	  chapter,	  for	  each	  intervention.	  Published	  literature	  was	  used	  to	  
conceptualise	  the	  requirements	  of	  each	  intervention	  in	  the	  first	  instance	  and	  
expert	  opinion	  was	  sought	  to	  verify	  that	  all	  relevant	  resources	  were	  identified.	  
Using	  clinical	  experts	  to	  crosscheck	  the	  descriptions	  of	  each	  intervention	  ensured	  
that	  the	  identification	  of	  resources	  was	  as	  consistent	  and	  accurate	  as	  possible.	  In	  
most	  cases,	  there	  was	  a	  dearth	  of	  published	  evidence	  about	  exactly	  which	  
resources	  should	  be	  identified	  for	  inclusion	  in	  an	  analysis.	  A	  further	  reason	  for	  
utilising	  expert	  opinion	  is	  that	  much	  of	  the	  published	  evidence	  was	  not	  directly	  
generalisable	  to	  the	  local	  setting,	  given	  that	  in	  many	  cases	  the	  healthcare	  system	  






Measuring	  resources	  used:	  
A	  microcosting	  approach	  was	  taken	  to	  measuring	  required	  medical	  resources	  (16).	  
Microcosting	  includes	  detailing	  all	  inputs	  used	  in	  the	  treatment	  of	  a	  particular	  
patient.	  This	  is	  in	  contrast	  to	  a	  gross	  costing	  approach,	  where	  average	  costs	  of	  
major	  events	  relating	  to	  an	  intervention	  or	  patient’s	  treatment	  are	  assigned	  as	  the	  
cost	  (206).	  Estimates	  for	  the	  cost	  of	  items	  that	  are	  required	  for	  the	  intervention	  to	  
function,	  in	  a	  clinical	  sense,	  were	  based	  on	  the	  purchase	  price	  where	  possible.	  
When	  such	  prices	  were	  not	  readily	  available,	  prices	  were	  sought	  using	  other	  
reasonable	  methods.	  For	  example,	  a	  price	  for	  the	  UV	  torch	  that	  is	  required	  for	  an	  
environmental-­‐cleaning	  bundle	  was	  unavailable	  from	  the	  study	  hospital.	  In	  lieu,	  
the	  price	  was	  sought	  from	  a	  healthcare	  technology	  supplier	  and	  uncertainty	  about	  
the	  price	  built	  into	  the	  economic	  model	  using	  a	  statistical	  distribution.	  
Measurement	  of	  non-­‐medical	  resources,	  such	  as	  staff	  time,	  was	  completed	  by	  
using	  best	  available	  estimates.	  Evidence	  from	  the	  literature,	  as	  well	  as	  expert	  
opinion	  was	  used	  to	  inform	  how	  best	  to	  measure	  non-­‐medical	  costs	  for	  each	  
intervention.	  Further	  details	  about	  the	  costs	  that	  were	  included	  in	  each	  cost	  
analysis	  can	  be	  seen	  in	  Tables	  6,	  8,	  11	  and	  13.	  
	  
Valuing	  resources:	  
For	  medical	  resources	  such	  as	  consumables,	  the	  price	  paid	  by	  the	  hospital	  was	  
used	  to	  populate	  the	  cost	  analysis	  for	  each	  intervention.	  Invoices	  and	  self-­‐reported	  




intervention.	  Items	  included	  in	  the	  cost	  analysis	  of	  each	  intervention	  as	  well	  as	  the	  
information	  required	  for	  that	  item	  and	  the	  source	  of	  such	  information	  can	  be	  
found	  in	  the	  following	  section,	  4.4.1:	  Intervention	  related	  costs.	  	  
	  
Each	  intervention	  required	  the	  valuation	  of	  staff	  time	  and	  the	  number	  of	  staff	  
required	  for	  each	  intervention	  differed,	  as	  did	  the	  pay	  scale	  for	  each	  profession.	  
The	  pay	  scale	  has	  an	  influence	  on	  the	  overall	  cost	  of	  each	  intervention	  given	  that	  
there	  is	  a	  large	  difference	  between	  pay	  rates	  across	  different	  professions	  in	  the	  
healthcare	  sector.	  In	  order	  to	  ensure	  accuracy,	  pay	  scales	  from	  Queensland	  Health	  
were	  used	  to	  calculate	  the	  staff	  time	  for	  each	  intervention.	  	  
	  
To	  avoid	  overestimation	  of	  staffing	  costs,	  only	  the	  extra	  hours	  that	  were	  required	  
of	  staff	  to	  implement	  or	  maintain	  an	  intervention	  were	  included	  in	  the	  cost	  
analysis.	  This	  ensures	  that	  only	  the	  incremental	  costs	  are	  considered	  and	  there	  is	  a	  
clear	  framework	  for	  dividing	  the	  labour	  costs	  of	  workers	  whose	  job	  cuts	  across	  a	  
range	  of	  duties.	  For	  example,	  to	  ensure	  that	  only	  the	  time	  spent	  by	  cleaning	  staff	  
on	  tasks	  relating	  to	  the	  environmental	  cleaning	  bundle	  were	  captured;	  we	  did	  not	  
factor	  in	  the	  costs	  of	  doing	  their	  ‘regular	  duties’.	  We	  included	  the	  cost	  of	  
undertaking	  specialist,	  isolation	  cleans	  and	  the	  cost	  of	  attending	  extra	  training	  
sessions	  related	  to	  the	  bundle,	  but	  we	  did	  not	  include	  the	  cost	  of	  annual	  




have	  occurred	  regardless	  of	  whether	  a	  new	  intervention	  was	  in	  place	  or	  not	  and	  
thus,	  do	  not	  need	  to	  be	  valued.	  
 
4.4.1	  Intervention	  Costs	  
Hygiene	  Improvement	  (environmental	  cleaning	  &	  hand	  hygiene)	  
Environmental	  cleaning	  programme	  
In	  the	  case	  of	  an	  environmental	  cleaning	  programme,	  the	  incremental	  costs	  of	  
implementing	  an	  environmental	  cleaning	  bundle	  have	  been	  used.	  Information	  has	  
been	  gathered	  from	  a	  research	  study	  that	  was	  conducted	  as	  part	  of	  the	  CRE-­‐RHAI	  
that	  focused	  on	  the	  implementation	  of	  a	  cleaning	  bundle	  for	  the	  purpose	  of	  
reducing	  healthcare	  associated	  infections	  at	  a	  medium	  sized	  Brisbane	  
metropolitan	  hospital	  (207).	  
	  
Development	  of	  the	  environmental	  cleaning	  bundle	  was	  undertaken	  using	  two	  
main	  processes	  –	  a	  structured	  literature	  review	  and	  a	  multi-­‐disciplinary	  expert	  
panel.	  The	  structured	  literature	  review	  revealed	  which	  interventions	  were	  suitable	  
for	  inclusion	  in	  the	  bundle.	  Evidence	  from	  Australia	  and	  abroad	  was	  reviewed	  and	  
the	  effectiveness,	  feasibility	  of	  implementation	  and	  cost	  of	  implementation	  was	  
considered.	  The	  results	  of	  the	  literature	  search	  were	  mixed	  -­‐	  with	  some	  evidence	  
readily	  available	  and	  other	  information	  difficult	  to	  accurately	  evaluate.	  For	  




scarce	  –	  as	  was	  information	  about	  the	  practicality	  of	  implementing	  new	  
interventions.	  
	  
Given	  the	  difficulties	  in	  relying	  solely	  on	  the	  literature,	  an	  expert	  panel	  was	  sought	  
to	  augment	  the	  literature	  and	  to	  prioritise	  the	  available	  interventions	  into	  a	  
bundle.	  A	  half-­‐day	  workshop	  was	  held	  with	  a	  multi-­‐disciplinary	  panel,	  which	  
included	  contributors	  from	  environmental	  services,	  infection	  prevention	  and	  
control,	  microbiology,	  infectious	  diseases	  and	  epidemiology.	  The	  experts	  were	  
from	  three	  states	  in	  Australia	  –	  Queensland,	  New	  South	  Wales	  and	  Tasmania.	  
In	  addition	  to	  the	  expert	  panel,	  consultation	  workshops	  were	  undertaken	  with	  
environmental	  service	  workers	  at	  the	  pilot	  site	  to	  target	  the	  bundle	  
implementation	  to	  suit	  the	  local	  situation.	  The	  bundle	  was	  implemented	  using	  an	  
implementation	  science	  framework	  –	  Promoting	  Action	  on	  Research	  
Implementation	  in	  Health	  Services	  (PARIHS).	  The	  costs	  relating	  to	  the	  cleaning	  
bundle	  were	  elicited	  in	  a	  number	  of	  different	  ways	  and	  the	  information	  source	  for	  
each	  item	  is	  noted	  in	  Table	  5.	  For	  example,	  some	  costs	  such	  as	  auditing	  time	  and	  
time	  taken	  to	  undertake	  new	  duties	  were	  self	  reported	  by	  the	  team	  at	  the	  pilot	  site.	  
Other	  costs,	  such	  as	  those	  associated	  with	  staff	  meetings	  were	  determined	  by	  
using	  Queensland	  Health	  staffing	  payscales.	  
	  
Multiple	  cost	  types	  have	  been	  collected	  as	  part	  of	  this	  process,	  including	  those	  




resources)	  and	  those	  resources	  that	  can	  be	  classified	  as	  being	  non-­‐medical,	  such	  as	  
staff	  time.	  All	  costs	  have	  been	  calculated	  for	  a	  year-­‐long	  period	  at	  a	  medium	  sized,	  
metropolitan	  hospital	  (between	  250	  and	  500	  beds)	  and	  include	  the	  costs	  required	  
to	  maintain	  the	  programme.	  Importantly,	  costs	  that	  already	  exist	  within	  a	  standard	  
cleaning	  programme	  -­‐	  sunk	  costs	  -­‐	  such	  as	  staff	  training	  already	  mandatorily	  
undertaken,	  have	  not	  been	  included.	  Multiple	  sources	  of	  evidence	  were	  used	  to	  
complete	  the	  cost	  analysis	  and	  can	  be	  seen	  in	  Table	  5.	  	  
Table	  5:	  Cost	  items,	  information	  required	  and	  source	  of	  evidence	  included	  in	  cost	  
analysis	  of	  the	  Environmental-­‐cleaning	  bundle.	  
Item	  Name	   Information	  Required	   Source	  
Training	  Session	   Staff	  wages	   Qld	  Health	  Payscales	  
	   Number	  /	  Grade	  of	  participants	   Meeting	  minutes	  
	   Length	  of	  training	  session	   Meeting	  minutes	  
Survey	   Staff	  wages	   Qld	  Health	  Payscales	  
	   Survey	  time	   Self	  reported	  
	   Number	  /	  Grade	  of	  participants	   Meeting	  minutes	  
Consultation	   Staff	  wages	   Qld	  Health	  Payscales	  
	   Consultation	  time	   Self	  reported	  
Audit	   Staff	  wages	   Qld	  Health	  Payscales	  
	   Audit	  time	   Self	  reported	  
Feedback	   Staff	  wages	   Qld	  Health	  Payscales	  
	   Feedback	  time	   Self	  reported	  
Weekly	  meetings	   Staff	  wages	   Qld	  Health	  Payscales	  
	   Length	  of	  meeting	   Meeting	  minutes	  
	   Number	  /	  Grade	  of	  participants	   Meeting	  minutes	  
	   Number	  of	  meetings	   Meeting	  minutes	  
Additional	  weekly	  tasks	   Staff	  wages	   Qld	  Health	  Payscales	  




Coordinator	   Staff	  wages	   Qld	  Health	  Payscales	  
	   Time	  taken	  to	  perform	  tasks	   Self	  reported	  
	   Number	  of	  weeks	  required	   Self	  reported	  
Isolation	  cleaning	   Minutes	  per	  clean	   Qld	  Health	  Statewide	  Services	  
	   Staff	  wages	   Qld	  Health	  Payscales	  
	   Number	  /	  Grade	  of	  participants	   Staff	  guidelines	  
	   Number	  of	  cleans	  required	   CDI	  cases	  per	  annum	  
Audit	  markers	   Cost	  of	  markers	   Invoice	  
UV	  torch	   Cost	  of	  UV	  torch	   Market	  price	  (Clinell)	  
Tablets	  for	  auditing	   Number	  of	  tablets	  required	   Self	  reported	  
	   Cost	  of	  tablets	   Invoice	  
iCombat	  software	   Cost	  per	  month	   Invoice	  
	   Number	  of	  months	  required	   Per	  annum	  
Medical	  consumables	   Cost	  of	  resources	  used	   Invoice	  
	   Amount	  of	  resources	  used	   Site	  records	  
Advertising	   Cost	  of	  posters	   Invoice	  
	   Cost	  of	  flipbooks	   Invoice	  
Training	  room	   Cost	  to	  book	  room	  (per	  hr)	   Self	  reported	  
	   Number	  of	  hours	  required	   Meeting	  minutes	  
	  
The	  costs	  that	  have	  been	  included	  as	  a	  result	  of	  the	  analysis	  can	  be	  seen	  in	  Table	  6.	  






Table	  6:	  Items,	  costs	  and	  distributions	  relating	  to	  the	  Environmental-­‐cleaning	  
bundle	  for	  use	  in	  the	  economic	  model.	  
Item	  Name	   Cost	  
Staff	  costs	   	  
Training	  session	   $1	  750.63	  
Consultation	   $239.62	  
Audit	   $478.23	  
Feedback	   $374.83	  
Weekly	  meetings	   $9	  664.00	  
Additional	  weekly	  tasks	   $785.20	  
Coordinator	   $2	  080.00	  
Isolation	  cleaning	   $11	  325.20	  
Equipment	   	  
Audit	  markers	   $72	  
UV	  torch	   $87.45	  
Tablets	  for	  auditing	   $800	  
iCombat	  software	   $3	  600	  
Consumables	   	  
Medical	  consumables	   $2	  097.80	  
Advertising	   $1	  420	  
Space	   	  
Training	  room	   $360	  
TOTAL	  COSTS:	  $35,134.96	  
	  
Hand	  hygiene	  programme	  
Estimating	  the	  cost	  of	  a	  hand	  hygiene	  programme	  has	  been	  the	  focus	  of	  a	  major	  
recent	  study	  within	  the	  HSR	  group	  at	  Queensland	  University	  of	  Technology.	  The	  




programme	  that	  was	  implemented	  across	  Australia.	  The	  Initiative	  was	  managed	  by	  
hand	  hygiene	  Australia	  and	  is	  designed	  to	  reduce	  healthcare	  associated	  infections	  
by	  improving	  the	  general	  level	  of	  hand	  hygiene	  amongst	  healthcare	  workers	  and	  
patient	  visitors.	  The	  study	  aimed	  to	  identify	  incremental	  changes	  to	  costs	  as	  a	  
result	  of	  adopting	  the	  NHHI	  in	  place	  of	  existing	  hand	  hygiene	  compliance	  
programmes.	  An	  extensive	  explanation	  of	  the	  methods	  and	  data	  collection	  relating	  
to	  this	  evaluation	  has	  already	  been	  published	  (208).	  
	  
Costs	  were	  collected	  according	  to	  four	  categories;	  hand	  hygiene	  Australia	  costs,	  
State	  health	  department	  costs,	  local	  hospital-­‐level	  running	  costs	  and	  consumables.	  
Information	  was	  gathered	  using	  a	  number	  of	  approaches,	  including	  semi	  
structured	  interviews,	  online	  survey,	  telephone	  interviews	  with	  relevant	  
stakeholders	  from	  hand	  hygiene	  Australia	  and	  expert	  opinion	  through	  steering	  
committee	  meetings	  with	  the	  Initiative’s	  funding	  body	  –	  the	  Australian	  
Commission	  for	  Safety	  and	  Quality	  in	  Health	  Care	  (ACSQHC).	  
Multiple	  sources	  of	  evidence	  were	  used	  to	  complete	  the	  cost	  analysis	  and	  can	  be	  





Table	  7:	  Cost	  items,	  information	  required	  and	  source	  of	  evidence	  included	  in	  cost	  
analysis	  of	  a	  hand	  hygiene	  initiative.	  
Item	  Name	   Information	  Required	   Source	  
Hand	  hygiene	  Australia	  costs	   	   	  
Annual	  running	  costs	   Staff	  wages	   State	  coordinator	  –	  HHA	  
	   Relevant	  staff	  mix	   State	  coordinator	  –	  HHA	  
	   Running	  costs	   State	  coordinator	  –	  HHA	  
State	  health	  Dept.	  costs	   	   	  
Local	  staff	  costs	   Staff	  wages	   Relevant	  payscales	  
	   Relevant	  staff	  mix	   Infection	  control	  management	  
Information	  technology	   Cost	  of	  equipment	   Infection	  control	  management	  
	   Type	  of	  equipment	  
required	  
Infection	  control	  management	  
Travel	  costs	   Relevant	  use	   Infection	  control	  management	  
Local	  hospital	  running	  costs	   	   	  
Auditing	   Staff	  wages	   Relevant	  payscales	  
	   Time	  taken	  to	  audit	   Infection	  control	  management	  
	   Staff	  who	  are	  auditing	   Infection	  control	  management	  
Education	  and	  training	   Staff	  wages	   Relevant	  payscales	  
	   Length	  of	  training	   Infection	  control	  management	  
	   Participants	   Infection	  control	  management	  
Meetings	   Staff	  wages	   Relevant	  payscales	  
	   Length	  of	  meeting	   Infection	  control	  management	  
	   Participants	   Infection	  control	  management	  
Consumables	   	   	  
Alcohol	  based	  hand	  rub	   Resource	  usage	   Qld	  Health	  clinical	  supplies	  
Brackets	  for	  mounting	  hand	  rub	   Number	  required	   Qld	  Health	  clinical	  supplies	  





The	  costs	  that	  have	  been	  included	  as	  a	  result	  of	  the	  analysis	  can	  be	  seen	  in	  Table	  8.	  
The	  total	  costs	  represent	  the	  combined	  cost	  of	  the	  NHHI	  for	  the	  50	  largest	  
hospitals	  in	  Australia.	  
	  
Table	  8:	  Items	  and	  costs	  relating	  to	  the	  hand	  hygiene	  programme	  for	  use	  in	  the	  
economic	  model.	  
Item	  Name	   Cost	  (annual)	  
Hand	  hygiene	  Australia	  costs	   $1,025,998	  
State	  health	  dept.	  costs	   $558,073	  
Local	  hospital	  running	  costs	   $3,631,372	  
Consumables	   $347,722	  
TOTAL	  COSTS:	  $5,563,164	  
	  
The	  total	  cost	  for	  a	  hygiene	  improvement	  programme,	  as	  described	  in	  this	  project,	  
incorporates	  the	  following	  costs:	  
• The	  annual	  cost	  of	  an	  environmental	  cleaning	  bundle	  
• The	  annual	  cost	  of	  a	  hand	  hygiene	  programme	  
The	  total	  cost	  of	  this	  intervention	  that	  will	  be	  incorporated	  in	  the	  economic	  model	  
for	  analysis	  can	  be	  seen	  in	  Table	  9.	  
Table	  9:	  Total	  annual	  cost	  of	  a	  hygiene	  improvement	  programme	  in	  one	  hospital.	  
Item	  Name	   Cost	  
Environmental	  cleaning	  bundle	   $35,135	  
Hand	  hygiene	  programme	   $111,263	  




Antimicrobial	  stewardship	  programme	  
Inappropriate	  use	  of	  antibiotics	  has	  existed	  for	  many	  years	  and	  studies	  have	  shown	  
that	  up	  to	  half	  of	  antimicrobial	  regimens	  that	  are	  prescribed	  in	  Australian	  
hospitals	  are	  considered	  inappropriate	  (209-­‐211).	  The	  recently	  recognised	  rapid	  
increase	  in	  multi-­‐drug	  resistant	  bacterial	  pathogens	  has	  triggered	  a	  shift	  in	  
approach	  to	  antibiotic	  use	  and	  management	  (212).	  The	  consequences	  of	  
inappropriate	  antimicrobial	  use	  are	  well	  recognised	  with	  patients	  at	  increased	  risk	  
of	  colonisation	  and	  infection	  with	  resistant	  organisms.	  Infected	  patients	  are	  more	  
likely	  to	  transmit	  infection	  to	  other	  patients	  and	  they	  are	  more	  likely	  to	  experience	  
treatment	  failure,	  longer	  hospital	  stays	  and	  an	  increased	  chance	  of	  mortality	  (213).	  
Exposure	  to	  antimicrobials	  is	  a	  well-­‐documented	  risk	  factor	  for	  Clostridium	  difficile	  
and	  the	  majority	  of	  infected	  individuals	  have	  had	  over-­‐exposure	  to	  antibiotics.	  The	  
judicious	  use	  of	  antimicrobials	  is	  imperative	  to	  ensure	  that	  their	  benefit	  is	  
optimised	  in	  our	  hospital	  system	  and	  that	  patients	  are	  protected	  from	  harm.	  
Antimicrobial	  stewardship	  involves	  a	  systematic	  approach	  to	  optimising	  the	  use	  of	  
antibiotics	  and	  is	  a	  key	  strategy	  employed	  at	  local	  level	  to	  reduce	  the	  incidence	  of	  
preventable	  healthcare	  associated	  infections	  like	  Clostridium	  difficile	  (212).	  	  
	  
The	  Australian	  Commission	  on	  Safety	  and	  Quality	  in	  HealthCare	  (ACSQHC)	  has	  
published	  guidelines	  for	  developing	  and	  managing	  AMS	  programmes	  specifically	  
for	  the	  Australian	  setting.	  The	  key	  elements	  of	  an	  established	  programme	  include	  




all	  stakeholders	  (212).	  A	  successful	  programme	  requires	  input	  from	  a	  variety	  of	  
clinical	  backgrounds	  and	  a	  robust	  communication	  strategy	  that	  makes	  use	  of	  AMS	  
specific	  information	  technology.	  The	  ideal	  AMS	  programme	  has	  a	  significant	  
‘staffing	  cost’	  element	  given	  that	  the	  programme	  should	  include	  an	  AMS-­‐dedicated	  
committee	  that	  meets	  on	  a	  regular	  basis	  and	  requires	  clinicians	  to	  undertake	  AMS-­‐
only	  duties	  each	  week	  (duties	  not	  related	  to	  their	  other	  clinical	  roles)	  (212).	  Other	  
costs,	  such	  as	  the	  cost	  of	  equipment	  used	  in	  the	  clinical	  laboratory	  and	  decision-­‐
guidance	  systems	  are	  also	  required	  to	  be	  included	  in	  any	  analysis	  of	  cost	  and	  cost-­‐
effectiveness.	  Table	  10	  shows	  information	  that	  is	  required	  to	  be	  collected	  about	  the	  





Table	  10:	  Information	  required	  for	  thorough	  costing	  of	  AMS	  programme	  
Item	  Name	   Information	  Required	   Source	  
Staffing	   	   	  
Committee	   Number	  of	  meetings	  required	   Self	  reported	  by	  Hospital	  
	   Participants	  of	  committee	   Clinical	  Guidelines	  
	   Grade	  of	  participants	   Clinical	  Guidelines	  
	   Length	  of	  meeting	  time	   Self	  reported	  by	  Hospital	  
	   Payscales	  of	  participants	   Qld	  Health	  Payscales	  
AMS-­‐only	  duties	   Members	  of	  AMS	  team	   Clinical	  Guidelines	  
	   Grade	  of	  participants	   Self	  reported	  by	  Hospital	  
	   Payscales	  of	  participants	   Qld	  Health	  Payscales	  
	   FTE	  for	  each	  participant	   Self	  reported	  by	  Hospital	  
Equipment	   	   	  
Instrument	  (Maldi-­‐tof)	   Cost	  of	  instrument	   Commercial-­‐in-­‐confidence	  
	   Average	  lifespan	  of	  equipment	   Supplier	  /	  Warranty	  
Guidance	  (IT	  system)	   Decision-­‐making	  system	   Commercial-­‐in-­‐confidence	  
	   Average	  lifespan	  of	  equipment	   Supplier	  /	  Warranty	  
	   License	  fee	   Commercial-­‐in-­‐confidence	  
	   Support	  fee	   Commercial-­‐in-­‐confidence	  
Space	   	   	  
Room	  booking	   Cost	  to	  book	  room	  for	  
meetings	  
Estimate	  (per	  hr)	  
	   Number	  of	  hours	  for	  meetings	   Self	  reported	  by	  Hospital	  
Consumables	   	   	  
Vitek	  MS	   Cost	  per	  identification	   Hospital	  quoted	  price	  
	   Number	  of	  identifications	  per	  
yr	  
Self	  reported	  by	  Hospital	  
	  
Costs	  have	  been	  collected	  using	  a	  microcosting	  approach	  –	  this	  is	  the	  same	  format	  
as	  for	  other	  interventions	  that	  are	  being	  evaluated	  in	  this	  project.	  Multiple	  cost	  




to	  the	  equipment	  that	  is	  required	  to	  run	  the	  programme	  and	  others	  being	  the	  cost	  
of	  the	  staff	  that	  are	  required	  for	  a	  programme	  to	  run	  effectively.	  The	  costs	  gathered	  
for	  this	  evaluation	  that	  relate	  to	  equipment	  include	  a	  decision	  support	  system	  
(known	  as	  ‘guidance’).	  This	  equipment	  is	  not	  present	  in	  all	  hospitals	  but	  it	  is	  
recommended	  in	  the	  ACQSHC	  guidelines	  as	  being	  of	  high	  priority	  at	  the	  local	  level	  
and	  has	  thus	  been	  included.	  Staffing	  costs	  include	  an	  AMS-­‐specific	  Committee	  
meeting	  held	  bi-­‐monthly	  for	  90	  minutes.	  They	  also	  include	  the	  cost	  of	  the	  
following	  clinicians	  working	  on	  AMS-­‐specific	  duties	  each	  week,	  to	  reflect	  the	  ideal,	  
multidisciplinary	  approach:	  
• 0.6	  FTE	  AMS	  Pharmacist	  (Queensland	  Health	  pay	  band	  HP5)	  
• 0.3	  FTE	  AMS	  Physician	  (Queensland	  Health	  pay	  band	  L22	  –	  MO1-­‐5)	  
• 0.1	  FTE	  AMS	  Microbiologist	  (Queensland	  Health	  pay	  band	  L22	  –	  MO1-­‐5)	  
	  
Total	  annual	  costs	  have	  been	  calculated	  and	  are	  shown	  in	  Table	  11.	  Equipment	  
costs	  have	  been	  amortised	  over	  the	  average	  lifespan	  to	  give	  an	  annual	  figure.	  The	  
number	  of	  tests	  run	  and	  therefore	  consumables	  used	  has	  been	  estimated	  based	  on	  
a	  large	  metropolitan	  hospital’s	  average	  annual	  throughput	  and	  could	  be	  adjusted	  





Table	  11:	  Annual	  costs	  of	  running	  an	  AMS	  programme	  
Item	  Name	   Cost	  (annual)	  
Staffing	   	  
Committee	  meeting	   $8,181.70	  
AMS-­‐specific	  duties	   $132,438.56	  
Equipment	   	  
Instrument	   $30,000	  
Guidance	   $26,298.49	  
Space	   	  
Meeting	  room	   $270	  
Consumables	   	  
Vitek	  MS	   $43,200	  
TOTAL	  COSTS	  =	  $240,388.76	  
	  




Fecal	  microbiota	  transplant	  (FMT)	  
Fecal	  transplant	  is	  a	  burgeoning	  field	  of	  treatment	  for	  patients	  suffering	  from	  
Clostridium	  difficile	  infection.	  Given	  that	  the	  treatment	  is	  still	  being	  developed	  and	  
yet	  to	  become	  mainstream	  in	  Australia,	  there	  is	  limited	  information	  made	  publicly	  
available	  about	  the	  treatment	  and	  the	  cost.	  There	  is	  a	  large	  private	  provider	  of	  
FMT	  based	  in	  Sydney,	  however	  data	  were	  unavailable.	  As	  such,	  costs	  relating	  to	  
the	  provision	  of	  a	  FMT	  service	  have	  been	  obtained	  from	  multiple	  sources	  and	  are	  
listed	  in	  Table	  12.	  	  
	  
Table	  12	  shows	  information	  required	  on	  all	  aspects	  of	  an	  FMT	  service.	  The	  table	  
also	  shows	  the	  source	  of	  the	  information,	  such	  as	  information	  from	  clinical	  
experts,	  industry	  quotes,	  clinical	  suppliers	  and	  the	  literature.	  	  
Table	  12:	  Information	  required	  for	  thorough	  costing	  of	  FMT	  service	  
Item	  Name	   Information	  Required	   Source	  
Medical	  consumables	   	   	  
Gloves,	  gown	  &	  mask	   Cost	  of	  resources	  used	   Market	  price	  
	   Number	  of	  resources	  used	   Expert	  opinion	  
Non-­‐consumable	  equipment	   	   	  
Specialist	  freezer	   Cost	  of	  freezer	   Invoice	  
Specialist	  blender	   Cost	  of	  blender	   Invoice	  
Staffing	   	   	  
Pre-­‐treatment	  work	  up	   Number	  of	  meetings	  required	   Expert	  opinion	  (Clinician)	  
	   Grade	  of	  medical	  participant/s	   Clinical	  Guidelines	  
	   Length	  of	  meeting	  (time)	   Expert	  opinion	  (Clinician)	  
	   Payscales	   Qld	  Health	  Payscales	  




	   Length	  of	  procedure	  (time)	   Expert	  opinion	  (Clinician)	  
	   Number	  of	  participants	   Expert	  opinion	  (Clinician)	  
	   Payscales	   Qld	  Health	  Payscales	  
Recovery	  time	   Grade	  of	  medical	  participant	   Clinical	  Guidelines	  
	   Length	  of	  time	  required	   Expert	  opinion	  (Clinician)	  
	   Number	  of	  participants	   Clinical	  Guidelines	  
	   Payscales	   Qld	  Health	  Payscales	  
Medical	  procedures	   	   	  
Testing	  patient	  prior	  to	  FMT	   Type	  of	  screening	  tests	   142	  
	   Number	  of	  tests	  required	   142	  
	   Cost	  of	  screening	  tests	   142	  
Testing	  donor	  prior	  to	  FMT	   Type	  of	  screening	  tests	   214	  
	   Number	  of	  tests	  required	   142;	  214	  
	   Cost	  of	  screening	  tests	   214	  
	   Number	  of	  donations	  required	   Expert	  opinion	  (Clinician)	  
Pre-­‐treatment	  drug	  therapy	   Type	  of	  antibiotic/s	  required	   Clinical	  Guidelines	  
	   Antibiotic	  regimen	   Clinical	  Guidelines	  
	   Cost	  of	  antibiotics	   197	  
Transplant	   	   	  
FMT	  preparation	   Grade	  of	  medical	  participant/s	   214	  
	   Time	  required	  to	  prepare	   214	  
Instillation	   	   	  
Colonoscopy	   Bowel	  lavage	   Market	  price	  
	   Loperamide	  for	  FMT	  retention	   Market	  price	  
	   Grade	  of	  medical	  participant/s	   Expert	  opinion	  (Clinician)	  
	   Cost	  of	  procedure	   195	  
Nasoduodenal	  delivery	   Grade	  of	  medical	  participant/s	   Expert	  opinion	  (Clinician)	  
	   Payscales	   Qld	  Health	  payscales	  
	   Length	  of	  time	  for	  procedure	   Clinical	  guidelines	  
	   Recovery	  time	   Clinical	  guidelines	  
Other	   	   	  
Advertising	  for	  donors	   Time	  to	  distribute	  flyers	   Self	  reported	  by	  Clinic	  





Donor	  incentives	   Number	  of	  donors	   Self	  reported	  by	  Clinic	  
	   Amount	  of	  gratuity	   Self	  reported	  by	  Clinic	  
	  
Costs	  have	  been	  collected	  using	  a	  microcosting	  approach	  –	  this	  is	  the	  same	  format	  
as	  for	  other	  interventions	  that	  are	  being	  evaluated	  in	  this	  project.	  Multiple	  cost	  
types	  have	  been	  collected	  as	  part	  of	  this	  process,	  including	  those	  directly	  required	  
to	  run	  the	  intervention	  from	  a	  medical	  point	  of	  view	  –	  for	  example,	  consumables,	  
medical	  equipment	  and	  medical	  procedures.	  The	  resources	  that	  can	  be	  classified	  as	  
being	  non-­‐medical,	  such	  as	  staff	  time,	  non-­‐consumable	  equipment	  and	  advertising	  
have	  also	  been	  collected.	  The	  costs	  have	  been	  broken	  down	  into	  a	  number	  of	  
different	  categories	  and	  can	  be	  clearly	  seen	  in	  Table	  13.	  All	  costs	  have	  been	  
calculated	  on	  a	  per-­‐treatment	  basis	  rather	  than	  on	  an	  annual	  basis.	  This	  allows	  the	  
comparison	  of	  costs	  for	  sites	  that	  conduct	  different	  numbers	  of	  treatments	  per	  
annum.	  Costs	  that	  already	  exist	  within	  a	  standard	  infection	  control	  programme	  –	  
sunk	  costs	  such	  as	  the	  cost	  of	  instrument	  sterilization,	  have	  not	  been	  included.	  
	  
The	  cost	  of	  recruiting	  donors,	  screening	  donated	  material,	  maintaining	  donated	  
material	  and	  preparing	  donated	  material	  has	  been	  included	  in	  this	  analysis	  
because	  at	  present	  there	  are	  no	  central	  ‘donation	  banks’	  that	  cater	  for	  multiple	  
sites.	  A	  donation	  bank	  model	  exists	  in	  the	  United	  States,	  where	  fecal	  transplant	  
has	  become	  more	  typical	  than	  in	  Australia.	  The	  donation	  bank	  model	  takes	  




reasonable	  assumption	  to	  make	  that	  in	  order	  to	  set	  up	  a	  fully	  functional	  FMT	  site	  
in	  Australia,	  all	  aspects	  relating	  to	  donation,	  management	  and	  preparation	  of	  
faeces	  should	  be	  accounted	  for.	  As	  such,	  the	  large	  costs	  relating	  to	  a	  specialist	  
freezer	  -­‐	  for	  the	  correct	  storing	  of	  donated	  material,	  and	  a	  specialist	  blender	  -­‐	  for	  
the	  preparation	  of	  the	  donated	  material	  prior	  to	  transplant,	  have	  been	  included.	  
They	  have	  had	  costs	  attached	  to	  them	  with	  the	  expected	  life	  of	  the	  equipment	  and	  
expected	  number	  of	  treatments	  per	  annum	  used	  to	  amortize	  the	  initial	  cost.	  For	  
example,	  a	  specialist	  -­‐80	  degree	  freezer	  that	  is	  required	  to	  store	  samples	  costs	  
$9000.	  However,	  for	  this	  analysis,	  the	  cost	  per	  treatment	  has	  been	  calculated	  by	  
using	  an	  expected	  life	  of	  5	  years	  ($9000/5	  =	  $1800	  per	  annum).	  This	  per	  annum	  cost	  
is	  then	  divided	  by	  the	  number	  of	  treatments	  conducted	  at	  a	  specific	  site	  (per	  year)	  
and	  the	  variation	  between	  a	  small	  site	  (10	  treatments	  per	  year	  -­‐	  $1800/10	  =	  $180)	  a	  
medium	  site	  (25	  treatments	  per	  year	  -­‐	  $1800/25	  =	  $72)	  and	  a	  large	  site	  (50	  
treatments	  per	  year	  -­‐	  $1800/50	  =	  $36)	  can	  be	  explored	  through	  sensitivity	  analysis.	  
	  
In	  the	  interest	  of	  consistency,	  costs	  relating	  to	  staffing	  have	  been	  calculated	  using	  
the	  pay	  scales	  from	  Queensland	  Health.	  These	  pay	  scales	  have	  been	  used	  in	  the	  
estimation	  of	  costs	  for	  other	  interventions	  and	  ensure	  that	  there	  is	  uniformity	  
across	  the	  evaluation.	  Staff	  costs	  do	  differ	  slightly	  from	  state-­‐to-­‐state	  in	  Australia,	  
but	  it	  is	  expected	  that	  the	  difference	  across	  jurisdictions	  is	  negligible.	  The	  
calculation	  of	  staffing	  costs	  has	  been	  set	  up	  in	  a	  manner	  that	  would	  allow	  simple	  




scales.	  To	  account	  for	  the	  fact	  that	  FMT	  can	  be	  delivered	  either	  nasoduodenally	  or	  
via	  colonoscopy,	  an	  averaged	  cost	  of	  both	  delivery	  modes	  is	  included	  in	  the	  total	  
cost.	  At	  present	  there	  is	  no	  clear	  evidence	  to	  suggest	  that	  either	  mode	  is	  more	  
efficacious	  than	  the	  other	  and	  the	  choice	  of	  delivery	  mode	  appears	  to	  be	  strongly	  
related	  to	  clinician	  preference.	  The	  items	  and	  costs	  relating	  to	  the	  FMT	  service	  are	  



















Table	  13:	  Items	  and	  costs	  relating	  to	  FMT	  service	  for	  use	  in	  the	  economic	  model	  
(cost	  per	  treatment	  is	  based	  on	  completing	  25	  treatments	  per	  annum)	  
Item	  Name	   Cost	  (per	  treatment)	   Notes	  
Medical	  consumables	   	   	  
Personal	  protective	  equipment	   $22.50	   	  
Non-­‐consumable	  equipment	   	   	  
-­‐80	  degree	  freezer	   $72	   Based	  on	  25	  treatments/yr	  
Specialist	  blender	   $12	   Based	  on	  25	  treatments/yr	  
Staffing	   	   	  
Pre-­‐treatment	  work	  up	   $60.00	   	  
Procedure	   $67.50	   	  
Recovery	  (post-­‐procedure)	   $81.00	   	  
Medical	  procedures	   	   	  
Testing	  patient	  prior	  to	  FMT	   $139.00	   	  
Pre-­‐treatment	  drug	  therapy	   $440.14	   	  
Testing	  donor	  prior	  to	  FMT	   $614.00	   	  
FMT	  preparation	   $87.00	   	  
Instillation	   	   	  
Via	  colonoscopy	   $989.56*	   Not	  included	  in	  total	  
Via	  Nasoduodenal	  delivery	   $241.50*	   Not	  included	  in	  total	  
Averaged	  cost	  of	  both	  delivery	  modes	   $615.53	   Included	  in	  total	  
Other	   	   	  
Recruitment	   $12.50	   	  
Advertising	   $3.48	   Total	  divided	  by	  25	  
treatments	  
TOTAL	  COSTS	  =	  $2,226.65	  (per	  treatment)	  
	  





Length	  of	  stay	  and	  its	  impact	  on	  risk	  of	  infection	  acquisition	  is	  well	  understood	  
(215-­‐216).	  Clearly,	  there	  are	  benefits	  that	  can	  be	  achieved	  from	  reducing	  a	  patient’s	  
length	  of	  stay,	  which	  could	  be	  realised	  across	  a	  number	  of	  different	  clinical	  spectra.	  
The	  reduction	  of	  hospital-­‐acquired	  infections	  like	  Clostridium	  difficile	  is	  only	  one	  
area	  that	  would	  benefit	  from	  a	  hospital-­‐wide	  approach.	  
	  
Given	  that	  an	  intervention	  of	  this	  kind	  would	  in	  practice	  be	  achieved	  through	  the	  
culmination	  of	  a	  hospital-­‐wide	  focus	  on	  reducing	  length	  of	  stay,	  it	  is	  impossible	  to	  
pinpoint	  the	  cost	  of	  this	  ‘intervention’	  in	  relation	  to	  Clostridium	  difficile	  only.	  As	  
such,	  I	  have	  not	  tied	  any	  cost	  to	  this	  intervention	  in	  this	  project	  and	  will	  present	  
the	  results	  relating	  to	  reducing	  length	  of	  stay	  in	  a	  separate	  section	  of	  the	  results	  
chapter	  –	  not	  in	  comparison	  to	  other,	  more	  practical	  interventions,	  such	  as	  
hygiene	  improvement	  or	  antimicrobial	  stewardship.	  
	  
Thoroughly	  analysing	  the	  impact	  that	  reducing	  length	  of	  stay	  could	  have	  on	  
Clostridium	  difficile	  will	  be	  more	  informative	  for	  the	  health	  system	  as	  a	  whole,	  
rather	  than	  for	  infection	  control	  practitioners,	  who	  would	  be	  more	  likely	  to	  benefit	  
indirectly	  from	  an	  overall	  strategy	  that	  focuses	  on	  length	  of	  stay.	  Yakob	  et	  al	  have	  
included	  estimates	  for	  reducing	  length	  of	  stay	  in	  their	  transmission	  model,	  which	  
enables	  the	  analysis	  of	  different	  scenarios	  to	  be	  included	  in	  the	  economic	  model.	  




of	  stay	  by	  any	  means,	  not	  as	  a	  result	  of	  a	  specific	  infection	  control	  intervention,	  has	  
on	  a	  hospital-­‐acquired	  infection	  like	  Clostridium	  difficile.	  
	  
4.4.2	  Infection	  related	  costs	  
Infection	  related	  costs	  
Costs	  relating	  to	  the	  infection	  itself	  have	  been	  categorised	  by	  diagnosis	  costs,	  
treatment	  costs	  and	  bedday	  costs.	  	  
	  
Diagnosis	  costs	  
Costs	  relating	  to	  the	  diagnosis	  of	  Clostridium	  difficile	  include	  all	  costs	  incurred	  by	  
the	  healthcare	  system	  when	  identifying	  and	  confirming	  the	  presence	  of	  the	  
infection.	  There	  are	  two	  routine	  tests	  that	  are	  required	  to	  identify	  and	  confirm	  the	  
presence	  of	  the	  infection.	  The	  first,	  a	  PCR	  test	  is	  required	  to	  determine	  if	  a	  patient	  
with	  suspected	  Clostridium	  difficile	  infection	  is	  a	  true	  positive.	  The	  second,	  a	  
ribotype	  test,	  is	  required	  in	  order	  to	  categorise	  the	  strain-­‐type	  that	  the	  patient	  is	  
infected	  with.	  Ribotyping	  is	  of	  benefit	  given	  that	  it	  provides	  treating	  physicians	  
greater	  context	  about	  the	  best	  treatment	  path	  to	  be	  followed	  and	  can	  aid	  in	  other	  
decisions	  about	  how	  an	  infected	  patient	  should	  be	  treated	  in	  the	  hospital	  
environment.	  For	  example,	  hypervirulent	  strains	  001,	  027	  &	  078	  have	  a	  more	  
urgent	  need	  for	  the	  isolation	  of	  infected	  patients,	  making	  the	  management	  of	  
patients	  infected	  with	  these	  strains	  different	  to	  other,	  less	  virulent	  strains	  of	  the	  




of	  the	  infection.	  Diagnosis	  costs	  for	  use	  in	  this	  project	  were	  collected	  from	  the	  
MBS	  and	  are	  captured	  on	  a	  per-­‐test	  basis	  ($28.65	  /	  test).	  The	  health	  states	  in	  the	  
model	  that	  accrue	  diagnosis	  costs	  can	  be	  seen	  in	  Table	  17.	  	  
	  
The	  confirmation	  of	  infection	  and	  identification	  of	  strain	  type	  is	  not	  uniform	  
across	  Australia,	  with	  slight	  differences	  in	  protocol	  existing	  between	  hospitals	  and	  
jurisdictions.	  There	  is	  also	  a	  difference	  in	  protocol	  between	  public	  hospitals	  and	  
private	  hospitals.	  Sir	  Charles	  Gairdner	  hospital	  has	  been	  used	  as	  the	  baseline	  for	  
this	  model	  because	  it	  has	  long	  been	  regarded	  as	  the	  gold	  standard	  for	  diagnosis	  
and	  typing	  of	  Clostridium	  difficile	  infection	  in	  Australia.	  It	  is	  one	  of	  only	  a	  handful	  
of	  sites	  that	  routinely	  test	  positive	  samples	  for	  ribotype	  and	  frequently	  undertakes	  
ribotyping	  on	  behalf	  of	  other	  sites	  around	  the	  country,	  at	  their	  request	  (193).	  
Although	  ribotyping	  is	  not	  routine	  in	  Australia,	  its	  cost	  has	  been	  included	  in	  this	  
evaluation	  because	  the	  benefits	  of	  knowing	  further	  information	  about	  the	  strain	  
type	  are	  wide-­‐ranging	  and	  clinically	  significant.	  Inclusion	  also	  ensures	  that	  the	  
evaluation	  reflects	  global	  best	  practice	  for	  the	  diagnosis	  of	  Clostridium	  difficile	  
infection.	  The	  cost	  of	  ribotyping	  has	  been	  provided	  by	  the	  Sir	  Charles	  Gairdner	  
Hospital	  in	  Western	  Australia,	  on	  a	  per-­‐test	  basis	  ($100/test).	  
	  
Treatment	  Costs	  
A	  microcosting	  approach	  to	  costs	  relating	  to	  the	  treatment	  of	  Clostridium	  difficile	  




Clostridium	  difficile	  vary	  according	  to	  illness	  severity,	  strain	  of	  infection	  (ribotype)	  
and	  whether	  the	  patient	  is	  suffering	  their	  first	  infection	  or	  is	  a	  recurrent	  patient.	  
To	  avoid	  over-­‐	  or	  under-­‐representation	  of	  treatment	  costs,	  each	  disease	  state	  in	  
the	  model	  that	  requires	  treatment,	  and	  therefore	  accrues	  treatment	  costs,	  only	  
includes	  the	  costs	  that	  are	  specific	  to	  the	  related	  treatment	  regimen.	  Treatment	  for	  
all	  disease	  states	  has	  been	  informed	  by	  the	  treatment	  guidelines	  published	  for	  
Clostridium	  difficile	  by	  the	  Australasian	  Society	  of	  Infectious	  Diseases	  and	  can	  be	  
seen	  in	  Table	  14	  (75).	  
	  
Table	  14:	  Guidelines	  for	  treatment	  of	  Clostridium	  difficile	  infection	  	  
Treatment	  of	  severe	  and	  non-­‐severe	  Clostridium	  difficile	  infection	  
Treatment	  Phase	   Non-­‐severe	  infection	   Severe	  infection	  
Initial	  episode	   Oral	  Metronidazole	  –	  400mg,	  3x	  
daily	  for	  10	  days	  
IV	  Metronidazole	  –	  500mg,	  8-­‐
hourly	  for	  10	  days	  
Oral	  Vancomycin	  –	  125mg,	  4	  x	  daily	  for	  
10	  days	  
IV	  Metronidazole	  –	  500mg,	  8-­‐hourly	  
for	  10	  days,	  plus	  retention	  enema	  of	  
vancomycin	  and	  500mg	  vancomycin	  
4x	  daily	  by	  nasogastric	  tube	  
Indications	  for	  surgery	   Nil	   Bowel	  perforation,	  toxic	  megacolon,	  
deterioration	  despite	  antibiotic	  
treatment	  
First	  recurrence	   As	  for	  initial	  episode	   As	  for	  initial	  episode	  
Second	  or	  subsequent	  
recurrence	  
Vancomycin	  in	  a	  tapering	  course	  (125mg	  orally,	  4x	  daily	  for	  14	  days,	  then	  
125mg	  2x	  daily	  for	  7	  days,	  then	  125mg	  every	  second	  day	  for	  2-­‐8	  weeks)	  
	  
As	  can	  be	  seen	  in	  the	  guidelines,	  the	  regimens	  for	  treatment	  vary	  according	  to	  
illness	  severity	  and	  provide	  options	  for	  oral	  or	  intravenous	  administration.	  Despite	  




available,	  only	  the	  cost	  of	  the	  most	  common	  treatment	  regimens	  have	  been	  
included,	  with	  specialty	  regimens	  or	  rarely	  used	  drugs	  deliberately	  ignored.	  As	  
such,	  the	  costs	  of	  treatment	  with	  metronidazole	  and	  vancomycin	  have	  been	  
included	  in	  the	  evaluation.	  	  
	  
The	  estimates	  relating	  to	  the	  cost	  of	  each	  drug	  have	  come	  from	  the	  prices	  listed	  on	  
the	  Australian	  Pharmaceutical	  Benefits	  Scheme	  (PBS).	  For	  consistency,	  the	  manual	  
of	  resource	  items	  and	  their	  associated	  costs,	  (217)	  published	  by	  the	  PBAC	  for	  use	  in	  
economic	  evaluations	  has	  been	  used	  to	  inform	  the	  decision	  about	  which	  cost	  to	  
include	  in	  the	  evaluation.	  As	  such,	  the	  DPMQ	  (Dispensed	  Price	  for	  Maximum	  
Quantity)	  has	  been	  used	  to	  calculate	  the	  cost	  of	  each	  regimen.	  Including	  the	  prices	  
from	  the	  PBS	  ensures	  that	  the	  approach	  taken	  to	  costing	  drugs	  in	  the	  model	  is	  
generalisable	  across	  Australia	  and	  less	  likely	  to	  be	  impacted	  by	  any	  local	  variation	  
in	  drug	  pricing.	  	  
	  
The	  breakdown	  of	  costs	  for	  each	  specific	  treatment	  regimen	  in	  relation	  to	  disease	  
severity	  and	  occurrence	  can	  be	  seen	  in	  Table	  15.	  The	  health	  states	  in	  the	  model	  





Table	  15:	  Costs	  of	  treatment	  according	  to	  infection	  severity	  and	  occurrence	  
Cost	  of	  treatments	  for	  severe	  and	  non-­‐severe	  Clostridium	  difficile	  infection	  
Treatment	  Phase	   Non-­‐severe	  infection	   Severe	  infection	  
Initial	  episode	   Oral	  -­‐	  $20.38	  
IV	  -­‐	  $53.82	  
Oral	  -­‐	  $465.20	  
IV	  -­‐	  $483.42	  
Surgery	   Nil	   Colectomy	  -­‐	  $1150.35	  
First	  recurrence	   As	  for	  initial	  episode	   As	  for	  initial	  episode	  
Second	  or	  subsequent	  
recurrence	  
Tapering	  course	  -­‐	  $1395.60	  
NB:	  All	  antibiotic	  costs	  sourced	  from	  PBS	  and	  calculated	  using	  regimen	  guidelines	  in	  ASID	  guidelines	  for	  
management	  Surgical	  cost	  is	  procedure	  cost	  only,	  sourced	  from	  MBS	  (code	  32004).	  
	  
Bed	  costs	  
The	  cost	  of	  recovering	  in	  a	  hospital	  bed	  represents	  a	  large	  proportion	  of	  total	  
infection-­‐related	  costs.	  This	  project	  values	  the	  marginal	  costs	  released	  by	  bed	  days	  
saved,	  due	  to	  the	  reduction	  of	  Clostridium	  difficile	  infections.	  The	  opportunity	  
costs	  of	  a	  bed	  day	  saved	  vary,	  according	  to	  the	  willingness	  to	  pay	  of	  other	  service	  
providers	  who	  are	  trying	  to	  utilise	  the	  marginal	  bed	  days	  available.	  This	  approach,	  
which	  focuses	  on	  economic	  costs	  rather	  than	  accounting	  costs,	  ensures	  a	  point	  of	  
difference	  in	  this	  research	  when	  compared	  with	  other	  studies	  in	  the	  literature	  (10).	  
Using	  the	  most	  common	  form	  of	  valuing	  a	  bed	  day,	  by	  dividing	  the	  hospital	  budget	  
by	  the	  number	  of	  bed	  days	  supplied,	  can	  be	  misleading	  for	  the	  purposes	  of	  making	  
economic	  decisions.	  This	  method	  provides	  the	  accounting	  costs	  of	  a	  bed	  day,	  
which	  is	  an	  historical	  cost,	  rather	  than	  the	  present	  opportunity	  costs,	  which	  is	  the	  
value	  of	  a	  bed	  day	  when	  released	  for	  other	  purposes	  (171)	  in	  the	  future.	  It	  is	  argued	  




fixed	  (74).	  Reducing	  HAIs	  has	  no	  economic	  impact	  on	  fixed	  costs	  and	  the	  
presentation	  of	  accounting	  costs	  may	  lead	  to	  an	  overestimation	  of	  hospital-­‐costs	  
relating	  to	  healthcare	  acquired	  infections	  in	  published	  papers	  (10).	  The	  value	  of	  an	  
ICU-­‐bed	  and	  ward-­‐bed	  day,	  using	  estimates	  relating	  to	  the	  opportunity	  costs	  of	  
those	  bed	  days	  allows	  a	  more	  realistic	  and	  accurate	  evaluation	  of	  the	  cost	  of	  
Clostridium	  difficile	  infection.	  	  
	  
As	  such,	  for	  this	  research	  bed	  days	  have	  been	  valued	  in	  two	  ways	  and	  each	  scenario	  
of	  the	  model	  will	  be	  run	  using	  the	  two	  different	  costing	  approaches	  for	  
comparison.	  Recent	  research	  conducted	  by	  Page	  et	  al	  (218)	  has	  argued	  that	  
including	  accounting	  costs	  in	  cost-­‐effectiveness	  analyses	  has	  led	  to	  uncertainty	  
about	  the	  accuracy	  of	  infection	  related	  cost	  parameters	  and	  subsequently,	  the	  
overall	  output	  of	  the	  model.	  The	  overvaluation	  of	  bed	  days	  can	  result	  in	  some	  
healthcare	  interventions	  appearing	  more	  cost-­‐effective	  than	  they	  are	  in	  reality.	  
Research	  published	  in	  the	  last	  decade	  using	  the	  accounting	  method	  for	  bed	  day	  
valuation,	  which	  includes	  unit	  costs	  that	  are	  both	  fixed	  and	  variable,	  have	  
estimated	  ICU	  beds	  to	  cost	  around	  $3000/day	  and	  ward	  beds	  to	  cost	  around	  
$800/day	  (199-­‐200).	  
	  
In	  turn,	  recently	  published	  findings	  have	  suggested	  that	  the	  willingness	  of	  key	  
healthcare	  decision-­‐makers,	  such	  as	  hospital-­‐based	  CEOs,	  to	  pay	  for	  a	  freed	  bed	  




for	  valuation.	  After	  conducting	  a	  multi-­‐faceted	  study	  in	  Australia	  that	  measured	  
decision-­‐makers’	  willingness	  to	  pay	  for	  bed	  days	  under	  different	  scenarios	  (e.g.	  low	  
occupancy	  vs.	  high	  occupancy,	  seasonal	  constraints	  and	  varied	  operating	  theatre	  
capacity),	  the	  average	  value	  of	  a	  ward	  bed	  was	  estimated	  to	  be	  $216/day	  and	  for	  an	  
ICU	  bed	  was	  $436/day	  (218).	  Stewardson	  et	  al	  conducted	  a	  similar	  survey	  in	  the	  
European	  setting	  and	  also	  found	  that	  accounting	  methods	  tend	  to	  overestimate	  
the	  opportunity	  costs	  of	  a	  bedday	  (221).	  
	  
To	  incorporate	  the	  cost	  estimates	  into	  the	  evaluation,	  the	  value	  of	  a	  bed	  day	  
(either	  an	  ICU-­‐bed	  or	  a	  ward-­‐bed,	  as	  appropriate)	  has	  been	  multiplied	  by	  the	  
number	  of	  people	  who	  were	  in	  the	  corresponding	  health	  state	  for	  that	  particular	  
cycle.	  A	  hypothetical	  example	  of	  the	  bed	  costs	  relating	  to	  the	  ‘non-­‐severe’	  health	  
state	  can	  be	  seen	  in	  Table	  16.	  The	  table	  shows	  the	  difference	  in	  bed	  day	  costs	  





Table	  16:	  Hypothetical	  example	  calculation	  of	  bed	  costs	  
	  
Accounting	  method	  
Model	  Cycle	   Health	  State	   	   Bed	  Cost	  ($)	   	  
	   Non-­‐Severe	   Severe	   Non-­‐Severe	  
($800/day)	  
Severe	  ($3,000/day)	  
1	   17	   6	   $13,600	   $18,000	  
2	   21	   9	   $16,800	   $27,000	  
3	   27	   13	   $21,600	   $39,000	  
Total	   	   	   $52,000	   $84,000	  
Willingness-­‐to-­‐pay	  method	  
Model	  Cycle	   Health	  State	   	   Bed	  Cost	  ($)	   	  
	   Non-­‐Severe	   Severe	   Non-­‐Severe	  
($216/day)	  
Severe	  ($436/day)	  
1	   17	   6	   $3,672	   $2,616	  
2	   21	   9	   $4,536	   $3,924	  
3	   27	   13	   $5,832	   $5,668	  
Total	   	   	   $14,040	   $12,208	  
	  
The	  health	  states	  in	  the	  model	  that	  accrue	  bed	  costs	  can	  be	  seen	  in	  Table	  17.	  It	  is	  
clear	  that	  the	  bed	  costs	  for	  each	  disease	  state	  is	  driven	  by	  illness	  severity	  and	  that	  






Table	  17:	  Health	  states	  from	  economic	  model	  and	  relevant	  cost-­‐type	  	  
Health	  State	   Diagnosis	  Costs	   Treatment	  Costs	   Bed	  Costs	  
At-­‐Risk	   ✗	   ✗	   ✗	  
Non-­‐Severe	   ✓	   ✓	   ✓	  
Severe	   ✓	   ✓	   ✓	  
DV	  1	   ✗	   ✗	   ✗	  
Recurrent	  Infection	   ✓	   ✓	   ✓	  
DV	  2	   ✗	   ✗	   ✗	  
Survive	  Healthy	   ✗	   ✗	   ✗	  
Dead	   ✗	   ✗	   ✗	  
Censored	   ✗ ✗ ✗ 
	  
4.5	  Chapter	  Summary	  
This	  chapter	  provides	  a	  description	  of	  the	  methods	  that	  underpin	  the	  research	  
project	  and	  offers	  an	  overview	  of	  what	  the	  research	  project	  aims	  to	  achieve.	  The	  
methods	  used	  to	  select	  the	  healthcare	  interventions	  that	  are	  included	  in	  the	  
evaluation	  have	  been	  described	  in	  full	  and	  a	  rationale	  for	  their	  inclusion	  has	  been	  
provided.	  A	  thorough	  description	  of	  each	  included	  intervention	  has	  also	  been	  
explained	  in	  the	  chapter.	  	  
The	  methods	  that	  underpin	  the	  process	  used	  to	  ascertain	  intervention-­‐related	  
costs	  and	  infection-­‐related	  costs	  has	  been	  discussed	  in	  detail	  and	  the	  manner	  in	  
which	  these	  costs	  were	  gathered	  for	  use	  in	  the	  analysis	  has	  been	  thoroughly	  
explained.	  Finally,	  the	  methods	  used	  to	  conceptualise,	  build	  and	  populate	  the	  
model	  used	  in	  the	  evaluation	  have	  been	  described,	  providing	  a	  clear	  and	  





Chapter	  5:	  Results	  
Chapter	  Overview	  
The	  results	  of	  the	  cost-­‐effectiveness	  analyses	  are	  presented	  in	  this	  chapter.	  Section	  
5.1	  pertains	  to	  the	  analysis	  of	  10	  ‘traditional’	  interventions	  designed	  to	  reduce	  
Clostridium	  difficile	  infection.	  These	  interventions	  are	  compared	  with	  one	  another	  
in	  order	  to	  determine	  which	  one	  provides	  the	  best	  health	  outcome	  per	  dollar	  
spent.	  	  
	  
Section	  5.2	  is	  an	  analysis	  of	  five	  scenarios	  that	  are	  related	  to	  reducing	  patient	  
length	  of	  stay,	  which	  in	  turn	  reduces	  infection	  transmission.	  Reducing	  LOS	  cannot	  
be	  described	  as	  a	  traditional	  infection	  control	  measure,	  so	  the	  results	  of	  the	  
analysis	  in	  section	  5.2	  should	  be	  considered	  in	  context.	  Estimates	  about	  the	  impact	  
that	  reducing	  LOS	  had	  on	  infection	  transmission	  were	  available	  from	  the	  
transmission	  model	  developed	  by	  Yakob	  et	  al,	  so	  it	  was	  possible	  to	  include	  these	  as	  
quasi-­‐interventions	  in	  a	  separate	  analysis.	  Due	  to	  the	  practical	  difficulty	  of	  
coordinating	  and	  sustaining	  a	  LOS-­‐reducing	  programme	  at	  hospital	  level,	  the	  
results	  should	  be	  regarded	  as	  speculative,	  rather	  than	  pragmatic.	  
	  
Section	  5.1	  is	  divided	  into	  5	  sub-­‐sections;	  (i)	  a	  description	  of	  the	  interventions	  
included	  in	  the	  analysis,	  (ii)	  baseline	  analysis,	  (iii)	  probabilistic	  analysis,	  (iv)	  




assessment	  of	  the	  impact	  that	  changing	  length	  of	  stay	  has	  on	  Clostridium	  difficile-­‐
related	  health	  outcomes	  and	  section	  5.3	  is	  a	  summary	  of	  the	  results.	  
	  
Section	  5.1:	  Cost-­‐effectiveness	  analysis	  of	  traditional	  infection	  
control	  interventions	  
5.1.1	  Interventions	  included	  in	  the	  analysis	  
The	  interventions	  that	  have	  been	  included	  in	  this	  analysis	  can	  be	  seen	  in	  Table	  18.	  
The	  process	  taken	  to	  identify	  these	  interventions	  has	  been	  explained	  in	  full	  detail	  





Table	  18:	  Interventions	  included	  in	  cost-­‐effectiveness	  analysis	  
Intervention	   Description	  
AMS	  1	   An	  antimicrobial	  stewardship	  programme	  that	  reduces	  antibiotic	  use	  
across	  the	  hospital	  from	  50%	  to	  25%	  
AMS	  2	   An	  antimicrobial	  stewardship	  programme	  that	  reduces	  antibiotic	  use	  
across	  the	  hospital	  from	  50%	  to	  40%	  
HYG	  1	   A	  hygiene	  improvement	  intervention	  that	  reduces	  the	  transmission	  rate	  
of	  Clostridium	  difficile	  by	  half	  due	  to	  its	  effectiveness	  
HYG	  2	   A	  hygiene	  improvement	  intervention	  that	  reduces	  the	  transmission	  rate	  
of	  Clostridium	  difficile	  by	  a	  quarter	  due	  to	  its	  effectiveness	  
FMT	  1	   Expedited	  gut	  recovery	  due	  to	  FMT	  for	  infected	  patients	  (time	  to	  
recovery	  halved	  –	  47	  days)	  
FMT	  2	   Expedited	  gut	  recovery	  due	  to	  FMT	  for	  infected	  patients	  (best	  reported	  
recovery	  rate	  –	  10	  days)	  
FMT	  3	   Expedited	  gut	  recovery	  due	  to	  FMT	  for	  infected	  patients	  (worst	  reported	  
recovery	  rate	  –	  62	  days)	  
AMS	  &	  HYG	  	   An	  antimicrobial	  stewardship	  programme	  and	  hygiene	  improvement	  
programme	  delivered	  as	  a	  bundle	  (reduction	  in	  antibiotic	  use	  from	  50%	  
to	  40%	  of	  patients;	  transmission	  rate	  halved	  due	  to	  effectiveness	  of	  
hygiene	  improvement	  programme)	  
HYG	  &	  FMT	  1	   A	  hygiene	  improvement	  programme	  delivered	  in	  conjunction	  with	  FMT	  
for	  recurrently	  infected	  patients	  (gut	  recovery	  time	  halved	  due	  to	  FMT;	  
transmission	  rate	  halved	  due	  to	  effectiveness	  of	  hygiene	  improvement	  
programme)	  
HYG	  &	  FMT	  2	   A	  hygiene	  improvement	  programme	  delivered	  in	  conjunction	  with	  FMT	  
for	  recurrent	  patients	  (best	  reported	  gut	  recovery	  rate	  due	  to	  FMT;	  







5.1.2	  Fixed	  value	  analysis	  
Fixed	  value	  analysis	  does	  not	  account	  for	  any	  uncertainty	  in	  the	  decision.	  The	  
results	  show	  that	  of	  the	  10	  interventions	  included,	  three	  are	  not	  cost-­‐saving.	  Those	  
interventions	  can	  be	  seen	  above	  the	  x-­‐axis	  in	  Figure	  10	  –	  their	  position	  on	  the	  cost-­‐
effectiveness	  plane	  is	  in	  the	  north-­‐east	  quadrant.	  The	  interventions	  that	  are	  cost-­‐
saving	  are	  seen	  in	  the	  south-­‐east	  quadrant	  of	  the	  cost-­‐effectiveness	  plane.	  HYG	  1	  
achieved	  the	  greatest	  health	  benefits	  of	  126.68	  QALYs	  gained	  and	  the	  lowest	  costs	  
of	  $2,137,843	  saved	  and	  dominates	  all	  other	  interventions.	  
	  
Figure	  10:	  Incremental	  cost-­‐effectiveness	  of	  interventions	  designed	  to	  reduce	  







The	  10	  interventions	  are	  presented	  in	  Table	  19	  for	  comparison.	  
Table	  19:	  Incremental	  outcomes	  of	  all	  interventions	  compared	  to	  standard	  care	  
Intervention	   Incremental	  Outcomes	   ICER	  
	   Costs	   QALYs	   	  
Standard	  Care	   -­‐	   -­‐	   Dominated	  
AMS	  1	   -­‐$21,145	   -­‐0.09	   Dominated	  
AMS	  2	   -­‐$381,142	   5.59	   Dominated	  
HYG	  1	   	   -­‐$2,137,843	   126.68	   Cost-­‐saving	  
HYG	  2	   $818,790	   102.11	   Dominated	  
FMT	  1	   $119,595	   107.87	   Dominated	  
FMT	  2	   -­‐$151,146	   109.91	   Dominated	  
FMT	  3	   $162,426	   103.89	   Dominated	  
AMS	  &	  HYG	  	   -­‐$2,052,003	   125.14	   Dominated	  
HYG	  &	  FMT	  1	   -­‐$1,395,540	   122.18	   Dominated	  
HYG	  &	  FMT	  2	   -­‐$1,332,211	   120.73	   Dominated	  
	  
Without	  consideration	  of	  uncertainty,	  HYG	  1	  dominates	  all	  other	  interventions	  
because	  it	  has	  the	  greatest	  costs	  saved	  and	  health	  benefits	  gained.	  	  
	  
5.1.3	  Probabilistic	  analysis	  
Probabilistic	  analysis	  accounts	  for	  uncertainty	  in	  the	  parameters	  used	  in	  the	  
model.	  Results	  of	  the	  probabilistic	  sensitivity	  analysis	  are	  presented	  below	  with	  
each	  plot	  showing	  the	  results	  of	  1000	  Monte	  Carlo	  simulations.	  The	  incremental	  
change	  in	  costs	  and	  health	  benefits	  for	  each	  intervention	  compared	  to	  standard	  





Figure	  11	  shows	  that	  simulations	  for	  AMS	  1	  and	  AMS	  2	  spanned	  all	  quadrants	  of	  the	  
cost-­‐effectiveness	  plane,	  suggesting	  that	  there	  is	  a	  large	  degree	  of	  uncertainty	  in	  
any	  decision	  about	  adopting	  these	  interventions.	  Given	  the	  wide	  spread	  of	  
simulations,	  results	  suggest	  that	  these	  interventions	  are	  not	  always	  more	  clinically	  
effective	  or	  cheaper	  than	  the	  alternative.	  
	  
Figure	  11:	  ICER	  cloud	  of	  AMS	  1	  and	  AMS	  2	  vs.	  Standard	  Care	  ($42,000/QALY	  
threshold)	  
	  
The	  remaining	  plots	  show	  that	  the	  majority	  of	  simulations	  for	  the	  corresponding	  
interventions	  are	  either	  in	  the	  north-­‐east	  or	  south-­‐east	  quadrants.	  Figure	  12	  shows	  
the	  simulations	  for	  HYG	  1	  and	  HYG	  2.	  The	  simulations	  for	  HYG	  1	  are	  almost	  
exclusively	  in	  the	  south-­‐east	  quadrant,	  representing	  cost-­‐savings.	  The	  simulations	  
for	  HYG	  2	  show	  the	  majority	  of	  simulations	  in	  the	  north-­‐east	  quadrant,	  









Figure	  13	  shows	  the	  simulations	  for	  the	  three	  FMT	  scenarios.	  These	  plots	  show	  
interventions	  that	  have	  some	  probability	  of	  being	  either	  cost-­‐saving	  or	  cost-­‐











Figure	  14	  shows	  the	  simulations	  for	  the	  three	  bundled	  approaches,	  AMS	  &	  HYG,	  
FMT	  &	  HYG	  1	  and	  FMT	  &	  HYG	  2.	  The	  majority	  of	  simulations	  show	  cost-­‐saving	  










In	  Table	  20	  the	  percentage	  of	  Monte	  Carlo	  simulations	  that	  are	  cost-­‐saving	  and	  the	  
percentage	  of	  simulations	  that	  show	  an	  increase	  in	  health	  benefits	  are	  reported	  for	  
each	  intervention.	  In	  the	  scatterplots	  shown	  above,	  simulations	  that	  represent	  
cost-­‐savings	  are	  those	  in	  the	  south-­‐east	  quadrant	  and	  simulations	  that	  represent	  





Table	  20:	  Percentage	  of	  Monte	  Carlo	  simulations	  that	  are	  cost-­‐saving	  or	  increase	  
health	  benefits	  for	  all	  interventions,	  compared	  to	  standard	  care	  
	   Percentage	  of	  simulations	  
Intervention	   Cost-­‐saving	   Increase	  health	  benefits	  
Standard	  Care	   Comparator	   Comparator	  
AMS	  1	   52%	   49%	  
AMS	  2	   70%	   57%	  
HYG	  1	   99%	   99%	  
HYG	  2	   13%	   99%	  
FMT	  1	   42%	   100%	  
FMT	  2	   60%	   100%	  
FMT	  3	   42%	   99%	  
AMS	  &	  HYG	  	   99%	   100%	  
HYG	  &	  FMT	  1	   99%	   99%	  
HYG	  &	  FMT	  2	   98%	   99%	  
	  
Three	  interventions	  (FMT1,	  FMT	  2	  &	  AMS/HYG	  bundle)	  had	  100%	  of	  simulations	  
showing	  an	  increase	  in	  health	  benefits.	  It	  can	  be	  seen	  that	  the	  majority	  of	  
interventions	  (8/10)	  had	  greater	  than	  99%	  of	  simulations	  showing	  this	  increase.	  It	  
is	  clear	  that	  the	  efficacy	  estimates	  from	  Yakob	  et	  al	  are	  positive	  for	  the	  majority	  of	  
interventions.	  Two	  interventions,	  HYG	  1	  and	  AMS/HYG	  bundle	  had	  the	  highest	  
percentage	  of	  simulations	  that	  were	  cost-­‐saving,	  with	  99%	  of	  all	  simulations	  
showing	  cost-­‐saving	  for	  both	  interventions.	  Hygiene	  improvement	  2	  had	  the	  





Issues	  with	  using	  the	  ICER	  for	  decision-­‐making	  exist	  given	  that	  using	  the	  ratio	  of	  
two	  numbers	  (as	  is	  the	  case	  with	  the	  ICER)	  has	  awkward	  statistical	  implications.	  In	  
the	  healthcare	  context,	  positive	  ICERs	  can	  be	  located	  in	  different	  quadrants	  of	  the	  
cost-­‐effectiveness	  plane	  despite	  representing	  divergent	  health	  outcomes.	  This	  is	  
the	  same	  for	  negative	  ICERs,	  making	  their	  use	  not	  fit	  for	  decision-­‐making	  
purposes.	  A	  parsimonious	  way	  to	  simplify	  ratio	  information	  to	  a	  single	  number	  is	  
the	  net	  monetary	  benefit	  (NMB)	  framework.	  The	  NMB	  framework	  provides	  an	  
explicit	  decision	  rule,	  as	  long	  as	  there	  is	  an	  agreement	  about	  the	  threshold	  value	  
for	  what	  is	  deemed	  to	  be	  ‘cost-­‐effective’.	  Calculation	  of	  the	  net	  monetary	  benefit	  
requires	  a	  linear	  arrangement	  of	  the	  ICER.	  Because	  of	  its	  linearity,	  using	  the	  net	  
benefit	  framework	  offers	  decision-­‐makers	  with	  easier	  comparison	  of	  multiple	  
interventions	  and	  the	  capacity	  to	  consider	  a	  range	  of	  willingness	  to	  pay	  thresholds	  
for	  health	  outcomes.	  This	  approach	  is	  ideal	  for	  decision-­‐makers	  who	  are	  looking	  to	  
maximise	  the	  health	  gain	  from	  their	  investment	  of	  scarce	  resources.	  
	  
Given	  the	  increased	  need	  to	  provide	  decision-­‐makers	  with	  clear	  and	  pragmatic	  
information,	  the	  net	  monetary	  benefit	  framework	  has	  been	  used	  to	  rank	  the	  
economic	  value	  of	  the	  interventions.	  At	  a	  threshold	  level	  of	  $42,000	  per	  QALY,	  
HYG	  1	  provides	  the	  highest	  mean	  NMB	  ($7,459,667).	  The	  bundled	  approach	  of	  
AMS/HYG	  delivered	  the	  next	  highest	  mean	  NMB	  ($7,305,565)	  and	  AMS	  1	  provided	  
the	  lowest	  mean	  NMB	  of	  all	  interventions	  ($15,029).	  Table	  21	  shows	  the	  results	  of	  




Table	  21:	  Incremental	  NMB	  analysis	  ($42,000/QALY	  threshold)	  
	   Incremental	  NMB	  
Intervention	   Mean	   95%	  credible	  interval	  
AMS1	   $15,029	   (-­‐$85,424	  -­‐	  $115,483)	  
AMS	  2	   $615,620	   ($515,598	  -­‐	  $715,642)	  
HYG	  1	   $7,459,667	   ($7,359,703	  -­‐	  $7,559,631)	  
HYG	  2	   $3,467,949	   ($3,364,420	  -­‐	  $3,571,478)	  
FMT	  1	   $4,410,725	   ($4,308,651	  -­‐	  $4,512,798)	  
FMT	  2	   $4,765,389	   ($4,663,102	  -­‐	  $4,867,676)	  
FMT	  3	   $4,200,470	   ($4,100,818	  -­‐	  $4,300,122)	  
AMS	  &	  HYG	   $7,305,565	   ($7,203,055	  -­‐	  $7,408,075)	  
HYG	  &	  FMT	  1	   $6,527,471	   ($6,424,081	  –	  $6,630,861)	  
HYG	  &	  FMT	  2	   $6,404,431	   ($6,305,101	  -­‐	  $6,503,762)	  
	  
Figure	  15	  shows	  the	  results	  of	  the	  NMB	  analysis	  for	  each	  intervention,	  where	  the	  
maximum	  and	  minimum	  NMB	  for	  all	  simulations	  is	  shown.	  





The	  intervention	  with	  the	  highest	  mean	  NMB	  is	  deemed	  to	  be	  the	  optimal	  
decision.	  As	  shown	  in	  the	  figure,	  the	  majority	  of	  interventions	  have	  a	  mean	  NMB	  
that	  is	  similar	  to	  others.	  The	  exceptions	  to	  this	  are	  both	  AMS	  interventions,	  AMS	  1	  
and	  AMS	  2,	  which	  have	  distinctly	  lower	  mean	  NMBs.	  The	  figure	  also	  shows	  the	  
range	  of	  expected	  NMBs	  for	  each	  intervention.	  Four	  interventions;	  HYG	  1,	  
AMS/HYG	  bundle,	  HYG/FMT	  bundle	  1	  and	  HYG/FMT	  bundle	  2,	  have	  an	  all-­‐
positive	  range	  of	  NMBs	  from	  the	  1000	  simulations,	  while	  the	  remaining	  six	  
interventions	  have	  a	  range	  spanning	  positive	  and	  negative	  values.	  If	  the	  NMB	  is	  
negative	  it	  means	  that	  the	  intervention	  is	  not	  cost-­‐effective,	  so	  for	  those	  
interventions	  that	  cross	  into	  negative	  territory	  for	  at	  least	  some	  simulations,	  the	  
benefits	  of	  the	  intervention	  will	  be	  outweighed	  by	  its	  costs	  in	  some	  instances.	  	  	  
	  
Figure	  16	  shows	  the	  cost-­‐effectiveness	  acceptability	  frontier	  (CEAF).	  The	  CEAF	  
plots	  the	  probability	  that	  the	  optimal	  intervention	  is	  cost-­‐effective,	  at	  different	  
threshold	  values,	  allowing	  exploration	  of	  different	  willingness	  to	  pay	  thresholds.	  It	  
has	  long	  been	  accepted	  that	  society’s	  objective	  should	  be	  to	  maximise	  health	  gain	  
and	  as	  such,	  the	  optimal	  intervention	  is	  that	  which	  has	  the	  highest	  expected	  net	  
benefit	  (222).	  
	  
The	  figure	  shows	  the	  cost-­‐effectiveness	  acceptability	  frontier	  (CEAF)	  relating	  to	  
the	  competing	  interventions,	  where	  the	  probability	  of	  being	  cost-­‐effective	  is	  shown	  




x-­‐axis.	  When	  there	  is	  a	  change	  in	  the	  optimal	  decision,	  that	  is,	  if	  a	  competing	  
intervention	  overtakes	  as	  optimal,	  the	  frontier	  switches	  at	  the	  corresponding	  
threshold	  value.	  
	  




The	  CEAF	  shows	  that	  at	  all	  threshold	  levels	  between	  $0/QALY	  and	  
$100,000/QALY,	  HYG	  1	  is	  the	  optimal	  decision	  because	  the	  frontier	  never	  ‘switches’	  
with	  another	  alternative.	  At	  the	  assumed	  decision-­‐maker’s	  threshold	  of	  
$42,000/QALY,	  the	  error	  probability	  associated	  with	  this	  decision	  is	  0.66.	  This	  
means	  that	  the	  chance	  of	  incorrectly	  choosing	  HYG	  1	  as	  the	  optimal	  intervention	  is	  




associated	  with	  this	  decision	  increases	  as	  the	  maximum	  willingness	  to	  pay	  
threshold	  increases.	  
	  
If	  the	  assumption	  that	  decision-­‐makers	  are	  willing	  to	  pay	  for	  improvements	  in	  
health	  outcomes	  is	  removed	  and	  instead	  the	  new	  threshold	  becomes	  $0/QALY	  
gained,	  the	  intervention	  with	  the	  highest	  mean	  NMB	  remains	  HYG	  1.	  A	  threshold	  
of	  $0/QALY	  requires	  interventions	  to	  be	  cost-­‐saving	  in	  order	  to	  be	  considered	  cost-­‐
effective.	  Figure	  17	  shows	  the	  results	  of	  the	  NMB	  analysis	  with	  the	  altered	  
threshold	  level.	  
	  







None	  of	  the	  interventions	  had	  their	  range	  of	  NMBs	  exclusively	  in	  positive	  territory,	  
meaning	  that	  in	  some	  instances	  the	  benefits	  of	  each	  intervention	  would	  be	  
outweighed	  by	  its	  costs.	  HYG	  1	  has	  the	  highest	  mean	  NMB	  ($2,137,569)	  with	  
AMS/HYG	  bundle	  having	  the	  second	  highest	  mean	  NMB	  ($2,052,174).	  HYG	  2	  has	  
the	  lowest	  mean	  NMB	  (-­‐$818,798).	  
Table	  22	  shows	  the	  results	  of	  the	  NMB	  analysis	  for	  all	  interventions.	  
	  
Table	  22:	  Incremental	  NMB	  analysis	  ($0/QALY	  threshold)	  
	   Incremental	  NMB	  
Intervention	   Mean	   95%	  credible	  interval	  
AMS	  1	   $20,523	   (-­‐$20,387	  -­‐	  $61,434)	  
AMS	  2	   $381,566	   ($339,931	  -­‐	  $423,201)	  
HYG	  1	   $2,137,569	   ($2,097,779	  -­‐	  $2,177,359)	  
HYG	  2	   -­‐$818,798	   (-­‐$862,662,	  -­‐$774,935)	  
FMT	  1	   -­‐$119,037	   (-­‐$160,273,	  -­‐$77,801)	  
FMT	  2	   $151,343	   ($109,382	  -­‐	  $193,305)	  
FMT	  3	   -­‐$163,657	   (-­‐$206,677,	  -­‐$120,637)	  
AMS	  &	  HYG	  	   $2,052,174	   ($2,011,102	  -­‐	  $2,093,246)	  
HYG	  &	  FMT	  1	   $1,395,687	   ($1,357,122	  -­‐	  $1,434,252)	  
HYG	  &	  FMT	  2	   $1,332,065	   ($1,291,139	  -­‐	  $1,372,991)	  
	  
5.1.4	  Scenario	  analysis	  
A	  number	  of	  scenarios	  have	  been	  examined,	  where	  key	  parameters	  of	  the	  model	  
have	  been	  altered.	  The	  modified	  scenarios	  reflect	  plausible	  situations	  and	  are	  




assessing	  uncertainty	  and	  provides	  decision-­‐makers	  with	  extra	  information	  that	  is	  
of	  practical	  value	  (223).	  
	  
For	  this	  analysis,	  four	  alternate	  scenarios	  were	  considered:	  
• The	  method	  for	  valuing	  bed	  costs:	  where	  accounting	  costs	  for	  an	  ICU	  and	  
ward-­‐bed	  were	  substituted	  by	  the	  healthcare	  decision-­‐maker’s	  willingness-­‐
to-­‐pay	  price.	  This	  concept	  has	  previously	  been	  discussed	  in	  greater	  detail	  in	  
section	  4.4.2	  of	  the	  methods	  chapter.	  The	  value	  used	  for	  a	  ward-­‐bed	  and	  an	  
ICU-­‐bed	  using	  accounting	  costs	  was	  $800/day	  and	  $3,000/day,	  respectively.	  
However,	  for	  the	  scenario	  analysis,	  the	  willingness-­‐to-­‐pay	  price	  for	  a	  ward-­‐
bed	  and	  an	  ICU-­‐bed	  was	  $216/day	  and	  $436/day,	  respectively.	  
• Patient	  LOS	  was	  increased:	  length	  of	  stay	  for	  infected	  patients	  was	  doubled.	  
A	  standard	  LOS	  for	  infected	  patients	  was	  used	  in	  the	  model,	  with	  that	  value	  
being	  informed	  by	  the	  literature	  (5.8	  days)	  (224).	  To	  account	  for	  variation	  
across	  jurisdictions,	  LOS	  for	  infected	  patients	  was	  doubled	  in	  this	  scenario	  
(11.6	  days).	  
• The	  overall	  infection	  rate	  was	  increased:	  the	  rate	  of	  infection	  was	  doubled.	  
Infection	  rates	  are	  not	  exactly	  the	  same	  in	  all	  jurisdictions.	  As	  such,	  to	  
model	  an	  increase	  in	  the	  average	  rate	  of	  infection,	  it	  was	  doubled,	  to	  
simulate	  differences	  that	  may	  exist	  around	  Australia.	  Doubling	  the	  rate	  of	  
infection	  was	  chosen	  because	  it	  is	  commonly	  noted	  that	  the	  infection	  rate	  is	  




• The	  mortality	  rate	  due	  to	  Clostridium	  difficile	  infection	  was	  increased:	  the	  
rate	  at	  which	  people	  died	  from	  Clostridium	  difficile	  infection	  was	  doubled.	  
In	  Australia,	  the	  mortality	  rate	  due	  to	  Clostridium	  difficile	  is	  quite	  low	  –	  
largely	  thanks	  to	  the	  absence	  of	  any	  outbreaks	  caused	  by	  any	  of	  the	  
hypervirulent	  strains.	  Doubling	  the	  rate	  at	  which	  people	  die	  from	  the	  
infection	  is	  a	  reasonable	  assumption	  to	  model	  serious	  outbreak	  conditions.	  
	  
The	  result	  of	  scenario	  analyses	  are	  summarised	  in	  Table	  23.	  
Table	  23:	  Optimal	  intervention	  given	  different	  scenarios	  
Scenario	   Optimal	  
Intervention	  
(Error	  probability)	  
Incremental	  Outcomes	   Mean	  NMB	  	  
(95%	  CI)	  	   QALYs	   Costs	  saved	  




124.6	   $535,723	   $5,770,401	  





123.8	   $2,138,438	   $7,337,386	  





164.6	   $4,692,889	   $11,605,010	  





127.9	   $2,026,338	   $7,398,668	  
($7,295,752	  -­‐	  $7,501,586)	  
	  
	  
Each	  scenario	  was	  examined	  and	  the	  optimal	  intervention	  for	  each	  scenario	  was	  
deemed	  to	  be	  the	  intervention	  that	  provided	  the	  highest	  mean	  NMB.	  A	  threshold	  
level	  of	  $42,000/QALY	  was	  used	  for	  decision-­‐making.	  At	  this	  threshold	  level,	  HYG	  




increased	  and	  when	  mortality	  rate	  was	  increased.	  Only	  when	  the	  infection	  rate	  was	  
increased	  was	  another	  intervention	  optimal.	  In	  this	  scenario	  the	  AMS/HYG	  
bundled	  intervention	  provided	  the	  highest	  mean	  NMB.	  The	  scenario	  with	  the	  
greatest	  amount	  of	  certainty	  (lowest	  error	  probability)	  was	  when	  the	  infection	  rate	  
was	  increased.	  In	  this	  situation	  the	  probability	  of	  incorrectly	  choosing	  the	  
AMS/HYG	  bundle	  as	  optimal	  is	  0.56.	  The	  error	  probabilities	  relating	  to	  the	  other	  
scenarios	  were	  all	  high	  –	  0.64	  for	  scenarios	  2	  and	  4	  and	  0.74	  for	  scenario	  1.	  This	  
means	  that	  despite	  being	  the	  intervention	  that	  provided	  the	  highest	  NMB,	  the	  
decision	  regarding	  HYG	  1	  as	  being	  optimal	  in	  multiple	  scenarios	  is	  highly	  
uncertain.	  
5.1.5	  Value	  of	  perfect	  information	  analysis	  
It	  has	  been	  demonstrated	  that	  decisions	  based	  on	  existing	  information	  are	  highly	  
uncertain	  and	  there	  is	  the	  possibility	  of	  making	  an	  incorrect	  decision.	  The	  
probability	  of	  making	  an	  incorrect	  decision	  was	  presented	  in	  the	  previous	  sections	  
as	  the	  error	  probability	  that	  is	  associated	  with	  that	  decision.	  Specifically,	  deciding	  
that	  HYG	  1	  was	  the	  optimal	  choice	  is	  based	  on	  the	  current	  estimate	  of	  expected	  net	  
monetary	  benefit	  but	  there	  is	  the	  possibility	  that	  other	  interventions	  could	  have	  
higher	  net	  benefits	  if	  the	  current	  uncertainty	  about	  the	  existing	  decision	  is	  settled.	  
If	  a	  decision-­‐maker	  had	  access	  to	  perfect	  information	  that	  would	  better	  inform	  
their	  decision,	  the	  possibility	  of	  making	  the	  wrong	  decision	  would	  be	  removed.	  




threshold	  value	  of	  $42,000/QALY,	  the	  expected	  value	  of	  perfect	  information	  (EVPI)	  
for	  this	  decision	  is	  $183.52	  and	  is	  represented	  in	  Figure	  18.	  	  
	  
Figure	  18:	  Expected	  value	  of	  perfect	  information	  (per	  infection)	  
	  
	  
The	  EVPI	  for	  the	  effective	  population	  has	  also	  been	  estimated.	  The	  effective	  
population	  is	  the	  total	  population	  that	  stands	  to	  benefit	  from	  additional	  
information,	  over	  the	  expected	  lifetime	  that	  results	  are	  valid.	  At	  a	  threshold	  value	  
of	  $42,000/QALY,	  the	  EVPI	  for	  the	  effective	  population	  in	  Australia	  is	  $3.4	  million	  







Figure	  19:	  Expected	  value	  of	  perfect	  information	  (whole	  population)	  	  
	  
	  
By	  estimating	  the	  value	  of	  perfect	  information,	  an	  upper	  monetary	  bound	  is	  placed	  
on	  the	  merit	  of	  conducting	  further	  research.	  The	  results	  show	  that	  if	  the	  cost	  of	  
further	  research	  were	  less	  than	  the	  population	  EVPI	  ($3.4	  million),	  pursuing	  that	  
research	  would	  be	  worthwhile	  and	  cost-­‐effective.	  
	  
The	  expected	  value	  of	  perfect	  parameter	  information	  (EVPPI)	  has	  been	  estimated	  
in	  two	  analyses.	  In	  the	  first	  instance,	  parameters	  were	  grouped	  together	  in	  large	  
groups,	  according	  to	  their	  similarity.	  For	  example,	  all	  cost	  parameters	  –	  diagnosis	  
costs,	  treatment	  costs,	  ward-­‐bed	  costs	  and	  ICU-­‐bed	  costs	  were	  grouped	  together.	  
Importantly,	  the	  EVPPI	  for	  individual	  parameters	  does	  not	  sum	  to	  the	  decision	  
EVPI.	  This	  is	  because	  when	  individual	  parameters	  are	  analysed	  on	  their	  own,	  they	  
may	  not	  resolve	  in	  a	  way	  that	  has	  an	  impact	  on	  net-­‐benefit,	  altering	  the	  decision.	  




Table	  24:	  Expected	  value	  of	  perfect	  parameter	  information	  (parameter	  groups)	  
	   Expected	  value	  of	  perfect	  information	  
Whole	  decision	   $3,440,744	  
	   	  
Parameter	  Groups	   EVPPI	  
Costs	   $0	  
QALYs	   $0	  
Transition	  probabilities	   $762,424	  
	  
At	  the	  assumed	  decision-­‐maker’s	  threshold	  of	  $42,000/QALY,	  both	  costs	  and	  
QALYs	  were	  associated	  with	  zero	  EVPPI.	  The	  expected	  value	  of	  further	  
information	  relating	  to	  transition	  probabilities	  was	  $762,424.	  The	  events	  in	  the	  
model,	  such	  as	  acquiring	  an	  infection	  are	  likely	  to	  be	  responsible	  for	  these	  results.	  
The	  uncertainty	  relating	  to	  the	  information	  about	  whether	  or	  not	  people	  suffer	  an	  
infection	  drives	  the	  uncertainty	  in	  the	  model,	  rather	  than	  uncertainty	  about	  the	  
estimates	  relating	  to	  costs	  and	  quality	  of	  life.	  
	  
The	  second	  analysis	  focused	  on	  the	  parameters	  that	  inform	  the	  transition	  
probabilities	  and	  provides	  information	  about	  which	  specific	  transition	  
probabilities	  are	  the	  most	  uncertain.	  The	  results	  of	  this	  analysis	  have	  been	  
summarised	  in	  Table	  25.	  It	  is	  important	  to	  note	  that	  the	  EVPPI	  for	  smaller	  groups	  






Table	  25:	  Expected	  value	  of	  perfect	  parameter	  information	  (transition	  
probabilities)	  
	   Expected	  value	  of	  perfect	  parameter	  information	  
All	  transition	  probabilities	   $762,424	  
	   	  
Transition	  groups	   EVPPI	  
Transmission	  rate	   $567,468	  
Vulnerable	  discharge	   $42,486	  
Healthy	  discharge	   $243,082	  
Recurrent	  infection	   $3,660	  
Mortality	   $0	  
	  
The	  results	  show	  that	  better	  information	  relating	  to	  the	  transmission	  rate	  is	  of	  the	  
most	  value	  ($567,468).	  Improving	  the	  information	  that	  informs	  the	  rate	  with	  
which	  people	  move	  from	  the	  ‘At-­‐Risk’	  health	  state	  to	  the	  ‘Severe’	  and	  ‘Non-­‐Severe’	  
health	  states	  (‘tpAR_Sev’	  and	  ‘tpAR_NonSev’	  in	  Table	  3)	  is	  of	  greater	  value	  than	  
improving	  other	  information	  relating	  to	  other	  transition	  probabilities.	  Information	  
relating	  to	  healthy	  hospital	  exit	  –	  being	  admitted	  for	  care	  but	  leaving	  without	  
suffering	  an	  infection	  (‘tpAR_DisHlthy’)	  -­‐	  is	  of	  some	  value	  ($243,082),	  but	  new	  
information	  about	  vulnerable	  discharge	  parameters	  (‘tpNonSev_DV1’,	  ‘tpSev_DV1’,	  
‘tpRemDV1’,	  ‘tpRecInf_DV2’	  &	  ‘tpRemDV2’)	  is	  less	  so	  ($42,486).	  Gaining	  better	  
information	  to	  inform	  parameters	  relating	  to	  recurrent	  infection	  is	  almost	  
negligible,	  with	  an	  expected	  value	  of	  perfect	  information	  for	  these	  parameters	  




Transitions	  relating	  to	  mortality	  were	  associated	  with	  an	  EVPPI	  of	  $0,	  suggesting	  
efforts	  to	  improve	  the	  evidence	  informing	  these	  parameters	  unproductive.	  




Section	  5.2:	  Impact	  of	  changing	  LOS	  on	  Clostridium	  difficile-­‐
related	  outcomes	  
It	  has	  been	  previously	  established	  that	  patient	  length	  of	  stay	  (LOS)	  has	  an	  
influence	  on	  the	  transmission	  of	  Clostridium	  difficile	  infection.	  The	  results	  of	  the	  
transmission	  model	  published	  by	  Yakob	  et	  al	  show	  that	  the	  longer	  a	  patient	  stays	  
in	  hospital,	  the	  greater	  the	  chance	  of	  infection.	  Reducing	  the	  average	  patient	  LOS	  
cannot	  be	  defined	  as	  a	  traditional	  infection	  control	  measure	  that	  directly	  targets	  a	  
reduction	  of	  hospital-­‐acquired	  infections.	  However,	  a	  reduction	  in	  Clostridium	  
difficile	  infections	  is	  a	  plausible	  positive	  externality.	  It	  would	  however	  require	  a	  
system-­‐wide	  improvement	  in	  patient	  management.	  Five	  LOS	  scenarios	  have	  been	  
considered	  in	  this	  evaluation,	  including	  bundled	  approaches	  that	  couple	  
traditional	  infection	  control	  practices	  with	  reducing	  LOS.	  The	  scenarios	  that	  have	  
been	  included	  in	  the	  analysis	  can	  be	  seen	  in	  Table	  26	  and	  the	  process	  taken	  to	  






Table	  26:	  Scenarios	  included	  in	  the	  analysis	  
Scenario	   Description	  
LOS	  1	   A	  reduction	  in	  the	  average	  LOS	  by	  1	  day	  (from	  5.8	  days	  to	  4.8	  days)	  
LOS	  2	   A	  reduction	  in	  the	  average	  LOS	  by	  2	  days	  (from	  5.8	  days	  to	  3.8	  days)	  
LOS	  &	  AMS	  1	   LOS	  &	  AMS	  bundle	  where	  the	  average	  LOS	  is	  reduced	  by	  1	  day	  and	  the	  
number	  of	  people	  exposed	  to	  antibiotics	  is	  reduced	  from	  50%	  to	  40%.	  
LOS	  &	  AMS	  2	   LOS	  &	  AMS	  bundle	  where	  the	  average	  LOS	  is	  reduced	  by	  2	  days	  and	  the	  
number	  of	  people	  exposed	  to	  antibiotics	  is	  reduced	  from	  50%	  to	  40%.	  
LOS	  &	  HYG	  1	   LOS	  &	  hygiene	  improvement	  bundle	  where	  the	  average	  LOS	  is	  reduced	  by	  
1	  day	  and	  the	  transmission	  rate	  of	  infection	  is	  halved	  by	  the	  effectiveness	  
of	  a	  hygiene	  improvement	  programme	  
	  
5.2.1	  Reducing	  LOS	  only	  
Given	  that	  the	  costs	  of	  implementing	  and	  maintaining	  a	  LOS-­‐reducing	  
intervention	  are	  almost	  impossible	  to	  quantify,	  this	  analysis	  focuses	  on	  the	  change	  
to	  Clostridium	  difficile-­‐related	  health	  outcomes	  when	  average	  inpatient	  LOS	  is	  
reduced.	  It	  is	  an	  incomplete	  picture	  of	  the	  change	  to	  costs	  and	  health	  outcomes.	  	  
The	  measurable	  changes	  to	  health	  outcomes,	  such	  as	  the	  increase	  or	  decrease	  of	  
QALYs	  and	  the	  number	  of	  recurrent	  infections	  present	  under	  usual	  conditions	  
(‘standard	  care’)	  have	  been	  compared	  to	  two	  different	  LOS-­‐reduced	  scenarios.	  The	  








Table	  27:	  Change	  in	  health	  outcomes	  due	  to	  reduction	  of	  inpatient	  LOS	  
	  
Scenario	   Change	  in	  Recurrent	  Infections	  	  
(95%	  CI)	  
Change	  in	  QALYs	  	  
(95%	  CI)	  
Standard	  Care	   Comparator	   Comparator	  
LOS	  1	   -­‐147.86	  
(-­‐139.11,	  -­‐156.61)	  
16.53	  
(13.44	  –	  19.61)	  
LOS	  2	   -­‐349.34	  
(-­‐340.98,	  -­‐357.69)	  
36.57	  
(33.64	  –	  39.50)	  
	  
The	  first	  scenario,	  where	  the	  average	  LOS	  is	  reduced	  by	  1	  day	  –	  from	  5.8	  days	  to	  4.8	  
days	  –	  shows	  an	  average	  gain	  of	  16.53	  QALYs,	  when	  compared	  with	  standard	  care.	  
An	  average	  reduction	  of	  147	  recurrent	  infections	  is	  also	  expected	  under	  this	  
scenario.	  
	  
The	  second	  scenario,	  where	  the	  average	  LOS	  is	  reduced	  by	  2	  days	  –	  from	  5.8	  days	  
to	  3.8	  days	  –	  shows	  an	  even	  larger	  average	  gain	  in	  QALYs.	  Compared	  to	  standard	  
care,	  reducing	  the	  average	  LOS	  by	  2	  days	  would	  result	  in	  36.57	  QALYs	  gained.	  The	  
QALY	  gains	  are	  realised	  because	  of	  a	  reduction	  in	  the	  underlying	  number	  of	  
infections	  for	  the	  at-­‐risk	  population,	  resulting	  in	  improved	  health	  outcomes.	  The	  
avoidance	  of	  infections	  drives	  the	  improvements	  in	  health	  outcomes.	  
	  
Avoiding	  infections	  is	  the	  precise	  objective	  of	  infection	  prevention	  and	  control	  
teams	  in	  the	  hospital	  setting	  and	  it	  is	  clear	  that	  if	  reducing	  average	  LOS	  was	  safely	  




the	  infection	  control	  department	  would	  not	  achieve	  these	  results	  on	  their	  own,	  as	  
the	  reduction	  in	  LOS	  is	  assumed	  to	  occur	  across	  all	  patient	  admissions,	  not	  just	  for	  
infected	  patients.	  It	  is	  far	  more	  likely	  that	  the	  positive	  health	  outcomes	  that	  could	  
be	  observed	  in	  the	  infection	  control	  setting	  would	  be	  as	  a	  consequence	  of	  a	  
coordinated,	  system-­‐wide	  approach	  to	  addressing	  average	  LOS	  for	  all	  admitted	  
patients.	  The	  improved	  health	  outcomes	  that	  could	  be	  observed	  in	  the	  infection	  
control	  setting	  would	  be	  only	  one	  area	  of	  the	  hospital	  where	  it	  would	  be	  feasible	  to	  
notice	  improvements	  due	  to	  reduced	  LOS.	  
	  
5.2.2	  Reducing	  LOS	  concurrently	  with	  other	  infection	  control	  practices	  
The	  impact	  of	  reducing	  LOS	  concurrently	  with	  other	  infection	  control	  practices	  
has	  also	  been	  evaluated	  in	  this	  analysis.	  It	  is	  a	  practical	  reality	  that	  at	  least	  one	  
standard	  infection	  control	  prevention	  strategy	  such	  as	  hand	  hygiene,	  antimicrobial	  
stewardship	  or	  environmental	  cleaning	  would	  be	  conducted	  at	  the	  same	  time	  as	  
any	  system-­‐wide	  LOS-­‐reducing	  strategy.	  	  
	  
Three	  scenarios	  were	  analysed	  where	  the	  transmission	  rate	  of	  Clostridium	  difficile	  
infection	  was	  altered	  by	  a	  reduction	  in	  average	  LOS	  and	  due	  to	  the	  effect	  of	  a	  
‘traditional’	  infection	  control	  intervention.	  Comparison	  of	  average	  change	  in	  the	  
total	  number	  of	  infections,	  QALYs	  gained	  and	  number	  of	  patients	  in	  ICU	  for	  each	  





Table	  28:	  Change	  in	  health	  outcomes	  due	  to	  reduction	  in	  LOS	  and	  existing	  
infection	  control	  practices	  




in	  ICU	  patients	  
(95%	  CI)	  
Average	  change	  in	  
RecInf	  
(95%	  CI)	  
Standard	  Care	   Comparator	   Comparator	   Comparator	  



















Two	  scenarios	  involving	  a	  reduction	  in	  LOS	  and	  a	  reduction	  in	  antimicrobial	  usage	  
were	  considered,	  compared	  to	  standard	  care.	  Both	  scenarios	  modelled	  a	  reduction	  
in	  antimicrobial	  use	  from	  50%	  to	  40%	  of	  the	  inpatient	  population,	  however	  the	  
reduction	  in	  LOS	  differed.	  The	  first	  scenario,	  LOS	  &	  AMS	  1,	  included	  a	  one-­‐day	  
reduction	  in	  average	  LOS,	  where	  the	  second	  scenario,	  LOS	  &	  AMS	  2,	  included	  a	  
two-­‐day	  reduction	  in	  average	  LOS.	  Both	  scenarios	  resulted	  in	  positive	  results	  
compared	  to	  standard	  care,	  with	  an	  improvement	  in	  QALYs	  and	  a	  reduction	  in	  the	  
number	  of	  infections,	  observed.	  Unsurprisingly,	  the	  results	  show	  a	  larger	  reduction	  
in	  the	  number	  of	  total	  infections	  and	  an	  increase	  in	  QALYs	  gained	  for	  the	  second	  
scenario	  (LOS	  &	  AMS	  2),	  compared	  to	  the	  first	  scenario.	  There	  is	  also	  a	  greater	  
reduction	  in	  the	  number	  of	  patients	  who	  are	  in	  ICU	  for	  the	  second	  scenario,	  when	  




of	  great	  importance,	  as	  the	  only	  difference	  between	  the	  two	  scenarios	  was	  a	  larger	  
reduction	  in	  average	  LOS	  for	  the	  second	  scenario.	  
	  
A	  scenario	  including	  a	  reduction	  in	  average	  LOS	  and	  an	  improvement	  in	  hospital	  
hygiene	  was	  also	  considered.	  As	  previously	  presented,	  hygiene	  improvement	  is	  
characterised	  by	  an	  increase	  in	  hand	  hygiene	  compliance	  and	  improved	  efficacy	  of	  
environmental	  cleaning,	  which	  results	  in	  a	  reduction	  in	  the	  transmission	  of	  
infection.	  When	  paired	  with	  a	  one-­‐day	  reduction	  in	  average	  LOS,	  from	  5.8	  days	  to	  
4.8	  days,	  this	  scenario	  resulted	  in	  a	  large	  number	  of	  total	  infections	  avoided	  (2690)	  
and	  a	  large	  gain	  in	  QALYs	  (37.27)	  when	  compared	  with	  standard	  care.	  There	  is	  also	  
a	  large	  reduction	  in	  the	  number	  of	  patients	  accessing	  the	  intensive	  care	  unit	  under	  
this	  scenario,	  compared	  to	  standard	  care.	  	  
	  
Section	  5.3:	  Summary	  of	  results	  
The	  results	  of	  this	  analysis	  show	  that	  at	  baseline,	  seven	  of	  the	  10	  ‘traditional’	  
infection	  control	  interventions	  result	  in	  health	  gains	  and	  cost-­‐savings.	  Without	  
considering	  uncertainty,	  HYG	  1	  dominates	  the	  other	  interventions	  by	  producing	  
the	  best	  combination	  of	  increased	  health	  benefits	  and	  cost-­‐savings.	  The	  
intervention	  generates	  126.68	  QALYs	  and	  cost-­‐savings	  of	  approximately	  $2.2M.	  By	  
undertaking	  probabilistic	  analysis,	  which	  incorporates	  uncertainty	  into	  the	  results,	  
HYG	  1	  remains	  the	  optimal	  choice	  of	  intervention	  at	  the	  threshold	  of	  




the	  other	  interventions.	  The	  scenario	  analyses	  showed	  that	  HYG	  1	  remains	  the	  
optimal	  decision	  under	  different	  clinical	  circumstances,	  including	  when	  mortality	  
rate	  is	  increased	  and	  when	  an	  infected	  patient’s	  LOS	  increases.	  Only	  when	  the	  
underlying	  infection	  rate	  was	  doubled	  was	  another	  intervention	  optimal	  –	  in	  this	  
case	  the	  AMS/HYG	  bundle.	  All	  outcomes	  were	  associated	  with	  high	  levels	  of	  
uncertainty,	  with	  the	  probability	  of	  error	  exceeding	  0.50	  in	  all	  analyses.	  
	  
The	  results	  of	  the	  LOS	  analysis	  show	  that	  Clostridium	  difficile	  related	  health	  
outcomes	  could	  be	  significantly	  improved	  if	  the	  average	  LOS	  of	  all	  admitted	  
patients	  was	  reduced.	  These	  findings	  are	  logical,	  given	  the	  increased	  risk	  that	  an	  
inpatient	  stay	  has	  on	  becoming	  infected.	  However,	  it	  is	  difficult	  to	  envisage	  from	  a	  
practical	  point	  of	  view,	  how	  these	  results	  could	  be	  effectively	  translated	  into	  the	  
hospital	  setting,	  given	  that	  time	  to	  safe	  patient	  discharge	  is	  impacted	  by	  numerous	  
factors	  within	  the	  healthcare	  system.	  Trying	  to	  implement	  a	  further	  reduction	  in	  
average	  LOS	  on	  clinicians	  who	  are	  already	  encouraged	  to	  juggle	  high	  occupancy	  
rates	  and	  high	  patient	  throughput	  is	  bound	  to	  be	  a	  difficult	  task.	  
	  




Chapter	  6:	  Discussion	  
Chapter	  Overview	  	  
This	  chapter	  is	  a	  discussion	  of	  the	  results	  of	  the	  research	  project	  and	  is	  presented	  
in	  seven	  sections.	  Section	  6.1	  is	  a	  summary	  of	  the	  project’s	  main	  findings	  and	  a	  
clear	  interpretation	  of	  the	  analyses.	  Section	  6.2	  is	  a	  discussion	  of	  how	  the	  project’s	  
findings	  should	  be	  used	  in	  a	  practical	  context	  and	  how	  they	  should	  influence	  
decision-­‐making	  with	  regard	  to	  Clostridium	  difficile.	  A	  description	  of	  the	  context	  
and	  generalisability	  of	  the	  results	  is	  provided	  in	  section	  6.3,	  while	  6.4	  is	  a	  summary	  
of	  the	  limitations	  that	  relate	  to	  the	  project.	  Section	  6.5	  summarises	  the	  
contribution	  to	  the	  existing	  knowledge	  base	  and	  examines	  the	  strengths	  of	  the	  
research	  project.	  Section	  6.6	  is	  a	  discussion	  about	  areas	  for	  further	  study	  and	  6.7	  
concludes	  the	  thesis.	  
	  
Section	  6.1:	  Interpretation	  of	  the	  analyses	  
Hospitals	  in	  Australia	  have	  multiple	  infection	  control	  interventions	  that	  are	  
designed	  to	  reduce	  the	  transmission	  of	  Clostridium	  difficile	  available	  to	  them.	  
Healthcare	  interventions	  can	  be	  delivered	  either	  on	  their	  own	  or	  in	  combination	  
with	  another	  intervention	  and	  as	  such,	  this	  analysis	  has	  included	  both	  singular	  and	  
bundled	  approaches	  to	  infection	  management.	  The	  interpretation	  of	  the	  study’s	  
findings	  are	  presented	  in	  this	  section,	  providing	  answers	  to	  the	  research	  questions,	  





1.	  What	  interventions	  are	  relevant	  to	  reduce	  Clostridium	  difficile	  infection	  and	  
what	  do	  they	  cost?	  
	  
Using	  a	  stochastic	  mathematical	  model,	  Yakob	  et	  al	  estimated	  the	  efficacy	  of	  all	  
intervention	  combinations.	  The	  baseline	  analysis	  shows	  that	  the	  majority	  of	  
interventions	  resulted	  in	  health	  improvements,	  which	  was	  measured	  by	  QALYs	  
gained.	  QALY	  gains	  were	  driven	  by	  a	  reduction	  in	  the	  number	  of	  infected	  patients	  
as	  a	  result	  of	  a	  successful	  intervention,	  when	  compared	  with	  the	  number	  of	  
infected	  patients	  who	  existed	  under	  the	  comparator	  situation.	  Despite	  producing	  
QALY	  gains,	  those	  generated	  by	  AMS	  2	  (5.59	  QALYs)	  were	  substantially	  less	  than	  
those	  generated	  by	  HYG	  1	  (126.68	  QALYs).	  The	  findings	  of	  the	  baseline	  analysis	  
show	  that	  if	  decision-­‐makers	  did	  not	  adopt	  any	  of	  the	  proposed	  interventions	  
(except	  AMS	  1),	  improvements	  in	  health	  outcomes	  would	  be	  forgone.	  If	  
investments	  are	  not	  made	  in	  interventions	  that	  clearly	  yield	  gains	  in	  health	  
outcomes	  compared	  to	  the	  status	  quo,	  the	  allocation	  and	  use	  of	  scarce	  healthcare	  
resources	  is	  inappropriate.	  The	  results	  of	  the	  baseline	  analysis	  also	  show	  that	  
bundled	  interventions,	  as	  opposed	  to	  stand-­‐alone	  interventions,	  offer	  the	  best	  
opportunity	  for	  health	  improvements.	  The	  four	  highest-­‐ranking	  interventions	  in	  
terms	  of	  highest	  expected	  QALY	  gains	  were	  all	  bundles	  (HYG	  1,	  AMS/HYG,	  
HYG/FMT	  1	  and	  HYG/FMT	  2).	  Given	  that	  improving	  patient	  outcomes	  is	  the	  




deemed	  as	  clinically	  ‘relevant’	  approaches	  to	  reducing	  Clostridium	  difficile	  
infection.	  	  
	  
The	  cost	  of	  each	  intervention	  was	  estimated	  using	  detailed	  and	  transparent	  
methods,	  which	  have	  been	  presented	  in	  full	  in	  Chapter	  4.4.1.	  The	  cost	  of	  
implementing	  each	  intervention	  is	  never	  going	  to	  be	  exactly	  the	  same	  between	  
hospitals,	  due	  to	  local	  variation	  in	  bed	  numbers,	  treatment	  approaches,	  baseline	  
infection	  rates	  and	  patient	  casemix,	  which	  all	  have	  an	  impact	  on	  the	  size	  of	  
intervention	  required	  for	  that	  specific	  setting.	  However,	  average	  intervention	  costs	  
were	  calculated	  and	  used	  in	  the	  economic	  model.	  The	  costs	  that	  were	  used	  in	  the	  
analysis	  are	  incremental	  costs	  and	  are	  annual	  running	  costs	  -­‐	  they	  do	  not	  include	  
start-­‐up	  costs.	  The	  AMS	  intervention	  is	  the	  most	  costly	  ‘stand	  alone’	  intervention	  
($240,388)	  and	  the	  cheapest	  ‘stand	  alone’	  intervention	  is	  FMT	  ($89,066).	  The	  cost	  
associated	  with	  the	  FMT	  intervention	  is	  dependent	  on	  clinical	  throughput,	  so	  in	  
reality	  is	  the	  most	  likely	  to	  change	  according	  to	  how	  many	  procedures	  are	  
undertaken	  per	  annum.	  The	  bundled	  interventions	  are	  more	  expensive	  than	  the	  
stand-­‐alone	  interventions.	  The	  AMS	  &	  HYG	  bundle	  is	  more	  expensive	  ($387,377)	  
than	  the	  HYG	  &	  FMT	  bundle	  ($236,054).	  
	  
These	  results	  consider	  the	  clinical	  effectiveness	  of	  each	  intervention	  to	  reduce	  




intervention	  in	  the	  hospital	  setting.	  However,	  the	  combination	  of	  cost	  and	  clinical	  
effectiveness	  is	  not	  considered	  and	  is	  covered	  in	  research	  question	  two.	  
	  
2.	  What	  is	  the	  most	  cost-­‐effective	  approach	  to	  managing	  Clostridium	  difficile	  
infection?	  
	  
At	  baseline	  level,	  HYG	  1	  is	  the	  best	  combination	  of	  increased	  health	  outcomes	  and	  
costs-­‐saved	  and	  would	  represent	  the	  best	  decision	  for	  implementation	  in	  the	  
absence	  of	  any	  consideration	  of	  uncertainty.	  The	  baseline	  analysis	  shows	  that	  3	  of	  
the	  10	  interventions	  do	  not	  result	  in	  cost-­‐savings	  (HYG2,	  FMT	  1	  &	  FMT	  3).	  This	  
means	  that	  in	  order	  to	  realise	  gains	  in	  health	  outcomes,	  they	  would	  come	  at	  a	  cost	  
to	  the	  healthcare	  provider.	  The	  remaining	  7	  interventions	  not	  only	  generate	  health	  
improvements,	  but	  they	  also	  result	  in	  cost-­‐savings.	  HYG	  1	  results	  in	  the	  largest	  
amount	  of	  costs	  being	  saved	  ($2,137,843)	  ahead	  of	  AMS/HYG	  ($2,052,003).	  The	  
probabilistic	  analysis,	  which	  includes	  uncertainty	  in	  the	  results,	  shows	  that	  HYG	  1	  
is	  the	  optimal	  decision	  because	  it	  returns	  the	  highest	  mean	  net	  monetary	  benefit	  
when	  compared	  with	  all	  other	  interventions.	  HYG	  1	  has	  a	  mean	  net	  monetary	  
benefit	  of	  $7,459,667,	  which	  is	  larger	  than	  AMS/HYG,	  the	  next	  best	  with	  a	  mean	  
net	  monetary	  benefit	  of	  $7,305,565.	  The	  results	  of	  the	  scenario	  analyses	  showed	  
that	  when	  mortality	  rate	  and	  length	  of	  stay	  were	  increased	  and	  the	  method	  for	  




intervention.	  Only	  when	  the	  infection	  rate	  was	  increased	  did	  another	  intervention	  
take	  over	  as	  being	  the	  best	  decision.	  In	  this	  scenario	  AMS/HYG	  was	  optimal.	  
	  
3.	  How	  does	  uncertainty	  in	  competing	  decisions	  impact	  on	  decision-­‐making?	  
	  
Healthcare	  decision-­‐makers	  are	  renowned	  for	  being	  unsettled	  by	  uncertainty,	  are	  
known	  to	  tend	  toward	  being	  risk-­‐averse	  and	  often	  favour	  the	  status	  quo	  when	  it	  
comes	  to	  decision-­‐making	  (225-­‐226).	  As	  a	  result,	  the	  outcomes	  of	  the	  probabilistic	  
analysis	  are	  likely	  to	  be	  more	  useful	  for	  decision-­‐makers	  as	  they	  include	  
consideration	  of	  uncertainty	  in	  the	  model’s	  parameters.	  	  
	  
The	  error	  probability	  associated	  with	  this	  decision	  is	  high,	  at	  66%,	  which	  could	  
serve	  to	  deter	  decision-­‐makers	  from	  choosing	  HYG	  1	  in	  their	  location.	  The	  error	  
probability	  associated	  with	  this	  decision	  means	  that	  if	  a	  decision-­‐maker	  
implemented	  HYG	  1	  in	  their	  hospital,	  they	  could	  expect	  it	  to	  be	  the	  correct	  
decision	  only	  34%	  of	  the	  time.	  In	  the	  remaining	  66%	  of	  the	  time,	  there	  is	  the	  
possibility	  that	  another	  intervention	  in	  the	  study	  would	  provide	  the	  largest	  net	  
monetary	  benefit	  and	  therefore	  be	  the	  optimal	  choice.	  The	  results	  of	  the	  scenario	  
analyses	  should	  be	  of	  great	  interest	  to	  decision-­‐makers	  who	  experience	  different	  
clinical	  or	  management	  circumstances	  than	  those	  represented	  and	  analysed	  in	  the	  




analyses	  was	  still	  high	  –	  greater	  than	  50%	  for	  all	  scenarios,	  however	  these	  results	  
do	  provide	  decision-­‐makers	  with	  extra	  information	  to	  support	  a	  decision.	  	  
	  
Reluctance	  to	  implement	  an	  intervention	  with	  an	  error	  probability	  that	  may	  be	  
deemed	  as	  too	  high	  could	  represent	  false	  logic,	  by	  not	  taking	  proper	  consideration	  
of	  the	  new	  evidence.	  Decision-­‐makers	  should	  be	  opting	  to	  implement	  
interventions	  that	  produce	  the	  highest	  net	  monetary	  benefit,	  regardless	  of	  the	  
probability	  of	  error,	  as	  there	  is	  no	  decision	  that	  is	  ever	  risk-­‐free.	  Refusing	  to	  
implement	  the	  optimal	  decision	  and	  instead	  maintaining	  the	  status	  quo	  is	  not	  a	  
less	  risky	  decision	  given	  that	  the	  decision-­‐maker	  does	  not	  have	  any	  information	  
relating	  to	  the	  error	  probability	  of	  maintaining	  the	  status	  quo.	  Healthcare	  
decision-­‐makers	  who	  find	  themselves	  with	  a	  decision	  that	  is	  associated	  with	  a	  
higher-­‐than-­‐acceptable	  error	  probability	  can	  choose	  to	  postpone	  their	  decision	  
until	  new	  evidence	  has	  been	  collected.	  It	  is	  worth	  noting	  that	  the	  level	  of	  
‘acceptability’	  is	  not	  a	  fixed	  value,	  common	  across	  all	  kinds	  of	  decision-­‐maker	  
(227).	  If	  decision	  uncertainty	  can	  be	  reduced	  to	  a	  more	  ‘acceptable’	  level	  with	  
improved	  information,	  decision-­‐makers	  have	  the	  opportunity	  to	  make	  a	  more	  
informed	  decision.	  Collecting	  new	  information	  does	  not	  always	  guarantee	  a	  
reduction	  in	  decision	  uncertainty	  and	  the	  cost	  and	  time	  taken	  to	  conduct	  further	  
research	  needs	  to	  be	  considered	  before	  the	  decision	  to	  postpone	  the	  





Decision-­‐makers	  have	  the	  choice	  to	  either	  adopt,	  reject	  or	  postpone	  their	  decision	  
regarding	  the	  implementation	  of	  a	  new	  intervention,	  based	  on	  the	  information	  
that	  they	  have	  available	  to	  them.	  Adopting	  or	  rejecting	  the	  decision	  based	  on	  
reported	  error	  probability	  varies	  according	  to	  the	  decision-­‐maker’s	  confidence	  in	  
the	  information	  that	  is	  being	  provided	  to	  them.	  Adopting	  interventions	  that	  report	  
error	  probabilities	  that	  are	  outside	  the	  level	  that	  is	  deemed	  to	  be	  ‘satisfactory’	  by	  
the	  individual	  decision-­‐maker	  are	  unlikely	  to	  be	  a	  favoured	  approach.	  This	  is	  
especially	  the	  case	  in	  the	  healthcare	  setting,	  where	  many	  decision-­‐makers	  appear	  
to	  be	  risk	  averse.	  Postponing	  a	  decision	  until	  the	  gaps	  in	  evidence	  are	  filled	  by	  new	  
data	  is	  a	  reasonable	  decision.	  For	  a	  postponed	  decision	  to	  be	  revisited,	  new	  
evidence	  needs	  to	  be	  supplied	  to	  the	  decision-­‐maker	  in	  a	  timely	  and	  cost-­‐effective	  
manner,	  given	  that	  there	  are	  likely	  to	  be	  many	  costs	  relating	  to	  improving	  the	  
current	  evidence.	  
	  
4.	  What	  is	  the	  expected	  value	  of	  perfect	  information	  (EVPI)	  relating	  to	  this	  
decision	  problem?	  
	  
It	  has	  been	  demonstrated	  in	  this	  study	  that	  decisions	  based	  on	  existing	  
information	  are	  uncertain	  and	  that	  by	  using	  current	  information	  there	  is	  the	  
possibility	  of	  making	  an	  incorrect	  decision.	  Specifically,	  deciding	  that	  HYG	  1	  was	  




monetary	  benefit	  but	  there	  is	  the	  possibility	  that	  other	  interventions	  could	  have	  
higher	  net	  benefits	  if	  the	  current	  uncertainty	  about	  the	  existing	  decision	  is	  settled.	  	  
	  
By	  estimating	  the	  expected	  value	  of	  perfect	  information	  in	  this	  study,	  an	  upper	  
monetary	  bound	  has	  been	  placed	  on	  the	  value	  of	  conducting	  further	  research	  and	  
understanding	  this	  threshold	  acknowledges	  that	  conducting	  further	  research	  
should	  be	  cost-­‐effective,	  itself.	  For	  this	  decision	  problem,	  if	  perfect	  information	  
could	  be	  attained	  for	  less	  than	  $3.4	  million,	  it	  would	  be	  deemed	  to	  be	  worthwhile	  
and	  cost-­‐effective.	  Specifically	  for	  this	  study,	  the	  expected	  value	  of	  perfect	  
parameter	  information	  (EVPPI)	  results	  show	  that	  better	  information	  relating	  to	  
the	  estimation	  of	  transition	  probabilities	  would	  result	  in	  the	  greatest	  reduction	  in	  
decision	  uncertainty,	  improving	  the	  probability	  of	  error.	  Strengthening	  
information	  about	  transmission	  rate;	  the	  movement	  from	  being	  ‘At-­‐Risk’	  to	  
infected	  with	  Clostridium	  difficile,	  and	  about	  healthy	  discharge;	  the	  rate	  at	  which	  
people	  transition	  from	  being	  admitted	  to	  hospital	  to	  being	  discharged	  without	  ever	  
being	  infected,	  would	  be	  of	  the	  greatest	  value	  to	  reducing	  uncertainty.	  Improving	  
information	  about	  vulnerable	  discharge;	  the	  rate	  at	  which	  people	  transition	  from	  
being	  infected	  to	  discharged	  from	  hospital,	  is	  of	  less	  value	  ($42,486)	  than	  
transmission	  rate	  ($567,468)	  and	  healthy	  discharge	  ($243,082),	  but	  is	  still	  more	  
worthwhile	  than	  better	  estimations	  of	  recurrent	  infection	  rate	  ($3,660)	  and	  




recurrent	  infection	  and	  mortality	  would	  not	  have	  a	  significant	  impact	  on	  decision	  
uncertainty	  and	  should	  not	  be	  the	  focus	  of	  further	  investigation.	  
	  	  
Section	  6.2:	  How	  to	  use	  the	  results	  in	  the	  real	  world	  
Prior	  to	  this	  research,	  Australian	  decision-­‐makers	  have	  had	  limited	  access	  to	  
economic	  evidence	  to	  inform	  their	  decision-­‐making	  about	  managing	  risk	  of	  
Clostridium	  difficile	  infection.	  Given	  that	  the	  results	  of	  this	  research	  have	  been	  
based	  on	  Australian	  costs	  and	  infection	  rates	  it	  does	  not	  require	  significant	  
adaptation	  of	  information	  from	  another	  country’s	  setting.	  Relying	  on	  information	  
from	  elsewhere	  in	  the	  world	  would	  be	  difficult	  for	  decisions	  about	  Clostridium	  
difficile	  infection	  because	  there	  is	  little	  economic	  evidence	  available	  from	  
jurisdictions	  that	  are	  similar	  to	  Australia.	  Although	  there	  is	  considerable	  
uncertainty	  in	  the	  results	  of	  this	  evaluation,	  doing	  nothing	  to	  change	  the	  
management	  approach	  relating	  to	  Clostridium	  difficile	  is	  a	  decision	  in	  itself	  that	  
should	  be	  weighed	  up	  with	  appropriate	  consideration.	  Decision-­‐makers	  need	  to	  
understand	  that	  remaining	  with	  the	  status	  quo	  –	  simply	  maintaining	  one’s	  current	  
or	  previous	  position	  -­‐	  is	  itself	  an	  explicit	  decision,	  which	  is	  often	  influenced	  by	  
bias.	  Maintaining	  the	  status	  quo	  can	  happen	  for	  a	  number	  of	  reasons	  –	  loss	  
aversion:	  where	  there	  is	  a	  perception	  that	  potential	  losses	  are	  weighted	  more	  
heavily	  than	  potential	  gains;	  avoidance	  of	  transition	  costs:	  where	  the	  cost	  of	  
making	  a	  change	  is	  valued	  over	  and	  above	  potential	  gains;	  or	  ongoing	  commitment	  




being	  too	  great	  to	  go	  back	  on	  (148;	  225;	  229).	  All	  of	  these	  factors	  have	  been	  
described	  in	  detail	  by	  economists	  as	  contributing	  to	  status	  quo	  bias	  in	  decision-­‐
making	  and	  examples	  of	  how	  this	  bias	  impacts	  healthcare	  policy	  are	  easily	  found	  
(230-­‐231).	  With	  this	  in	  mind,	  healthcare	  decision-­‐makers	  in	  Australia	  should	  
consider	  the	  findings	  of	  this	  research	  and	  use	  them	  to	  inform	  change	  in	  policy	  
and/or	  practice,	  if	  it	  is	  deemed	  to	  be	  required,	  with	  all	  other	  evidence	  considered.	  	  
	  
Despite	  a	  broader	  awakening	  to	  its	  value	  in	  the	  wider	  healthcare	  sector,	  economic	  
evidence	  has	  been	  underutilised	  in	  the	  infection	  control	  setting	  in	  Australia	  (232).	  
In	  recent	  years	  there	  has	  been	  an	  increase	  in	  interest	  about	  economic	  evidence	  and	  
the	  commissioning	  of	  economic	  evaluations	  has	  slowly	  developed	  but	  it	  is	  not	  
current	  practice	  for	  economic	  evidence	  to	  be	  included	  in	  submissions	  for	  funding	  
at	  the	  hospital-­‐level.	  It	  is	  also	  clear	  that	  the	  inclusion	  of	  economic	  evidence	  is	  not	  
yet	  embedded	  in	  the	  infection	  control	  decision-­‐making	  process.	  Despite	  a	  growth	  
in	  demand	  and	  increased	  interest	  in	  the	  discipline,	  it	  has	  been	  implied	  by	  
researchers	  that	  there	  is	  evidence	  to	  suggest	  that	  decision-­‐makers	  have	  used	  
economic	  evaluation	  to	  ‘rubber	  stamp’	  policies	  that	  are	  already	  in	  place	  (233-­‐234)	  
rather	  than	  to	  use	  economic	  evaluation	  to	  drive	  change,	  if	  it	  is	  shown	  to	  be	  
required.	  This	  has	  created	  an	  impression	  that	  economic	  evidence	  is	  currently	  being	  
used	  to	  support	  ‘policy	  based	  evidence’,	  rather	  than	  informing	  ‘evidence	  based	  
policy’	  in	  the	  healthcare	  sector.	  A	  notable	  and	  clear	  example	  of	  this	  can	  be	  seen	  




Hygiene	  Initiative.	  This	  study	  was	  commissioned	  by	  the	  ACSQHC,	  an	  indication	  of	  
the	  growing	  interest	  in	  economic	  evidence	  in	  relation	  to	  the	  infection	  control	  
setting.	  However,	  when	  the	  results	  were	  presented	  in	  a	  different	  light	  to	  what	  was	  
expected	  by	  stakeholders,	  attempts	  were	  made	  to	  block	  the	  dissemination	  of	  
findings	  and	  the	  methods	  used	  to	  undertake	  the	  study	  were	  criticised.	  This	  
experience	  is	  not	  new,	  with	  researchers	  from	  other	  sectors	  noting	  that	  the	  
censorship	  and	  control	  of	  research	  topics	  by	  funding	  bodies	  is	  a	  major	  obstacle	  to	  
ensuring	  that	  evidence	  informs	  policy	  and/or	  practice	  (235).	  	  
	  
The	  results	  of	  this	  research	  project	  are	  intended	  to	  be	  used	  to	  shape	  decisions	  
about	  where	  money	  is	  invested;	  firstly	  in	  relation	  to	  Clostridium	  difficile	  infection	  
and	  secondly	  as	  a	  contribution	  to	  a	  wider	  infection	  control	  programme.	  However,	  
infection	  control’s	  place	  in	  the	  overall	  healthcare	  sector	  needs	  to	  be	  understood	  
before	  budgetary	  decisions	  are	  made.	  Whilst	  infection	  control	  is	  a	  critical	  
component	  of	  the	  healthcare	  system,	  it	  is	  an	  overarching	  support	  rather	  than	  one	  
stand-­‐alone	  aspect	  of	  a	  hospital,	  such	  as	  an	  ICU	  or	  an	  item	  of	  equipment	  for	  the	  
imaging	  department.	  Because	  of	  the	  way	  that	  infection	  control	  works	  in	  a	  hospital,	  
there	  are	  not	  going	  to	  be	  any	  cash	  returns	  on	  the	  investment	  in	  its	  programmes.	  
What	  there	  will	  be	  is	  an	  improvement	  in	  hospital	  efficiency	  –	  an	  effective	  infection	  
control	  programme	  will	  free	  up	  beds,	  allowing	  the	  treatment	  of	  extra	  patients,	  so	  
the	  infection	  control	  department	  does	  not	  necessarily	  see	  any	  direct	  ‘cash	  saving’	  




opposite	  effect	  –	  an	  increase	  in	  costs	  due	  to	  the	  investment	  in	  new	  programmes,	  
with	  the	  health	  gains	  being	  measurable	  elsewhere	  in	  the	  system.	  It	  is	  also	  clear	  
that	  the	  economic	  benefits	  of	  good	  infection	  control	  practice	  are	  widespread	  and	  
may	  not	  necessarily	  relate	  to	  the	  financial	  bottom	  line	  for	  the	  infection	  control	  
department.	  For	  example,	  adherence	  to	  national	  infection	  control	  targets	  can	  
contribute	  to	  a	  reputational	  advantage	  for	  high	  achieving	  hospitals.	  This	  
reputational	  advantage	  is	  unlikely	  to	  impact	  the	  infection	  control	  department’s	  
flow	  of	  monetary	  resources,	  but	  benefits	  to	  other	  areas	  of	  that	  hospital	  could	  be	  
attained.	  
	  
Given	  that	  resources	  are	  scarce	  and	  clinical	  need	  is	  seemingly	  unlimited,	  the	  need	  
for	  investment	  in	  other	  areas	  of	  the	  hospital	  has	  to	  be	  weighed	  up	  with	  the	  
investment	  that	  is	  being	  considered	  for	  infection	  control.	  To	  ensure	  that	  decisions	  
are	  made	  in	  the	  appropriate	  context,	  a	  number	  of	  matters	  need	  to	  be	  considered	  in	  
the	  decision-­‐making	  process.	  Firstly,	  if	  resources	  are	  going	  to	  be	  allocated	  to	  a	  new	  
infection	  control	  intervention,	  they	  must	  be	  allocated	  in	  place	  of	  an	  existing	  
infection	  control	  programme,	  or	  because	  investment	  in	  infection	  control	  is	  more	  
beneficial	  than	  investment	  in	  other	  clinical	  areas.	  This	  is	  a	  simple	  financial	  
restraint	  faced	  by	  the	  majority	  of	  decision-­‐makers	  who	  have	  to	  manage	  a	  rigid	  
healthcare	  budget	  that	  does	  not	  generally	  make	  allowances	  for	  new	  funding,	  
rather,	  requiring	  decision-­‐makers	  to	  prioritise	  their	  expenditure	  from	  a	  fixed	  




money-­‐invested	  need	  to	  prioritise	  their	  decisions	  based	  on	  the	  number	  of	  people	  
who	  stand	  to	  benefit	  from	  that	  investment.	  As	  such,	  the	  allocation	  and	  
prioritisation	  of	  resources	  needs	  to	  reflect	  the	  clinical	  impact	  that	  a	  health	  
problem	  has,	  or	  can	  have,	  on	  the	  wider	  population.	  The	  health	  problems	  that	  have	  
the	  capacity	  to	  cause	  the	  greatest	  damage	  to	  the	  healthcare	  system	  and	  wider	  
population	  need	  to	  be	  prioritised	  over	  other	  issues.	  Finally,	  the	  quality	  of	  evidence	  
that	  is	  informing	  a	  decision	  is	  also	  of	  importance	  to	  decision-­‐makers,	  as	  is	  the	  level	  
of	  uncertainty	  that	  may	  surround	  the	  safety	  and	  clinical	  effectiveness	  of	  the	  
proposed	  intervention.	  All	  of	  these	  matters	  need	  to	  be	  considered	  and	  understood	  
before	  scarce	  resources	  are	  allocated	  to	  an	  infection	  control	  programme,	  ahead	  of	  
another	  clinical	  area	  (232).	  
	  
The	  use	  of	  the	  results	  from	  this	  research	  project	  will	  vary	  according	  to	  who	  is	  
planning	  on	  using	  them.	  The	  requirements	  of	  one	  decision-­‐maker	  are	  unlikely	  to	  
be	  the	  same	  as	  another,	  necessitating	  information	  to	  be	  tailored	  to	  need.	  The	  
project	  was	  developed	  with	  three	  different	  types	  of	  healthcare	  decision-­‐makers	  in	  
mind:	  	  
1. Hospital-­‐level	  clinical	  staff,	  such	  as	  infectious	  disease	  doctors	  and	  infection	  





2. Infection	  control	  policy	  makers,	  who	  may	  have	  a	  broader	  interest	  in	  the	  
outcomes	  of	  health	  services	  research	  and	  the	  impact	  it	  has	  on	  the	  regional	  
or	  national	  approach	  to	  infection	  control	  
3. Hospital-­‐based	  decision-­‐makers	  who	  make	  choices	  about	  the	  allocation	  of	  
the	  hospital’s	  budget	  
	  
Decision-­‐maker	  1:	  hospital-­‐level	  clinical	  staff	  
The	  results	  show	  that	  from	  a	  clinical	  viewpoint,	  delivering	  interventions	  in	  
‘bundles’	  makes	  economic	  and	  clinical	  sense.	  The	  most	  cost-­‐effective	  intervention	  
was	  a	  combination	  of	  two	  of	  the	  cornerstones	  of	  infection	  control	  –	  hand	  hygiene	  
and	  environmental	  cleaning.	  There	  are	  obvious	  synergies	  that	  are	  realised,	  both	  in	  
clinical	  effect	  and	  cost,	  when	  a	  bundled	  approach	  to	  intervention	  is	  taken.	  	  
It	  is	  clear	  that	  for	  intervention	  into	  Clostridium	  difficile	  infection,	  taking	  a	  bundled	  
approach	  maximises	  health	  outcomes	  and	  clinical	  staff	  should	  campaign	  for	  this	  to	  
occur	  if	  it	  is	  not	  already	  in	  place	  at	  their	  hospital.	  If	  a	  hospital	  already	  has	  these	  
interventions	  in	  place,	  the	  results	  show	  that	  the	  greater	  the	  efficacy	  of	  those	  
interventions,	  that	  there	  will	  likely	  be	  larger	  reductions	  in	  infection	  incidence.	  
The	  findings	  of	  this	  research	  have	  also	  shown	  that	  the	  combination	  of	  
interventions	  included	  in	  a	  bundle	  is	  vitally	  important.	  This	  result	  supports	  
findings	  from	  other	  studies	  that	  have	  found	  bundle	  composition	  to	  be	  of	  
importance	  in	  infection	  control	  (236-­‐237).	  Multiple	  ‘bundled’	  approaches	  were	  




outperformed	  those	  that	  bundled	  fecal	  bacteriotherapy	  or	  antimicrobial	  
stewardship.	  Antimicrobial	  stewardship	  interventions	  did	  not	  perform	  well	  when	  
compared	  with	  others	  in	  the	  study.	  This	  has	  implications	  for	  clinical	  staff,	  who	  
should	  reconsider	  the	  inclusion	  of	  AMS	  programmes	  for	  the	  control	  of	  this	  
infection	  if	  it	  is	  in	  place	  in	  their	  hospital.	  AMS	  programmes	  are	  useful	  for	  multiple	  
types	  of	  healthcare-­‐associated	  infections,	  so	  as	  an	  intervention	  it	  should	  not	  be	  
completely	  disregarded.	  However,	  the	  results	  do	  suggest	  that	  if	  AMS	  programmes	  
are	  not	  in	  place	  for	  the	  intervention	  into	  Clostridium	  difficile,	  it	  should	  not	  be	  
considered	  ahead	  of	  a	  hand	  hygiene	  and	  environmental	  cleaning	  bundle.	  Fecal	  
transplant	  interventions,	  despite	  being	  the	  focus	  of	  much	  attention	  both	  clinically	  
and	  in	  the	  general	  public,	  should	  not	  be	  pursued	  on	  their	  own	  ahead	  of	  other	  
available	  programmes.	  Including	  fecal	  transplant	  in	  a	  bundle	  was	  preferential	  to	  as	  
a	  stand-­‐alone	  intervention	  for	  all	  scenarios.	  These	  findings	  make	  intuitive	  sense,	  
given	  that	  FMT	  has	  shown	  greatest	  efficacy	  for	  patients	  suffering	  recurrences	  of	  
infection,	  rather	  than	  as	  a	  front-­‐line	  intervention.	  These	  findings	  are	  useful	  for	  
practitioners	  who	  work	  at	  the	  coalface	  of	  infection	  control	  in	  a	  hospital,	  as	  it	  gives	  
them	  practical	  information	  on	  where	  effort	  and	  finances	  should	  be	  channelled	  for	  
best	  chances	  of	  return.	  Clinicians	  should	  use	  these	  findings	  to	  tailor	  their	  current	  
practice	  according	  to	  their	  situation.	  If	  they	  are	  currently	  undertaking	  AMS	  as	  a	  
frontline	  programme	  for	  the	  reduction	  of	  Clostridium	  difficile	  incidence,	  they	  
should	  reconsider	  this	  approach	  in	  favour	  of	  the	  development	  of	  a	  hand	  hygiene	  




environmental	  cleaning	  programme	  in	  place,	  all	  efforts	  should	  be	  spent	  to	  ensure	  
that	  the	  efficacy	  of	  these	  approaches	  is	  as	  high	  as	  possible,	  to	  ensure	  maximum	  
gains	  are	  achieved.	  
	  
Decision-­‐maker	  2:	  infection	  control	  policy	  makers	  	  
For	  infection	  control	  policy	  makers,	  the	  results	  of	  this	  research	  project	  should	  be	  
used	  to	  help	  inform	  Australia-­‐wide	  policy	  on	  the	  most	  cost-­‐effective	  approach	  to	  
reducing	  Clostridium	  difficile	  transmission.	  The	  results	  are	  appropriate	  for	  
inclusion	  to	  existing	  guideline	  or	  policy	  documents	  that	  advocate	  best	  practice.	  For	  
example,	  the	  current	  Australasian	  Society	  for	  Infectious	  Diseases	  (ASID)	  guidelines	  
for	  the	  diagnosis	  and	  treatment	  of	  Clostridium	  difficile	  do	  not	  offer	  any	  advice	  on	  
the	  most	  cost-­‐effective	  approach	  to	  managing	  transmission	  of	  the	  infection	  (188).	  
It	  can	  be	  argued	  that	  this	  information	  is	  missing	  from	  the	  current	  guidelines	  
because	  until	  this	  point	  there	  has	  not	  been	  any	  locally	  valid	  findings	  that	  can	  be	  
incorporated	  into	  the	  policy	  document.	  The	  role	  of	  the	  ASID	  is	  to	  provide	  
guidance	  to	  clinicians	  about	  the	  most	  appropriate	  methods	  for	  treating	  cases	  of	  
infection	  as	  well	  as	  preventing	  and	  controlling	  its	  spread.	  The	  National	  Infection	  
Control	  Guidelines,	  published	  by	  the	  ACSQHC,	  is	  another	  example	  of	  a	  policy	  
document	  that	  would	  benefit	  from	  the	  findings	  of	  this	  research.	  In	  section	  C1.3.4:	  
Resource	  allocation,	  the	  funding	  of	  infection	  control	  interventions	  is	  discussed	  and	  
recommendations	  about	  the	  provision	  of	  financial	  and	  human	  resources	  are	  made.	  




HAIs	  should	  be	  gathered	  and	  utilised,	  in	  order	  to	  improve	  infection	  prevention	  
and	  control	  services,	  would	  enhance	  the	  document.	  Despite	  not	  being	  an	  
organisation	  that	  directly	  funds	  hospital-­‐based	  interventions,	  the	  ACSQHC	  are	  a	  
well-­‐regarded	  provider	  of	  National	  guidelines.	  Their	  influence	  on	  Australian	  
clinical	  practice	  is	  far-­‐reaching	  and	  their	  attention	  relating	  to	  Clostridium	  difficile	  
matters	  is	  worth	  striving	  for.	  By	  supporting	  the	  results	  of	  this	  study,	  through	  
inclusion	  in	  infection	  control	  guidelines	  and	  other	  policy	  documents,	  the	  case	  for	  
investment	  in	  Clostridium	  difficile-­‐related	  health	  services	  will	  continue	  to	  be	  
pushed.	  Economic	  evidence	  that	  provides	  comparative	  analysis	  of	  intervention	  
options,	  such	  as	  the	  evidence	  presented	  in	  this	  study,	  is	  of	  high	  value	  in	  a	  resource-­‐
constrained	  environment.	  Policy	  makers	  are	  now	  in	  a	  position	  to	  promote	  the	  
results	  and	  push	  the	  case	  for	  extra	  funding	  to	  be	  provided,	  or	  diverted	  from	  other	  
clinical	  areas,	  to	  infection	  control	  departments	  across	  Australia.	  
	  
Decision-­‐maker	  3:	  budget	  allocators	  	  
For	  those	  making	  budgetary	  decisions	  in	  the	  hospital,	  the	  most	  important	  and	  
useful	  findings	  of	  this	  research	  relate	  to	  where	  money	  invested	  is	  most	  likely	  to	  
result	  in	  benefit.	  The	  results	  show	  that	  in	  relation	  to	  Clostridium	  difficile-­‐related	  
outcomes,	  investment	  in	  antimicrobial	  stewardship	  is	  less	  likely	  to	  yield	  positive	  
outcomes	  when	  compared	  to	  all	  other	  intervention	  options.	  If	  antimicrobial	  
stewardship	  is	  currently	  in	  place	  as	  a	  frontline	  programme	  for	  reducing	  




approach.	  The	  findings	  also	  show	  that	  investment	  in	  a	  hygiene	  improvement	  
programme	  that	  couples	  hand	  hygiene	  and	  environmental	  cleaning	  is	  likely	  to	  
result	  in	  cost-­‐savings	  due	  to	  a	  reduction	  in	  treatment	  costs	  and	  gains	  in	  health	  
outcomes	  due	  to	  a	  reduction	  in	  infection	  incidence.	  Implementing	  a	  bundled	  
approach	  that	  includes	  hygiene	  improvement	  was	  found	  to	  be	  of	  greater	  benefit	  
than	  implementing	  an	  AMS	  programme	  on	  its	  own	  or	  an	  FMT	  programme	  on	  its	  
own.	  This	  means	  that	  although	  the	  cost	  of	  running	  a	  hygiene	  improvement	  
programme	  alongside	  an	  FMT	  programme	  is	  markedly	  greater	  than	  running	  the	  
FMT	  programme	  by	  itself,	  there	  are	  clinical	  and	  economic	  gains	  to	  be	  realised	  
from	  the	  investment	  of	  more	  funds.	  The	  results	  provide	  new	  evidence	  that	  
compares	  current	  infection	  control	  practices	  with	  one	  another	  in	  order	  to	  
determine	  where	  scarce	  resources	  are	  best	  invested.	  If	  budget	  allocators	  are	  serious	  
about	  providing	  healthcare	  interventions	  that	  offer	  the	  best	  value	  for	  money,	  
without	  compromising	  patient	  outcomes,	  they	  need	  to	  heed	  comparative	  results,	  
such	  as	  these,	  and	  base	  their	  investment	  decisions	  on	  evidence	  that	  includes	  an	  
economic	  perspective.	  
 
Section	  6.3:	  Context	  and	  generalisability	  of	  the	  results	  	  
Given	  that	  the	  results	  of	  this	  research	  have	  been	  produced	  using	  predominantly	  
Australian	  data,	  they	  are	  primarily	  intended	  for	  the	  Australian	  setting.	  The	  
baseline	  infection	  rate	  and	  transition	  probabilities	  have	  been	  estimated	  from	  




Queensland.	  In	  order	  to	  make	  the	  results	  applicable	  to	  all	  Australian	  jurisdictions,	  
some	  generalisation	  across	  State	  and	  Territory	  borders	  occurred.	  This	  is	  not	  a	  
significant	  issue	  given	  that	  there	  is	  no	  substantial	  difference	  in	  the	  management	  of	  
Clostridium	  difficile	  infection	  or	  notably	  different	  rates	  of	  infection	  across	  Australia	  
(55;	  75).	  
	  
Generalisability	  of	  the	  results	  to	  healthcare	  systems	  that	  are	  in	  other	  countries	  is	  
more	  difficult.	  Variation	  in	  clinical	  practice,	  interventions	  that	  are	  available,	  the	  
costs	  of	  care,	  rate	  of	  infection	  and	  length	  of	  stay	  due	  to	  infection	  all	  have	  an	  
impact	  on	  the	  generalisability	  of	  the	  results.	  The	  likelihood	  of	  gaining	  anything	  of	  
benefit	  from	  this	  research	  is	  reduced	  if	  the	  characteristics	  of	  the	  at-­‐risk	  population	  
in	  this	  study	  differ	  from	  those	  in	  another	  jurisdiction	  (238).	  
	  
Additionally,	  for	  there	  to	  be	  any	  chance	  of	  reciprocity	  of	  the	  results,	  there	  needs	  to	  
be	  a	  clear	  and	  coherent	  specification	  of	  the	  decision	  problem	  that	  is	  underlying	  the	  
need	  for	  the	  evaluation.	  Countries	  such	  as	  New	  Zealand,	  Canada	  and	  those	  in	  the	  
United	  Kingdom	  share	  similar	  healthcare	  system	  features	  such	  as	  universal	  
healthcare	  and	  taxation-­‐based	  funding	  with	  the	  Australian	  system.	  This	  means	  
that	  these	  countries	  will	  have	  the	  greatest	  chance	  of	  benefitting	  from	  the	  findings.	  
However,	  there	  are	  many	  aspects	  apart	  from	  the	  provision	  of	  universal	  healthcare	  
that	  need	  to	  be	  similar	  for	  comparison	  to	  be	  worthwhile	  or	  accurate.	  For	  results	  




this	  research	  project	  would	  need	  to	  be	  appropriate	  for	  the	  new	  setting.	  If	  the	  
model	  structure	  is	  highly	  specific	  to	  local	  settings,	  then	  it	  is	  far	  less	  likely	  that	  
results	  could	  be	  generalised.	  The	  structure	  of	  the	  model	  in	  this	  project	  was	  heavily	  
influenced	  by	  data	  availability	  and	  it	  is	  difficult	  to	  judge	  if	  the	  model	  in	  this	  study	  
is	  directly	  transferrable	  to	  another	  country,	  needing	  only	  locally	  valid	  data	  to	  be	  
used	  to	  populate	  the	  parameters	  and	  inform	  a	  decision.	  	  
	  
An	  assessment	  of	  the	  model’s	  inputs	  needs	  to	  be	  undertaken	  by	  decision-­‐makers	  in	  
jurisdictions	  outside	  of	  Australia	  who	  are	  interested	  in	  using	  the	  findings	  from	  this	  
project	  to	  inform	  their	  local	  infection	  control	  decisions.	  
 
Section	  6.4:	  Limitations	  of	  the	  research	  
This	  research	  project	  has	  a	  number	  of	  limitations,	  which	  are	  addressed	  in	  this	  
section.	  There	  are	  issues	  that	  relate	  to	  the	  way	  that	  Clostridium	  difficile	  infection	  is	  
classified	  and	  reported	  in	  Australia.	  The	  definition	  of	  what	  constitutes	  an	  infection	  
is	  well	  known	  and	  is	  easily	  accessible	  (75)	  but	  there	  remains	  a	  concern	  about	  the	  
accuracy	  with	  which	  hospital-­‐acquired	  and	  community-­‐acquired	  infections	  are	  
described.	  Given	  that	  the	  major	  risk	  factors	  for	  infection	  are	  prolonged	  use	  of	  
antibiotics,	  old	  age	  and	  comorbidity,	  elderly	  people	  living	  in	  residential	  care	  
environments	  face	  a	  significant	  risk	  of	  both	  community-­‐acquired	  infection	  and	  
hospital	  admission.	  There	  is	  bound	  to	  be	  some	  overlap	  between	  genuine	  hospital-­‐




confirmed	  during	  a	  hospital	  stay.	  This	  issue	  has	  an	  impact	  on	  the	  epidemiology	  of	  
the	  infection,	  although	  there	  is	  evidence	  to	  suggest	  that	  incidence	  is	  more	  likely	  to	  
be	  under-­‐reported	  than	  overestimated	  (239).	  This	  is	  especially	  true	  for	  non-­‐severe	  
patients	  who	  may	  have	  self-­‐resolving	  diarrhoea	  that	  is	  never	  tested	  and	  confirmed	  
as	  a	  hospital-­‐acquired	  ‘case’	  because	  they	  are	  discharged	  before	  a	  formal	  test	  and	  
diagnosis	  was	  deemed	  necessary.	  For	  the	  purposes	  of	  this	  research,	  only	  people	  
who	  had	  the	  ICD-­‐10	  code	  for	  Clostridium	  difficile	  infection	  (AO4.7)	  as	  part	  of	  their	  
formal	  diagnosis	  during	  their	  stay	  were	  included	  in	  any	  analysis.	  This	  may	  have	  
lead	  to	  an	  under-­‐reporting	  of	  cases	  of	  infection,	  especially	  for	  mild	  cases	  of	  
diarrhoea	  where	  quickly	  resolving	  symptoms	  are	  not	  uncommon.	  
	  
Results	  of	  model-­‐based	  evaluations	  are	  always	  dependent	  on	  the	  assumptions	  that	  
are	  made	  relating	  to	  model	  on	  which	  they	  are	  based.	  Models	  are	  simplifications	  of	  
real-­‐life	  events	  and	  as	  such,	  only	  events	  that	  were	  deemed	  to	  impact	  either	  the	  
costs	  and/or	  health	  outcomes	  were	  included	  in	  the	  model	  for	  this	  project.	  Some	  
elements	  of	  the	  natural	  history	  of	  the	  disease	  were	  either	  simplified	  or	  excluded	  
from	  the	  model’s	  structure.	  For	  example,	  the	  clinical	  classification	  of	  disease	  
severity	  was	  simplified,	  due	  to	  a	  limitation	  in	  the	  best	  available	  data.	  The	  ASID	  
guidelines	  for	  managing	  Clostridium	  difficile	  suggest	  a	  number	  of	  clinical	  tests	  for	  
determining	  whether	  a	  patient	  is	  classified	  as	  suffering	  severe	  or	  non-­‐severe	  
infection.	  Given	  the	  absence	  of	  the	  results	  of	  these	  clinical	  tests	  in	  the	  available	  




that	  those	  patients	  who	  had	  a	  confirmed	  case	  of	  infection	  and	  a	  parallel	  stay	  in	  
ICU	  suffered	  severe	  infection	  and	  those	  who	  did	  not	  were	  classified	  as	  non-­‐severe	  
cases.	  Furthermore,	  a	  clinically	  plausible	  treatment	  pathway,	  surgery,	  was	  
excluded	  from	  the	  model	  structure.	  This	  treatment	  was	  excluded	  from	  the	  analysis	  
because	  it	  was	  decided	  that	  its	  inclusion	  would	  unnecessarily	  complicate	  the	  
evaluation.	  The	  focus	  of	  this	  evaluation	  is	  on	  interventions	  that	  are	  designed	  to	  
reduce	  Clostridium	  difficile	  transmission	  rather	  than	  analyse	  the	  most	  cost-­‐
effective	  treatment	  programme.	  Exclusions	  and	  simplifications	  are	  not	  uncommon	  
limitations	  of	  model-­‐based	  evaluations.	  	  
	  
Related	  to	  issues	  with	  model	  structure,	  there	  were	  limitations	  on	  how	  transition	  
probabilities	  were	  estimated	  in	  this	  project.	  With	  the	  exception	  of	  the	  underlying	  
mortality	  rate	  in	  non-­‐infected	  patients,	  all	  transition	  probabilities	  were	  based	  on	  
data	  that	  was	  captured	  in	  one	  State	  of	  Australia	  (Western	  Australia)	  over	  a	  specific	  
time	  period.	  For	  the	  model	  to	  inform	  nation-­‐wide	  findings,	  the	  assumption	  that	  all	  
States	  and	  Territories	  in	  Australia	  experience	  similar	  clinical	  outcomes	  must	  be	  
upheld.	  Given	  that	  the	  Western	  Australian	  healthcare	  setting	  is	  not	  vastly	  different	  
to	  other	  jurisdictions,	  there	  is	  no	  known	  reason	  for	  why	  this	  assumption	  would	  not	  
be	  upheld.	  In	  a	  perfect	  world,	  data	  that	  was	  as	  rich	  as	  the	  Western	  Australian	  
dataset	  would	  be	  available	  from	  every	  State	  and	  Territory	  but	  this	  is	  not	  the	  case	  at	  
this	  juncture	  in	  time	  and	  a	  compromise	  was	  made.	  Clostridium	  difficile	  incidence	  




so	  there	  is	  no	  reason	  to	  believe	  that	  using	  data	  only	  from	  Western	  Australia	  would	  
cause	  major	  inaccuracies	  in	  the	  project’s	  findings.	  	  
	  
Collecting	  cost	  data	  is	  a	  difficult	  process,	  especially	  when	  costs	  are	  not	  routinely	  
collected	  at	  hospital	  level	  for	  research	  purposes.	  As	  such,	  assumptions	  were	  made	  
regarding	  some	  of	  the	  cost	  data	  used	  in	  the	  analysis.	  Accounting	  costs	  were	  used	  
for	  the	  main	  cost-­‐effectiveness	  analyses,	  relating	  to	  treatment,	  bed	  days	  and	  
diagnosis	  of	  infection	  parameters.	  This	  means	  that	  the	  opportunity	  cost	  of	  these	  
parameters	  was	  not	  considered,	  which	  could	  have	  resulted	  in	  an	  underestimation	  
of	  total	  infection-­‐related	  costs.	  Intervention-­‐related	  costs	  were	  collected	  according	  
to	  checklists	  that	  had	  been	  developed	  specifically	  for	  this	  research	  project,	  but	  it	  
was	  impossible	  to	  collect	  nationwide	  cost	  information.	  Estimates	  were	  made	  about	  
the	  amount	  of	  staff	  time	  required	  for	  each	  intervention,	  as	  well	  as	  the	  staffing	  mix	  
(in	  terms	  of	  profession)	  and	  pay	  level	  of	  the	  staff	  required.	  Costs	  relating	  to	  human	  
resources	  (e.g.	  pay	  scales),	  consumables	  and	  equipment	  was	  collected	  using	  
Queensland	  data	  and	  has	  been	  assumed	  to	  be	  comparable	  across	  Australian	  
jurisdictions.	  Estimates	  relating	  to	  costs	  were	  made	  with	  the	  guidance	  of	  experts	  in	  
the	  majority	  of	  cases.	  Somewhat	  ironically,	  given	  the	  current	  emphasis	  on	  
prioritising	  low	  expenditure	  and	  cost-­‐effective	  healthcare	  improvement	  strategies,	  
collecting	  cost	  data	  can	  be	  a	  sensitive	  subject	  with	  healthcare	  providers.	  Finding	  
good	  quality	  evidence	  to	  inform	  a	  cost-­‐effectiveness	  analysis	  was	  difficult	  at	  times.	  




providers	  were	  reluctant	  to	  participate	  in	  any	  cost	  gathering	  exercise	  unless	  a	  non-­‐
specific	  breakdown	  of	  costs	  was	  guaranteed	  to	  be	  presented	  in	  any	  analysis.	  Best	  
estimates	  were	  used	  when	  first	  hand	  data	  was	  not	  available;	  such	  was	  the	  case	  for	  
some	  medical	  consumables	  relating	  to	  clinical	  interventions	  in	  this	  study.	  
However,	  the	  amount	  predicted	  is	  so	  minor	  that	  it	  is	  unlikely	  to	  impact	  results	  
even	  if	  it	  has	  been	  inaccurately	  estimated.	  
	  
The	  estimation	  of	  quality	  of	  life	  utility	  weights	  was	  not	  possible	  from	  primary	  data	  
or	  data	  that	  was	  from	  Australia	  for	  all	  health	  states	  in	  the	  model.	  This	  lack	  of	  
evidence	  is	  not	  surprising	  given	  the	  significant	  cost	  and	  labour	  required	  to	  obtain	  
health	  utility	  scores	  for	  a	  specific	  and	  rare	  infection.	  Utility	  weights	  were	  estimated	  
from	  other	  relevant	  cost-­‐effectiveness	  analyses	  for	  the	  health	  states,	  where	  
appropriate.	  For	  those	  health	  states	  that	  were	  not	  in	  any	  previously	  published	  
model	  for	  Clostridium	  difficile,	  expert	  opinion	  was	  sought	  and	  used	  in	  the	  model.	  
	  
Limitations	  relating	  to	  intervention	  efficacy	  exist	  given	  that	  the	  data	  used	  to	  
inform	  these	  parameters	  was	  not	  all	  from	  the	  Australian	  setting.	  The	  evidence	  that	  
was	  synthesised	  included	  results	  from	  clinical	  studies	  in	  the	  UK,	  North	  America	  
and	  Europe	  and	  preference	  was	  shown	  towards	  studies	  that	  reviewed	  bundled	  
approaches	  to	  infection	  control.	  Given	  that	  the	  results	  of	  the	  transmission	  model	  
were	  published	  in	  2014,	  all	  studies	  that	  were	  included	  are	  from	  prior	  to	  this	  date,	  




there	  does	  remain	  scope	  for	  updating	  the	  results	  of	  the	  transmission	  model	  with	  
findings	  that	  have	  been	  published	  more	  recently.	  This	  could	  be	  particularly	  
important	  for	  fecal	  transplant	  efficacy	  results,	  given	  that	  there	  has	  been	  a	  large	  
influx	  of	  new	  information	  published	  since	  2014,	  which	  could	  show	  an	  improvement	  
in	  treatment	  effectiveness	  due	  to	  technical	  advancement	  of	  this	  relatively	  novel	  
treatment.	  Furthermore,	  the	  clinical	  effectiveness	  results	  were	  derived	  from	  a	  
modelling	  study,	  which	  carries	  with	  it	  limitations	  that	  have	  been	  previously	  
discussed	  in	  this	  section.	  The	  findings	  of	  the	  research	  project	  are	  heavily	  
influenced	  by	  the	  effectiveness	  information	  and	  as	  such,	  the	  data	  that	  is	  used	  for	  
these	  estimates	  should	  be	  the	  best	  available.	  The	  intervention	  efficacy	  data	  was	  the	  
best	  available	  for	  this	  project,	  but	  as	  supplementary	  or	  newer	  evidence	  becomes	  
available,	  the	  model	  should	  be	  updated	  to	  reflect	  the	  new	  evidence.	  The	  strengths	  
of	  the	  efficacy	  data	  are	  discussed	  in	  the	  following	  section	  (6.5).	  
	  
The	  choice	  of	  interventions	  for	  inclusion	  in	  the	  project	  was	  simplified	  and	  did	  not	  
include	  all	  possible	  interventions	  that	  relate	  to	  Clostridium	  difficile	  infection.	  The	  
choice	  of	  interventions	  was	  guided	  by	  expert	  opinion	  and	  by	  available	  evidence	  
that	  could	  be	  used	  to	  inform	  a	  meaningful	  analysis.	  The	  model	  is	  structured	  to	  
allow	  the	  inclusion	  of	  other	  interventions	  if	  there	  is	  a	  desire	  to	  include	  another	  





The	  use	  of	  mixed	  quality	  data	  is	  inevitable	  and	  a	  practical	  reality	  in	  all	  research	  
settings.	  This	  section	  of	  the	  chapter	  is	  a	  thorough	  and	  transparent	  explanation	  of	  
the	  limitations	  relating	  to	  this	  project.	  Concerted	  effort	  was	  made	  to	  thoroughly	  
source	  the	  best	  available	  evidence	  for	  each	  aspect	  of	  the	  research	  in	  order	  to	  
produce	  a	  high	  quality	  analysis.	  
 
Section	  6.5:	  Strengths	  of	  the	  research	  and	  contribution	  to	  the	  
literature	  
The	  strengths	  of	  this	  research	  project	  are	  discussed	  in	  further	  detail	  in	  this	  section.	  
Firstly,	  the	  results	  of	  this	  research	  are	  novel	  for	  the	  Australian	  healthcare	  setting.	  
No	  economic	  evaluation	  of	  Clostridium	  difficile	  infection	  has	  ever	  been	  undertaken	  
in	  this	  setting,	  making	  the	  findings	  an	  important	  addition	  to	  existing	  clinical	  
knowledge.	  The	  findings	  of	  this	  project	  are	  relevant	  to	  a	  wide	  range	  of	  healthcare	  
providers	  and	  should	  be	  of	  interest	  to	  clinical	  staff	  as	  well	  as	  decision-­‐makers	  who	  
make	  budgetary	  decisions.	  
	  
Despite	  having	  limitations,	  modelling	  studies	  also	  have	  noteworthy	  strengths.	  No	  
prospective	  randomised	  control	  trial	  could	  be	  designed	  and	  commissioned	  to	  
address	  the	  range	  of	  research	  questions	  that	  are	  covered	  in	  this	  project.	  Given	  the	  
flexibility	  of	  modelling	  studies,	  this	  project	  is	  not	  a	  simplistic	  head-­‐to-­‐head	  
evaluation	  of	  treatment	  strategies,	  which	  has	  been	  the	  focus	  of	  research	  in	  other	  




practical	  information	  for	  decision-­‐makers	  who	  are	  not	  just	  interested	  in	  the	  best	  
option	  for	  treating	  the	  infection	  but	  the	  most	  cost-­‐effective	  way	  of	  intervening	  in	  
its	  spread.	  The	  model	  structure	  that	  was	  used	  for	  this	  study	  drew	  on	  expertise	  from	  
a	  multidisciplinary	  team,	  which	  also	  had	  its	  benefits.	  Clinical	  synergies,	  most	  
notably	  between	  those	  in	  the	  infection	  control,	  microbiology	  and	  infectious	  
disease	  departments,	  were	  realised	  that	  may	  not	  be	  evident	  on	  a	  daily	  level	  in	  
practice.	  It	  was	  an	  explicit	  aim	  to	  combine	  high	  quality	  clinical	  advice	  with	  
technical	  modelling	  skills	  to	  ensure	  that	  the	  findings	  are	  useful	  for	  those	  at	  the	  
clinical	  coalface	  rather	  than	  simply	  producing	  research	  for	  research’s	  sake.	  
	  
A	  further	  strength	  of	  the	  research	  relates	  to	  the	  source	  of	  the	  majority	  of	  the	  data	  
used	  to	  inform	  the	  results.	  The	  data	  used	  to	  estimate	  transition	  probabilities	  came	  
from	  a	  large	  and	  thoroughly	  collected	  primary	  dataset	  from	  Australia.	  The	  quality	  
of	  the	  evidence	  used	  to	  estimate	  transitions	  between	  health	  states	  in	  the	  model	  
was	  high	  and	  its	  relevance	  to	  the	  Australian	  setting	  is	  of	  value.	  Cost	  data	  was	  also	  
locally	  sourced	  for	  all	  interventions,	  which	  to	  date	  has	  not	  been	  published	  in	  any	  
other	  studies	  focused	  on	  Clostridium	  difficile	  infection.	  Furthermore,	  cost	  data	  was	  
thoroughly	  collected	  using	  reproducible	  methods	  in	  an	  effort	  to	  maximise	  
accuracy.	  The	  evidence	  used	  to	  inform	  the	  effectiveness	  component	  of	  the	  model	  
came	  from	  synthesised	  information	  of	  high	  quality.	  Efficacy	  estimations	  had	  
already	  been	  published	  prior	  to	  use	  in	  this	  research	  project,	  meaning	  that	  this	  




examination	  process.	  The	  process	  used	  to	  identify	  plausible	  and	  worthwhile	  
interventions	  for	  review	  was	  systematic,	  thorough	  and	  transparent.	  The	  
uncertainty	  in	  the	  findings	  has	  been	  thoroughly	  evaluated	  using	  standard	  methods	  
of	  Monte	  Carlo	  simulation	  and	  scenario	  analysis.	  The	  probability	  of	  error	  has	  also	  
been	  calculated	  for	  optimal	  decisions	  in	  an	  effort	  to	  provide	  decision-­‐makers	  with	  
as	  much	  useful	  evidence	  as	  possible,	  in	  order	  to	  facilitate	  an	  informed	  decision.	  
Finally,	  the	  methods	  that	  have	  been	  used	  in	  this	  research	  project	  are	  transparent,	  
reproducible	  and	  follow	  published	  standards	  for	  this	  type	  of	  evaluation.	  All	  
assumptions	  and	  limitations	  have	  been	  made	  explicit	  and	  accounted	  for	  and	  the	  
best	  available	  evidence	  was	  used	  to	  furnish	  the	  model.	  
	  
The	  following	  contributions	  to	  the	  knowledge	  base	  about	  Clostridium	  difficile	  
infection	  have	  already	  been	  made:	  
1. Dissemination	  of	  preliminary	  results	  to	  infection	  control	  practitioners	  at	  
the	  4th	  International	  Australian	  College	  for	  Infection	  Prevention	  and	  Control	  
(ACIPC)	  conference,	  November	  2015.	  Oral	  presentation.	  
2. Dissemination	  of	  preliminary	  results	  to	  health	  services	  researchers	  and	  
health	  policy	  makers	  at	  the	  9th	  Health	  Services	  and	  Policy	  Research	  
(HSRAANZ)	  conference,	  December	  2015.	  Oral	  presentation.	  
	  
The	  following	  papers	  are	  either	  planned	  for	  publication,	  are	  in	  draft	  form	  or	  have	  




1. Merlo,	  G.,	  Graves,	  N.,	  Brain,	  D	  &	  Connelly,	  L.	  Economic	  evaluation	  of	  faecal	  
microbiota	  transplantation	  for	  the	  treatment	  of	  recurrent	  Clostridium	  
difficile	  infection	  in	  Australia.	  Journal	  of	  Gastroenterology	  and	  Hepatology	  
(accepted	  for	  publication	  –	  31/3/16).	  
2. Brain,	  D.,	  Graves,	  N.,	  Yakob,	  L.,	  Riley,	  T.,	  Barnett,	  A.,	  Clements,	  A	  &	  
Halton,	  K.	  Economic	  evaluation	  of	  interventions	  designed	  to	  reduce	  
Clostridium	  difficile	  infection.	  Planned	  paper.	  
3. Brain,	  D.,	  Graves,	  N.,	  Yakob,	  L.,	  Riley,	  T.,	  Barnett,	  A.,	  Clements,	  A	  &	  
Halton,	  K.	  Setting	  the	  research	  agenda:	  analysing	  the	  expected	  value	  of	  
perfect	  information	  in	  relation	  to	  Clostridium	  difficile	  infection.	  Planned	  
paper.	  
4. Brain,	  D.,	  Graves,	  N.,	  Yakob,	  L.,	  Riley,	  T.,	  Barnett,	  A.,	  Clements,	  A	  &	  
Halton,	  K.	  Reducing	  length	  of	  stay	  to	  improve	  Clostridium	  difficile-­‐related	  
health	  outcomes	  Planned	  paper.	  
5. Brain,	  D.,	  Graves,	  N.,	  Barnett,	  A	  &	  Riley,	  T.	  The	  economic	  cost	  of	  
Clostridium	  difficile	  infection	  in	  Australian	  Hospitals.	  Planned	  paper.	  
	  
An	  improvement	  in	  understanding	  the	  complex	  issues	  relating	  to	  Clostridium	  
difficile	  management	  in	  Australia	  will	  be	  achieved	  by	  disseminating	  the	  findings	  of	  
this	  research	  at	  conferences,	  in	  academic	  journals	  and	  through	  contributions	  to	  




relevant	  conferences	  as	  part	  of	  a	  plan	  to	  disseminate	  the	  findings	  as	  widely	  and	  
thoroughly	  as	  possible:	  
1. Title:	  Using	  health	  economics	  to	  improve	  resource	  allocation	  decisions	  
relating	  to	  Clostridium	  difficile.	  	  
Conference:	  Australasian	  College	  for	  Infection	  Prevention	  and	  Control,	  
Melbourne,	  2016.	  	  
Status:	  Accepted	  for	  Oral	  Presentation	  
2. Title:	  Assessing	  the	  most	  cost-­‐effective	  approach	  to	  managing	  Clostridium	  
difficile	  infection	  in	  the	  Australian	  setting.	  
Conference:	  Asia-­‐Pacific	  Academic	  Consortium	  for	  Public	  Health,	  Tokyo,	  
2016.	  
Status:	  Accepted	  for	  Oral	  Presentation	  
3. Title:	  Reducing	  length	  of	  stay	  to	  improve	  Clostridium	  difficile-­‐related	  health	  
outcomes	  
Conference:	  International	  Meeting	  on	  Emerging	  Diseases	  and	  Surveillance,	  
Vienna,	  2016	  
Status:	  Accepted	  for	  Poster	  Presentation	  
 
Section	  6.6:	  Areas	  for	  future	  study	  
Areas	  for	  future	  study	  are	  addressed	  in	  further	  detail	  in	  this	  section	  of	  the	  chapter.	  
Improvement	  in	  the	  way	  that	  Clostridium	  difficile	  data	  are	  collected,	  maintained	  




evidence	  relating	  to	  Clostridium	  difficile	  infection	  meaning	  that	  for	  this	  study,	  
multiple	  assumptions	  were	  made.	  Incidence	  and	  prevalence	  data	  are	  available	  
from	  State	  and	  Territory	  jurisdictions,	  but	  there	  is	  limited	  nationally	  coordinated	  
data	  available	  for	  research	  purposes.	  The	  results	  of	  the	  EVPPI	  analysis	  showed	  that	  
increasing	  the	  quality	  of	  information	  about	  the	  transmission	  rate	  was	  associated	  
with	  the	  greatest	  expected	  value	  ($567,468)	  for	  this	  decision	  model.	  Improving	  the	  
evidence	  about	  the	  rate	  with	  which	  people	  move	  from	  being	  ‘At-­‐Risk’	  to	  being	  
infected	  –	  to	  either	  ‘Severe’	  or	  ‘Non-­‐Severe’	  infection	  -­‐	  would	  reduce	  the	  number	  of	  
assumptions	  that	  needed	  to	  be	  made.	  This	  makes	  logical	  sense,	  given	  that	  the	  
method	  for	  working	  out	  the	  number	  of	  infected	  cases	  and	  the	  severity	  of	  each	  case	  
was	  complicated	  in	  this	  study,	  due	  to	  data	  availability	  limitations.	  The	  EVPPI	  
analysis	  showed	  that	  the	  greatest	  benefit	  for	  decision	  clarity	  revolved	  around	  
improving	  understanding	  of	  moving	  to	  an	  infectious	  state,	  compared	  to	  other	  
transitions	  around	  the	  model	  –	  such	  as	  from	  ‘Non-­‐Severe’	  to	  ‘Discharged	  
Vulnerable’,	  ‘Severe’	  to	  ‘Dead’	  or	  from	  ‘At-­‐Risk’	  to	  ‘Discharged	  Healthy’.	  Two	  
options	  exist	  for	  improving	  this	  information.	  The	  first	  option	  is	  simply	  an	  
improvement	  on	  the	  currently	  available	  data.	  This	  would	  require	  information	  
about	  patient	  characteristics	  (e.g.	  age,	  gender,	  BMI,	  comorbidity	  status),	  admission	  
status	  (e.g.	  date	  admitted,	  date	  discharged)	  and	  identification	  of	  Clostridium	  
difficile	  to	  be	  routinely	  collected	  with	  a	  focus	  on	  improving	  the	  accuracy	  of	  
infection	  diagnosis	  in	  order	  to	  better	  estimate	  the	  transition	  from	  being	  ‘At-­‐Risk’	  




Territories,	  with	  information	  submitted	  and	  maintained	  in	  a	  single	  database.	  The	  
second	  option	  would	  require	  a	  well	  designed	  study	  to	  be	  undertaken,	  generating	  
bespoke	  data	  that	  would	  likely	  be	  more	  informative	  but	  also	  more	  expensive.	  The	  
study	  design	  would	  be	  a	  prospective	  study	  where	  individual	  patients	  are	  followed	  
from	  admission	  to	  discharge	  and	  their	  infection	  status	  monitored	  on	  a	  frequent	  
(e.g.	  daily)	  basis	  throughout	  their	  admission.	  Ideally,	  the	  cohort	  of	  patients	  that	  
are	  followed	  would	  be	  randomised,	  to	  ensure	  that	  the	  cohort	  is	  representative	  of	  
the	  wider	  population.	  This	  kind	  of	  study	  would	  be	  more	  expensive	  than	  the	  first	  
option	  –	  there	  would	  be	  an	  increased	  time-­‐burden	  on	  staff,	  which	  would	  need	  to	  
be	  thoroughly	  evaluated	  from	  a	  cost	  perspective,	  but	  this	  approach	  should	  improve	  
the	  quality	  of	  the	  data	  that	  is	  available.	  Whether	  this	  type	  of	  study,	  undertaken	  on	  
an	  appropriate	  scale,	  could	  be	  designed	  and	  implemented	  for	  less	  than	  the	  upper	  
bound	  identified	  in	  the	  EVPPI	  analysis	  ($567,468)	  is	  uncertain,	  however.	  What	  is	  
clear	  is	  the	  future	  research	  agenda	  for	  economic	  evaluations	  -­‐	  if	  decision-­‐makers	  
are	  too	  concerned	  by	  the	  current	  level	  of	  uncertainty	  associated	  with	  the	  current	  
findings,	  investment	  in	  further	  research	  that	  improves	  the	  understanding	  about	  
transitioning	  from	  ‘At-­‐Risk’	  to	  ‘Non-­‐Severe’	  or	  ‘Severe’	  will	  be	  the	  most	  worthwhile	  
and	  will	  reduce	  decision	  uncertainty.	  
	  
Riley	  et	  al	  produced	  an	  abridged	  estimate	  of	  the	  cost	  of	  an	  episode	  of	  infection	  but	  
there	  is	  yet	  to	  be	  an	  update	  on	  this	  work	  that	  was	  published	  in	  1995	  (240).	  The	  




relating	  to	  Clostridium	  difficile-­‐related	  extra	  LOS,	  cost	  of	  diagnosis,	  treatment	  and	  
recovery	  (bed	  costs)	  has	  not	  been	  readily	  available.	  Infection-­‐related	  extra	  LOS	  has	  
been	  under-­‐researched	  to	  date	  and	  due	  to	  data	  collection	  issues,	  there	  was	  no	  way	  
of	  accurately	  estimating	  it	  from	  the	  Western	  Australia	  dataset	  that	  was	  used	  in	  this	  
project.	  There	  were	  not	  any	  accurate	  dates	  for	  when	  cases	  of	  infection	  were	  
formally	  diagnosed	  or	  when	  patients	  were	  discharged	  upon	  resolution	  of	  the	  
infection,	  so	  extra	  LOS	  due	  to	  infection	  could	  not	  be	  estimated.	  Improving	  the	  
accuracy	  of	  the	  data	  collection,	  to	  allow	  extra	  LOS	  to	  be	  accurately	  assessed	  would	  
expand	  the	  scope	  for	  further	  research.	  
	  
Given	  that	  there	  are	  several	  strains	  of	  Clostridium	  difficile	  and	  that	  the	  strain	  a	  
patient	  contracts	  can	  have	  serious	  implications	  on	  their	  outcomes,	  improving	  this	  
evidence	  would	  also	  be	  of	  great	  benefit.	  The	  current	  cost	  of	  ribotyping	  is	  less	  than	  
$100	  per	  test,	  but	  there	  are	  less	  than	  10	  sites	  in	  Australia	  undertaking	  the	  test	  to	  
ascertain	  strain	  type	  at	  time	  of	  diagnosis.	  This	  reduces	  the	  overall	  epidemiological	  
understanding	  of	  the	  infection	  and	  does	  not	  allow	  scope	  for	  tailoring	  treatment.	  
Certain	  strains,	  such	  as	  ribotype	  027,	  have	  been	  associated	  with	  severe	  outbreaks	  
in	  other	  countries,	  causing	  greater	  than	  usual	  mortality	  (241-­‐242)	  and	  have	  been	  
linked	  with	  higher	  recurrence	  rates	  compared	  to	  other	  strains	  (243).	  Australia’s	  
current	  capacity	  to	  deal	  with	  severe	  strains	  is	  yet	  to	  be	  proven	  or	  properly	  
understood.	  Improving	  capacity	  for	  ribotyping	  to	  take	  place	  in	  more	  jurisdictions,	  




recording	  of	  outcomes,	  would	  ensure	  that	  clinicians	  across	  Australia	  could	  more	  
specifically	  tailor	  their	  intervention	  and	  treatment	  approaches.	  	  
Further	  study	  could	  also	  be	  undertaken	  to	  assess	  other	  healthcare	  interventions	  
that	  are	  designed	  to	  reduce	  the	  transmission	  of	  Clostridium	  difficile	  infection.	  The	  
model	  used	  in	  this	  project	  is	  capable	  of	  being	  updated	  or	  extended	  to	  include	  other	  
interventions.	  Assessing	  the	  cost-­‐effectiveness	  of	  screening	  all	  admitted	  patients	  
who	  are	  receiving	  antibiotics	  for	  Clostridium	  difficile	  infection	  is	  of	  interest.	  It	  has	  
been	  established	  that	  transmission	  of	  infection	  can	  come	  from	  symptomatic	  or	  
asymptomatic	  patients	  and	  that	  targeting	  those	  who	  are	  colonised	  with	  the	  
infection	  would	  be	  a	  plausible	  way	  to	  reduce	  its	  further	  spread.	  It	  has	  been	  
suggested	  that	  there	  has	  not	  been	  enough	  focus	  on	  targeting	  asymptomatic	  
carriers	  (those	  who	  are	  colonised	  but	  not	  suffering	  symptoms)	  when	  trying	  to	  
disrupt	  the	  transmission	  of	  the	  disease	  (244-­‐245).	  Further	  research	  in	  this	  area	  
would	  require	  an	  accurate	  microbiological	  test	  to	  be	  available	  and	  would	  hinge	  on	  
significant	  buy-­‐in	  from	  clinicians	  to	  add	  a	  rectal	  swab	  to	  routine	  patient	  testing	  
but	  the	  findings	  would	  provide	  interesting	  new	  information.	  The	  results	  would	  
inform	  our	  understanding	  of	  how	  much	  infection	  is	  actually	  community-­‐acquired	  
and	  brought	  in	  to	  hospital,	  rather	  than	  truly	  originating	  in	  hospital,	  by	  identifying	  
those	  who	  are	  colonised	  prior	  to	  their	  hospital	  stay.	  The	  results	  would	  also	  provide	  
a	  better	  understanding	  of	  the	  role	  that	  asymptomatic	  carriers	  play	  in	  disease	  
transmission	  and	  provide	  the	  opportunity	  to	  more	  accurately	  identify	  cases	  of	  




referred	  for	  a	  test	  by	  a	  doctor	  on	  the	  ward.	  It	  is	  likely	  to	  be	  an	  expensive	  exercise,	  
given	  the	  increased	  workload	  for	  the	  microbiological	  department	  and	  due	  to	  the	  
cost	  of	  processing	  more	  tests,	  but	  like	  any	  research	  project	  the	  value	  of	  its	  results	  
cannot	  be	  perfectly	  quantified	  prior	  to	  it	  commencing.	  Assessing	  the	  cost-­‐
effectiveness	  of	  using	  isolation	  as	  a	  strategy	  for	  reducing	  infection	  transmission	  is	  
also	  of	  interest.	  The	  role	  that	  the	  patient	  environment	  plays	  in	  transmission	  has	  
been	  well	  established	  (76;	  246).	  From	  a	  practical	  point	  of	  view,	  there	  are	  two	  
options	  available	  for	  using	  isolation	  as	  an	  infection	  control	  intervention	  strategy.	  
In	  the	  first	  instance,	  clinicians	  have	  the	  option	  of	  removing	  infected	  patients	  from	  
the	  general	  ward	  population	  until	  their	  infection	  has	  cleared,	  to	  reduce	  the	  risk	  of	  
them	  spreading	  it	  further.	  This	  option	  is	  only	  possible	  if	  there	  is	  sufficient	  space	  in	  
a	  hospital	  to	  move	  infected	  patients	  around	  and	  given	  that	  many	  hospitals	  report	  
operating	  above	  their	  bed-­‐capacity,	  this	  may	  not	  always	  be	  a	  plausible	  option	  (247-­‐
248).	  The	  second	  option	  that	  is	  available	  is	  to	  alter	  the	  design	  of	  a	  hospital	  so	  that	  
it	  comprises	  single	  rooms	  for	  at	  least	  part	  of	  the	  hospital.	  This	  is	  likely	  to	  be	  more	  
practical	  for	  brand	  new	  hospitals	  or	  where	  upgrade/refurbishment	  is	  taking	  place	  
and	  the	  option	  for	  changing	  design	  is	  obtainable.	  In	  certain	  jurisdictions,	  such	  as	  
Scotland	  and	  Canada,	  health	  authorities	  have	  announced	  that	  all	  new	  build	  
hospitals	  should	  comprise	  a	  majority	  of	  single	  patient	  rooms	  if	  providing	  all	  rooms	  
as	  single	  is	  not	  possible	  (249).	  There	  have	  been	  studies	  published	  in	  the	  northern	  
hemisphere	  suggesting	  that	  Clostridium	  difficile	  infection	  rates	  have	  reduced	  as	  a	  




been	  published	  in	  Australia,	  to	  date.	  Evaluating	  the	  impact	  that	  single	  patient	  
rooms	  has	  on	  Clostridium	  difficile	  infection	  rates	  in	  Australia	  would	  be	  of	  great	  
interest	  and	  provide	  novel	  evidence	  for	  clinical	  and	  management	  staff.	  	  
	  
Section	  6.7:	  Conclusions	  
The	  findings	  of	  this	  research	  project	  have	  been	  presented	  and	  the	  assumptions	  
associated	  with	  those	  findings	  have	  been	  transparently	  laid	  out.	  The	  strengths	  of	  
the	  project	  and	  areas	  for	  further	  research	  have	  also	  been	  identified,	  as	  have	  the	  
limitations.	  Until	  now,	  economic	  evidence	  relating	  to	  Clostridium	  difficile	  infection	  
has	  not	  been	  available	  for	  the	  Australian	  setting	  and	  the	  results	  of	  this	  project	  
should	  be	  used	  to	  inform	  improvements	  in	  the	  management	  of	  this	  infection.	  The	  
results	  support	  further	  investment	  in	  infection	  control	  interventions,	  providing	  
evidence	  that	  such	  investment	  is	  an	  efficient	  use	  of	  scarce	  resources,	  as	  cost-­‐
effective	  outcomes	  are	  likely	  to	  be	  realised.	  This	  novel	  evidence	  is	  of	  value	  to	  the	  
infection	  control	  department	  within	  a	  hospital,	  who	  petition	  for	  resources	  
alongside	  other	  clinical	  departments.	  It	  should	  also	  serve	  to	  guide	  clinical	  
decision-­‐makers	  who	  may	  wish	  to	  use	  the	  findings	  as	  evidence	  to	  divert	  resources	  
from	  one	  intervention	  to	  another	  in	  search	  of	  more	  cost-­‐effective	  outcomes.	  
The	  results	  have	  been	  presented	  with	  acknowledgment	  of	  the	  uncertainty	  relating	  
to	  the	  decision,	  providing	  decision-­‐makers	  with	  clear	  and	  pragmatic	  information.	  




too	  high,	  they	  have	  options	  for	  reducing	  such	  uncertainty	  by	  commissioning	  
further,	  more	  targeted	  research.	  	  
	  
This	  research	  delivers	  economic	  evidence	  for	  infection	  control	  decisions,	  however	  
there	  are	  several	  practical	  realities	  that	  need	  to	  also	  be	  considered.	  Economic	  
evidence	  is	  an	  important	  component	  of	  good	  healthcare	  decision-­‐making,	  but	  
viewing	  it	  in	  isolation	  from	  other	  information	  is	  not	  its	  intended	  function.	  In	  
addition,	  due	  to	  the	  fact	  that	  infection	  prevention	  programmes	  are	  designed	  to	  
reduce	  multiple	  infectious	  organisms	  at	  the	  same	  time,	  it	  is	  a	  difficult	  task	  to	  
decommission	  interventions	  completely,	  when	  they	  might	  be	  useful	  for	  another	  
organism	  outside	  the	  scope	  of	  this	  study.	  As	  a	  result,	  the	  findings	  of	  this	  project	  
should	  be	  considered	  together	  with	  other	  relevant	  information	  that	  is	  appropriate	  
at	  a	  local	  level,	  such	  as	  clinical	  outcomes,	  budget	  constraints	  and	  treatment	  
priorities.	  If	  this	  occurs,	  the	  findings	  will	  be	  a	  beneficial	  addition	  to	  support	  logical	  
and	  thorough	  decision-­‐making	  about	  Clostridium	  difficile	  infection	  in	  the	  
Australian	  hospital	  setting.	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Appendix	  A:	  Hierarchy	  of	  evidence	  for	  use	  in	  economic	  





Appendix	  B:	  Progression	  of	  the	  model	  design	  
First	  draft	  of	  model	  
The	  first	  draft	  of	  the	  model	  only	  considered	  complications	  relating	  to	  severe	  
infection.	  It	  focused	  on	  symptomatic	  disease	  for	  the	  accrual	  of	  costs	  and	  health	  








Second	  draft	  of	  model	  
The	  second	  draft	  of	  the	  model	  considered	  death	  from	  a	  number	  of	  states	  but	  not	  
from	  first	  time	  infectious	  states.	  It	  considered	  three	  recurrences	  and	  assumed	  that	  
recurrences	  were	  only	  ever	  ‘severe’	  or	  ‘moderate’,	  never	  ‘mild’.	  The	  model	  did	  not	  
account	  for	  remaining	  in	  a	  state	  for	  more	  than	  one	  cycle	  
	  




Third	  draft	  of	  model	  	  
The	  third	  draft	  of	  the	  model	  considered	  the	  concept	  of	  a	  ‘discharged	  vulnerable’	  
state	  but	  there	  was	  confusion	  about	  whether	  all	  infections	  could	  result	  permanent	  
‘vulnerability’.	  Infection	  was	  separated	  into	  3	  categories	  and	  there	  was	  no	  
consideration	  of	  how	  people	  became	  infected,	  as	  the	  model	  starts	  with	  infected	  
patients.	  
	  




Fourth	  draft	  of	  model	  
The	  fourth	  draft	  of	  the	  model	  considered	  death	  from	  infection	  and	  separated	  
recurrent	  infection	  into	  different	  severity	  categories.	  It	  also	  introduced	  the	  
capacity	  to	  remain	  in	  a	  health	  state	  for	  more	  than	  1	  cycle,	  but	  incorrectly	  assumed	  
that	  a	  patient	  could	  move	  from	  being	  ‘discharged	  vulnerable’	  to	  ‘survive	  healthy’.	  
The	  model	  also	  incorrectly	  starts	  at	  the	  ‘diseased’	  state.	  
	  
	  




Appendix	  C:	  Outputs	  from	  Yakob’s	  transmission	  model	  used	  in	  
to	  inform	  the	  effectiveness	  parameters	  for	  the	  economic	  model	  
The	  outputs	  from	  Yakob’s	  model	  were	  used	  to	  inform	  the	  effectiveness	  component	  
of	  the	  economic	  model.	  Yakob’s	  model	  estimates	  change	  to	  C.	  difficile	  incidence	  
rate	  (numbers	  in	  black),	  for	  each	  stand-­‐alone	  and	  bundled	  intervention.	  	  
Output	  1:	  Antimicrobial	  Stewardship	  (Across)	  and	  Fecal	  Transplant	  (Down)	  
	  




Output	  2:	  Hygiene	  Improvement	  (Across)	  and	  Antimicrobial	  Stewardship	  (Down)	  
	  
	  




Output	  3:	  Hygiene	  Improvement	  (Across)	  and	  Fecal	  Transplant	  (Down)	  
	  
	  




Output	  4:	  Reducing	  LOS	  (Across)	  and	  Antimicrobial	  Stewardship	  (Down)	  
	  
	  












Output	  6:	  Reducing	  LOS	  (Across)	  and	  Fecal	  Transplant	  (Down)	  
	  
	  
